


L1 HAS NO ANSWERS  
L1 STR



G1 H, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:32:46 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 17210 TO ITERATE

11.6% PROCESSED 2000 ITERATIONS 2 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 336341 TO 352059  
PROJECTED ANSWERS: 96 TO 592

L2 2 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 10:34:21 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 343733 TO ITERATE

100.0% PROCESSED 343733 ITERATIONS 587 ANSWERS  
SEARCH TIME: 00.00.14

L3 587 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	187.32	187.54

FILE 'CAPLUS' ENTERED AT 10:34:42 ON 10 DEC 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Dec 2009 VOL 151 ISS 24  
 FILE LAST UPDATED: 9 Dec 2009 (20091209/ED)  
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009  
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3  
 L4 19 L3

=> b stng		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.50	188.04

FILE 'STNGUIDE' ENTERED AT 10:35:29 ON 10 DEC 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Dec 4, 2009 (20091204/UP).

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.14	188.18

FILE 'CAPLUS' ENTERED AT 10:36:27 ON 10 DEC 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Dec 2009 VOL 151 ISS 24  
FILE LAST UPDATED: 9 Dec 2009 (20091209/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAPLUS now includes complete International Patent Classification (IPC)  
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> s US20070010511/pn  
L5 1 US20070010511/PN

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.74	190.92

FILE 'REGISTRY' ENTERED AT 10:36:54 ON 10 DEC 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 DEC 2009 HIGHEST RN 1196786-45-4  
DICTIONARY FILE UPDATES: 9 DEC 2009 HIGHEST RN 1196786-45-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d his

(FILE 'HOME' ENTERED AT 10:32:12 ON 10 DEC 2009)

FILE 'REGISTRY' ENTERED AT 10:32:20 ON 10 DEC 2009

L1 STRUCTURE UPLOADED  
L2 2 S L1  
L3 587 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:34:42 ON 10 DEC 2009  
L4 19 S L3

FILE 'STNGUIDE' ENTERED AT 10:35:29 ON 10 DEC 2009

FILE 'CAPLUS' ENTERED AT 10:36:27 ON 10 DEC 2009  
L5 1 S US20070010511/PN

FILE 'REGISTRY' ENTERED AT 10:36:54 ON 10 DEC 2009

=> tra rn  
L6 TRANSFER L5 1- RN : 1646 TERMS  
L7 1646 L6

=> s 17 and 13\  
L8 0 L7 AND L3\

=> del 18 y

=> s 17 and 13  
L8 490 L7 AND L3

=> s 13 not 18  
L9 97 L3 NOT L8

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	6.31	212.81

FILE 'CAPLUS' ENTERED AT 10:37:58 ON 10 DEC 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Dec 2009 VOL 151 ISS 24  
FILE LAST UPDATED: 9 Dec 2009 (20091209/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 18

L10 2 L8

=> s 19

L11 17 L9

=> d bib 110 tot

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2006:1037703 CAPLUS  
DN 145:397375  
TI Preparation of 4-(4-piperidinyl)phenols and related compounds as aspartic  
protease inhibitors  
IN Herold, Peter; Mah, Robert; Stutz, Stefan; Stojanovic, Aleksandar;  
Tschinke, Vincenzo; Jotterand, Nathalie; Schumacher, Christoph  
PA Speedel Experimenta A.-G., Switz.  
SO Eur. Pat. Appl., 67pp.  
CODEN: EPXXDW  
DT Patent  
LA German  
FAN.CNT 1  
PATENT NO. KIND DATE APPLICATION NO. DATE  
-----  
PI EP 1707202 A1 20061004 EP 2006-111981 20060330  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,  
BA, HR, IS, YU  
PRAI EP 2005-102559 A 20050331  
OS MARPAT 145:397375  
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)  
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2005:588898 CAPLUS  
DN 143:115449  
TI Preparation of piperidines as renin inhibitors useful against  
hypertension  
and other disorders  
IN Herold, Peter; Mah, Robert; Stutz, Stefan; Stojanovic, Aleksandar;  
Tschinke, Vincenzo; Jotterand, Nathalie  
PA Speedel Experimenta A.-G., Switz.  
SO PCT Int. Appl., 252 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1  
PATENT NO. KIND DATE APPLICATION NO. DATE  
-----  
PI WO 2005061457 A1 20050707 WO 2004-EP52389 20040930  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG  
EP 1670760 A1 20060621 EP 2004-820600 20040930  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK  
EP 1961752 A2 20080827 EP 2008-100929 20040930  
EP 1961752 A3 20081119  
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR  
US 20070010511 A1 20070111 US 2006-574108 20060331  
US 20090012055 A1 20090108 US 2008-68443 20080206  
PRAI CH 2003-1669 A 20031001  
CH 2004-343 A 20040227  
EP 2004-820600 A3 20040930  
WO 2004-EP52389 W 20040930  
US 2006-574108 A3 20060331  
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OS CASREACT 143:115449; MARPAT 143:115449  
OSC.G 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)  
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:32:12 ON 10 DEC 2009)

FILE 'REGISTRY' ENTERED AT 10:32:20 ON 10 DEC 2009

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 587 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:34:42 ON 10 DEC 2009

L4 19 S L3

FILE 'STNGUIDE' ENTERED AT 10:35:29 ON 10 DEC 2009

FILE 'CAPLUS' ENTERED AT 10:36:27 ON 10 DEC 2009

L5 1 S US20070010511/PN

FILE 'REGISTRY' ENTERED AT 10:36:54 ON 10 DEC 2009

FILE 'CAPLUS' ENTERED AT 10:37:04 ON 10 DEC 2009

L6 TRA L5 1- RN : 1646 TERMS

FILE 'REGISTRY' ENTERED AT 10:37:04 ON 10 DEC 2009

L7 1646 SEA L6

L8 490 S L7 AND L3

L9 97 S L3 NOT L8

FILE 'CAPLUS' ENTERED AT 10:37:58 ON 10 DEC 2009

L10 2 S L8

L11 17 S L9

=> d ibib abs hitstr tot


L11 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2009:1326027 CAPLUS  
 DOCUMENT NUMBER: 151:491007  
 TITLE: Preparation of 3-aminosulfonyl- or 2-heterocyclylsulfonylbenzamide derivatives as long-chain fatty acid elongation enzyme inhibitor  
 INVENTOR(S): Jitsuoka, Makoto; Nagase, Tsuyoshi; Sato, Nagaaki; Tsukahara, Daisuke  
 PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 154pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009131065	A1	20091029	WO 2009-JP57725	20090417
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: JP 2008-113340 A 20080424


GI

L11 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




AB There are specifically disclosed long-chain fatty acid elongation enzyme (LCE) inhibitors comprising compds. represented by formula [I]; W = each (un)substituted C1-6 alkyl, C3-8 cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, NR1R2; R1, R2 = H, each (un)substituted (un)substituted C1-6 alkyl, C3-8 cycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl; or NR1R2 form N-containing heterocyclic ring; X = each (un)substituted aryl, heteroaryl, aralkyl, or heteroaralkyl; Y = (CH2)n1NHCO, (CH2)n2NHCONH, (CH2)n3CONH, (CH2)n4NHCO2O; n1, n2, n3, n4 = 0, 1; Z = H, HO, cyano, CO2H, SO3H, halo, C1-6 alkyl, halo-C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkoxy, halo-C1-6 alkoxy, hydroxy-C1-6 alkyl, amino-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, each (un)substituted NH2, CONH2, SO2NH2, SH, or carbamoylamino, etc.; A1, A2, A3, A4 = CH, N] or pharmaceutically acceptable salt thereof as active ingredients. These compds. are useful as prophylactic agents or therapeutic agents for cardiovascular diseases, nervous system diseases, metabolic diseases, genital diseases, gastrointestinal diseases, neoplasm, infectious diseases, and others or herbicides. Thus, 76.6 mg (1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane monohydrochloride and 0.16 mL Et3N were sequentially added to a solution of 80.0 mg 3-[[4-(4-isopropoxyphenyl)amino]carbonyl]benzenesulfonyl chloride in 3.0 mL THF and the resulting mixture was stirred at room temperature overnight to give,

L11 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 after workup and silica gel chromatog., 85%  
 N-(4-isopropoxyphenyl)-3-[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylsulfonyl]benzamide (II). II and 5-isopropoxy-3-[(3-[(2-methylpyrrolidin-1-yl)sulfonyl]benzoyl)amino]-1H-pyrazole (III). HCl inhibited human long-chain fatty acid elongation enzyme with showed IC50 of 0.030 and 0.0050  $\mu$ M, resp.  
 IT 933716-44-0, 2-[[[(Piperidin-3-yl)oxy]methyl]pyridine  
 933758-64-6, 3-[[[(Piperidin-3-yl)oxy]methyl]pyridine  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of 3-aminosulfonyl- or 2-heterocyclylsulfonylbenzamide derivs. as long-chain fatty acid elongation enzyme inhibitor)  
 RN 933716-44-0 CAPLUS  
 CN Pyridine, 2-[(3-piperidinyl)oxy]methyl]- (CA INDEX NAME)



RN 933758-64-6 CAPLUS  
 CN Pyridine, 3-[(3-piperidinyl)oxy]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L11 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2007:1396423 CAPLUS  
 DOCUMENT NUMBER: 148:55081  
 TITLE: Preparation of pyridinone and pyridazinone derivatives  
 INVENTOR(S): as inhibitors of poly(adp-ribose)polymerase (parp) Jones, Philip; Kinzel, Olaf; Pescatore, Giovanna; Llauger Buñi, Laura; Schultz-Fadenrecht, Carsten; Ferrigno, Federica  
 PATENT ASSIGNEE(S): Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA, Italy  
 SOURCE: PCT Int. Appl., 101 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007138351	A2	20071206	WO 2007-GB50295	20070525
WO 2007138351	A3	20080807		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AF, EA, EP, OA			
AU 2007266836	A1	20071206	AU 2007-266836	20070525
CA 2653529	A1	20071206	CA 2007-2653529	20070525
EP 2029551	A2	20090304	EP 2007-733716	20070525
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
JP 2009538896	T	20091112	JP 2009-512681	20070525
US 20090176765	A1	20090709	US 2008-227513	20081119
IN 2008DN09794	A	20090320	IN 2008-DN9794	20081125
MX 2008015014	A	20090417	MX 2008-15014	20081126
KR 2009015092	A	20090211	KR 2008-729132	20081127
CN 101501006	A	20090805	CN 2007-80020136	20081201
NO 2008005397	A	20090225	NO 2008-5397	20081229
PRIORITY APPLN. INFO.:			GB 2006-10680	A 20060531
			WO 2007-GB50295	W 20070525


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): CASREACT 148:55081; MARPAT 148:55081  
 GI



L11 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I



II

AB Title compound I [R1 independently = alkyl, haloalkyl, halo or CN; m and n independently = 0 or 1; R2 independently = OH, halo, CN, alkyl, etc.; p = 0-3; R5 = H, OH, CN, alkyl, etc.; X1 = N or CH; X2 = (CH2)c(CO)d(NR3)e(Z=O)f(O)g(CH2)h(NR4)i; where R3 and R4 independently = or alkyl; Z = C or SO; c and h independently = 0-6; d, e, f, g, and i independently = 0 or 1], and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of poly(adp-ribose)polymerase (parp).

Thus, e.g., the trifluoroacetate salt of II was prepared by acetylation of 4-(5-[(5-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl]-2-fluorobenzoyl)-1,4-diazepane trifluoroacetate salt (preparation given). The exemplified compds. described and tested by PARP-1 SPA assay were found to have an IC50 value of less than 5  $\mu$ M. I should prove useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.

IT 933716-44-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of pyridinone and pyridazinone derivs. as inhibitors of poly(adp-ribose)polymerase)  
 RN 933716-44-0 CAPLUS  
 CN Pyridine, 2-[(3-piperidinyloxy)methyl]- (CA INDEX NAME)


L11 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:538689 CAPLUS  
 DOCUMENT NUMBER: 146:521800  
 TITLE: Heterocyclic compounds as tyrosine kinase modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases  
 INVENTOR(S): Anikin, Alexey Vyacheslavovich; Gantla, Vidyasagar Reddy; Gregor, Vlad Edward; Jiang, Luyong; Liu, Yahua;  
 Mcgee, Danny Peter Claude; Mikel, Charles  
 Chamchounis; Pickens, Jason Conrad; Webb, Thomas Roy; Zheng, Yan; Zhu, Tong; Kadushkin, Aleksander; Zozulya, Sergey; Chucholowski, Alexander; McGrath, Douglas Eric; Sviridov, Sergey  
 PATENT ASSIGNEE(S): Chembridge Research Laboratories, Inc., USA  
 SOURCE: PCT Int. Appl., 385pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007056155	A1	20070518	WO 2006-US42982	20061102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006311914	A1	20070518	AU 2006-311914	20061102
CA 2669736	A1	20070518	CA 2006-2669736	20061102
EP 1960382	A1	20080827	EP 2006-836883	20061102
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
PRIORITY APPLN. INFO.:			US 2005-734050P	P 20051103
			WO 2006-US42982	W 20061102


OTHER SOURCE(S): MARPAT 146:521800  
 GI

L11 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
 (2 CITINGS)

L11 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




II

AB The invention provides compds. of formula I and related compds., capable of modulating tyrosine kinases, compns. comprising the compds. and methods of their use. Compds. of formula I wherein R1 is (un)substituted heterocyclyl, (un)substituted alkyl, (un)substituted sulfonyl, acyl, etc.;


R2 is H, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkylalkyl, (un)substituted (hetero)aryl(alkyl), heterocycloalkyl, etc.; Q1, Q2, Q3 and Q4 are independently. C1-5 alkyl; and their stereoisomers, tautomers, salts, hydrates and prodrugs thereof, are claimed. Example compound II

was prepared by amidation of 2-[2-hydroxy-5-(2-methoxypyridin-3-yl)phenyl]benzimidazole-5-carboxylic acid with 1-methoxy-2-propylamine. All the invention compds. were evaluated for their tyrosine kinase modulatory activity (some data given).

IT 933716-44-0 933758-64-6  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (starting material; preparation of heterocyclic compds. as tyrosine kinase modulators and their use in the treatment of diseases)  
 RN 933716-44-0 CAPLUS  
 CN Pyridine, 2-[(3-piperidinyloxy)methyl]- (CA INDEX NAME)



RN 933758-64-6 CAPLUS  
 CN Pyridine, 3-[(3-piperidinyloxy)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD



L11 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L11 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:1009703 CAPLUS  
 DOCUMENT NUMBER: 145:377324  
 TITLE: Preparation of phenylalkanoic acid derivatives  
 containing cyclic amino moiety as PPAR $\alpha$  agonists  
 Nomura, Masahiro; Takano, Yasuo; Yumoto, Kazuhiro;  
 Okada, Kyoko; Shinozaki, Takehiro; Isogai, Shigeki  
 Kyorin Pharmaceutical Co., Ltd., Japan  
 PATENT ASSIGNEE(S):  
 SOURCE: PCT Int. Appl., 129pp.  
 CODEN: FIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006101108	A1	20060928	WO 2006-JP305654	20060322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2600074	A1	20060928	CA 2006-2600074	20060322
EP 1862464	A1	20071205	EP 2006-729621	20060322
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2007DN07314	A	20071109	IN 2007-DN7314	20070921
KR 2007116644	A	20071210	KR 2007-724323	20071023
US 20090036489	A1	20090205	US 2007-886909	20071109
CN 101189231	A	20080528	CN 2006-80017369	20071119
PRIORITY APPLN. INFO.:			JP 2005-83024	A 20050323
			WO 2006-JP305654	W 20060322


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): MARPAT 145:377324  
 GI

L11 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



AB Title compds. I [ring Ar = (un)substituted aryl, (un)substituted aromatic heterocycle or its condensed ring; Y = alkylene, alkenylene, alkynylene, etc.; ring W = saturated heterocycle containing N; Z = O, S, -(CH<sub>2</sub>)<sub>n</sub>; n = 0-2; X = H, halo, optionally substituted alkyl with halo, etc.; Q = single bond, methylene, O, etc.; R<sub>1</sub>, R<sub>2</sub> = H, optionally substituted alkyl with halo;  
 R3 = H, alkyl; -QCR<sub>1</sub>R<sub>2</sub>CO<sub>2</sub>R<sub>3</sub> is substituted at o- or m-position of ring W] and their pharmaceutically acceptable salts were prepared. For example, treatment of (Z)-N-[1-[2-(2-methylthio-2-methylsulfinylethynyl)phenyl]piperidin-3-ylmethyl]-2-(4-chlorophenyl)-4-methylthiazole-5-carboxamide, e.g., prepared from 2-(4-chlorophenyl)-4-methylthiazole-5-carboxylic acid in 4 steps, with methanolic HCl followed hydrolysis using aqueous KOH afforded compound II.  
 In human PPAR $\alpha$  transcription activation assays, the EC<sub>50</sub> value of compound II was 0.0001  $\mu$ mol/L. Compds. I are claimed useful for the treatment of arteriosclerosis, diabetes, etc.  
 IT 876147-61-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of phenylalkanoic acid derivs. containing cyclic amino moiety as PPAR $\alpha$  agonists)  
 RN 876147-61-4 CAPLUS  
 CN Piperidine, 3-[[2-(4-chlorophenyl)-4-methyl-5-thiazolyl]methoxy]- (CA INDEX NAME)

L11 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT


L11 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:841647 CAPLUS  
 DOCUMENT NUMBER: 145:271649  
 TITLE: Preparation of piperidines as antibacterial agents  
 INVENTOR(S): Basarab, Greg; Dangel, Brian; Fleming, Paul Robert;  
 Gravestock, Michael Barry; Green, Oluyinka; Hauck,  
 Sheila Irene; Hill, Pamela; Hull, Kenneth Gregory;  
 Mullen, George; Sherer, Brian; Zhou, Fei  
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited  
 SOURCE: PCT Int. Appl., 249 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006087543	A1	20060824	WO 2006-GB529	20060216
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006215399	A1	20060824	AU 2006-215399	20060216
CA 2598423	A1	20060824	CA 2006-2598423	20060216
EP 1853586	A1	20071114	EP 2006-709766	20060216
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008500321	T	20080110	JP 2007-514146	20060216
JP 4058106	B2	20080305		
MX 2007010072	A	20080128	MX 2007-10072	20070817
ZA 2007006920	A	20080625	ZA 2007-6920	20070817
IN 2007DN06591	A	20070921	IN 2007-DN6591	20070824
NO 2007004703	A	20071114	NO 2007-4703	20070914
JP 2007326882	A	20071220	JP 2007-239383	20070914
JP 2007326883	A	20071220	JP 2007-239427	20070914
JP 2008024715	A	20080207	JP 2007-239467	20070914
KR 2007113233	A	20071128	KR 2007-721453	20070918
CN 101163693	A	20080416	CN 2006-80013058	20071018
PRIORITY APPLN. INFO.:			US 2005-654670P	P 20050218
			JP 2007-514146	A3 20060216
			WO 2006-GB529	W 20060216

OTHER SOURCE(S): MARPAT 145:271649



L11 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 RN 907545-01-1 CAPLUS  
 CN 1H-Pyrrole-2-carboxamide, 3,4-dichloro-5-methyl-N-[(3R,4S)-3-(2-thiazolylmethoxy)-4-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS  
 RECORD (5 CITINGS)  
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L11 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 GI



AB Title compds. I [R1 = independently (un)substituted H, NO2, halo, CN, alk(en/yn)yl, etc.; R3 = (un)substituted H, NO2, OH, halo, CN, C:N-OH and derivs.; W = a direct bond, NH and derivs., CH2 and derivs.; X = a direct bond, XH2, CO, SO, SO2; A = carbocyclyl, heterocyclyl with proviso; R4, R5 = substituents on C and independently selected from halo, NO2, CN, OH, NH2, CO2H, etc.; n = 1-4; m = 0-4; and their pharmaceutically acceptable salts] were prepared for use in the treatment of bacterial infections.

For example, II was prepared, in 3 steps, from Me

4-[(1-methyl-1-phenylethyl)amino]carbonyl]-2-(methylthio)-1,3-thiazole-5-carboxylate (preparation given) and cis-4-chloro-N-(3-methoxypiperidin-4-yl)-5-methyl-1H-pyrrole-2-carboxamide (preparation given). I generally displayed an IC50 value < 20 µg/mL for the inhibition of DNA gyrase B ATPase activity using an ammonium molybdate/malachite green-based phosphate detection assay. II had a min. inhibitory concentration of 0.13 µg/mL against Streptococcus pneumoniae.



IT 907545-01-1P  
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (Intermediate; preparation of piperidines as antibacterial agents)

L11 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:152548 CAPLUS  
 DOCUMENT NUMBER: 144:233066  
 TITLE: Preparation of cyclic aminobenzoic acid derivatives as PPARα agonists  
 INVENTOR(S): Nomura, Masahiro; Takano, Yasuo; Yumoto, Kazuhiro; Shinozaki, Takehiro; Isogai, Shigeki; Murakami, Koji  
 PATENT ASSIGNEE(S): Kyorin Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 244 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006016637	A1	20060216	WO 2005-JP14718	20050811
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005272389	A1	20060216	AU 2005-272389	20050811
CA 2575039	A1	20060216	CA 2005-2575039	20050811
EP 1780210	A1	20070502	EP 2005-770805	20050811
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
CN 101014595	A	20070808	CN 2005-80027318	20050811
BR 2005015015	A	20080701	BR 2005-15015	20050811
ZA 2007000064	A	20071227	ZA 2007-64	20070102
IN 2007DN00168	A	20070803	IN 2007-DN168	20070105
NO 2007000750	A	20070308	NO 2007-750	20070208
MX 2007001634	A	20070423	MX 2007-1634	20070209
US 20070249580	A1	20071025	US 2007-659854	20070305
KR 2007050475	A	20070515	KR 2007-705755	20070312
PRIORITY APPLN. INFO.:			JP 2004-234603	A 20040811
			WO 2005-JP14718	W 20050811

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): MARPAT 144:233066  
 GI

L11 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




AB Title compds. I [Ar = (un)substituted aryl, (un)substituted heteroaryl, etc.; Y = alkylene, alkenylene, alkynylene, etc.; Z = O, S, -(CH<sub>2</sub>)<sub>n</sub>; n = 0-2; X = H, halo, optionally substituted alkyl with halo, etc.; R = H, alkyl; -CO<sub>2</sub>R is substituted at o- or m-position of Ph group to ring W] were prepared For example, reaction of compound II [R<sub>1</sub> = H], e.g., prepared from 2-(4-chlorophenyl)-4-methylthiazole-5-carboxylic acid in 2 steps, with 2-fluorobenzoic acid Me ester followed by hydrolysis afforded compound II [R<sub>1</sub> = 2-carboxyphenyl]. In PPAR $\alpha$  transcription activation assays, the EC<sub>50</sub> value of compound II [R<sub>1</sub> = 2-carboxyphenyl] was 0.065  $\mu$ mol/L. Compds. I are claimed useful for the treatment of arteriosclerosis, diabetes, etc.

IT 876147-61-4P 876148-44-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of cyclic aminobenzoic acid derivs. as PPAR $\alpha$  agonists for treatment of arteriosclerosis, diabetes, etc.)


RN 876147-61-4 CAPLUS  
 CN Piperidine, 3-[[2-(4-chlorophenyl)-4-methyl-5-thiazolyl]methoxy]- (CA INDEX NAME)

L11 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 876148-44-6 CAPLUS  
 CN Piperidine, 3-[[2-(4-chlorophenyl)-4-methyl-5-thiazolyl]methoxy]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L11 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:70486 CAPLUS  
 DOCUMENT NUMBER: 142:176825  
 TITLE: Preparation of heterocyclic compounds, their use as tyrosine kinase inhibitors and antitumor agents, and treatment of tumor with (prodrugs of) the compounds Imamura, Shinichi; Tasaka, Akihiro; Yoshida, Kiyoshi; Ishikawa, Tomoyasu; Nishikawa, Yoichi  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 99 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005023007	A	20050127	JP 2003-189055	20030630
PRIORITY APPLN. INFO.:			JP 2003-189055	20030630

OTHER SOURCE(S): MARPAT 142:176825  
 GI




AB Title compds. I [ring A<sub>1</sub>, A<sub>2</sub> = (un)substituted aromatic hydrocarbon ring, (un)substituted aromatic heterocyclic ring; B<sub>1</sub>, B<sub>2</sub> = (un)substituted aromatic heterocyclic ring; X<sub>1</sub>, X<sub>2</sub> = bond, ethylene, vinylene; Y<sub>1</sub>, Y<sub>2</sub> = bond, (un)substituted C<sub>1</sub>-3 alkylene; Z<sub>1</sub>, Z<sub>2</sub> = bond, O, (un)substituted N, (oxidized) S, etc., W = (un)substituted C<sub>1</sub>-10 alkylene, (un)substituted nonarom. hydrocarbon ring, (un)substituted nonarom. heterocyclic ring, etc.] or their salts are prepared Thus, oximation of 1,5-bis[[2-[(E)-2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-oxazol-4-yl]methoxy]-3-pentanone with HONH<sub>2</sub>.HCl gave the corresponding oxime, which inhibited phosphorylation of receptor tyrosine kinase in human breast cancer cell line BT 474 with IC<sub>50</sub> value of 8.4 nM.

IT 832730-45-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of heterocyclic compds. as tyrosine kinase inhibitors for treatment of tumor)

RN 832730-45-7 CAPLUS  
 CN Piperidine, 3-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.

L11 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




● HCl

L11 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STN  
 ACCESSION NUMBER: 2004:282381 CAPLUS  
 DOCUMENT NUMBER: 141:1173  
 TITLE: Impact of Scoring Functions on Enrichment in Docking-Based Virtual Screening: An Application Study on Renin Inhibitors  
 AUTHOR(S): Krovat, Eva M.; Langer, Thierry  
 CORPORATE SOURCE: Institute of Pharmacy, Department of Pharmaceutical Chemistry, University of Innsbruck, Innsbruck, Austria  
 A-6020,  
 SOURCE: Journal of Chemical Information and Computer Sciences (2004), 44(3), 1123-1129  
 CODEN: JCISD8; ISSN: 0095-2338  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The docking program LigandFit/Cerius2 has been used to perform shape-based virtual screening of databases against the aspartic protease renin, a target of determined three-dimensional structure. The protein structure was used in the induced fit binding conformation that occurs when renin is bound to the highly active renin inhibitor (IC50 = 2 nM). The scoring was calculated using several different scoring functions to get insight into the predictability of the magnitude of binding interactions. A database of 1000 diverse and drug-like compds., comprised of 990 members of a virtual database generated by using the iLib diverse software and 10 known active renin inhibitors, was docked flexibly and scored to determine appropriate scoring functions. All seven scoring functions used (LigScore1, LigScore2, PLP1, PLP2, JAIN, PMF, LUDDI) were able to retrieve at least 50% of the active compds. within the first 20% (200 mols.) of the entire test database. A hit rate of 90% in the top 1.4% resulted using the quadruple consensus scoring of LigScore2, PLP1, PLP2, and JAIN. Addnl., a focused database was created with the iLib diverse software and used for the same procedure as the test database. Docking and scoring of the 990 focused compds. and the 10 known actives were performed. A hit rate of 100% in the top 8.4% resulted with use of the triple consensus scoring of PLP1, PLP2, and PMF. As expected, a ranking of the known active compds. within the focused database compared to the test database was observed. Adequate virtual screening conditions were derived empirically. They can be used for proximate docking and scoring application of compds. with putative renin inhibiting potency.  
 IT 304025-53-4 304025-56-7 304025-70-5  
 304025-71-6  
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Impact of scoring functions on enrichment in docking-based virtual screening in application study on renin inhibitors)  
 RN 304025-53-4 CAPLUS  
 CN Acetamide, N-[2-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-


L11 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)  
 quinolinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 304025-56-7 CAPLUS  
 CN 1(2H)-Quinolinepropanol, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 304025-70-5 CAPLUS  
 CN Methanesulfonamide, N-[2-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-quinolinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RN 304025-71-6 CAPLUS  
 CN Sulfamide, N-[2-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-quinolinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 26 THERE ARE 26 CAPLUS RECORDS THAT CITE THIS RECORD (26 CITINGS)  
 REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT


L11 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2009 ACS ON STN  
 ACCESSION NUMBER: 2004:20479 CAPLUS  
 DOCUMENT NUMBER: 140:82221  
 TITLE: Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant  
 INVENTOR(S): Riedl, Jutta; Kannah, Satish; Dieterle, Walter  
 PATENT ASSIGNEE(S): Speedel Pharma A.-G., Switz.  
 SOURCE: PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002466	A1	20040108	WO 2003-EP50266	20030625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MG, SD, SL, SG, TE, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 200325527	A1	20040119	AU 2003-25527	20030625
EP 1517682	A1	20050330	EP 2003-761592	20030625
EP 1517682	B1	20061102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 200553816	T	20051110	JP 2004-516786	20030625
AT 344026	T	20061115	AT 2003-761592	20030625
ES 2276110	T3	20070616	ES 2003-761592	20030625
US 20050147629	A1	20050707	US 2004-515817	20041126
PRIORITY APPLN. INFO.:			CH 2002-1124	A 20020628
			WO 2003-EP50266	W 20030625

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 AB Composition comprising (1) a non-peptide renin inhibitor which is poorly soluble to readily soluble in water and (2) at least one physiol. tolerated anionic surfactant, at least one physiol. tolerated amphoteric surfactant, at least one physiol. tolerated neutral surfactant, or a mixture of at least two of these surfactants, with the quantity of readily soluble renin inhibitor being at least 10% by weight, and the quantity of a poorly soluble renin inhibitor being at least 35% by weight, based on the composition  
 In oral administration forms, the composition exhibits increased bioavailability.  
 IT 188881-10-9 304025-53-4  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant)  
 RN 188881-10-9 CAPLUS  
 CN Quinoline, 1,2,3,4-tetrahydro-7-[[[(3R,4R)-4-[4-[3-[(2-


L11 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 304025-53-4 CAPLUS  
CN Acetamide, N-[2-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-quinolinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)  
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2002:754196 CAPLUS  
DOCUMENT NUMBER: 137:257677  
TITLE: Methods of treating or preventing Alzheimer's disease using 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes  
INVENTOR(S): Nieman, James A.; Fang, Lawrence; Jagodzinska, Barbara  
PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company  
SOURCE: PCT Int. Appl., 449 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076440	A2	20021003	WO 2002-US9100	20020321
WO 2002076440	A3	20021128		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SE, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002306848	A1	20021008	AU 2002-306848	20020321
US 20060079533	A1	20060413	US 2004-472868	20040202
PRIORITY APPLN. INFO.:			US 2001-278371P	P 20010323
			US 2001-308729P	P 20010730
			WO 2002-US9100	W 20020321

OTHER SOURCE(S): MARPAT 137:257677  
GI




AB Disclosed are methods for treating or preventing Alzheimer's disease, and

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
other diseases, and/or inhibiting  $\beta$ -secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, using 3,4-disubstituted piperidinyl compds. (I) wherein the variables R1, R2, R3, R4, Q, W, X, Z, m, and n are defined below. Although neither the compds. nor the methods of prepn. are claimed, .apprx.150 example prepn., translations from the German examples of patent WO 9709311, are included. I inhibit  $\beta$ -secretase with IC50 < 50  $\mu$ M; compds. that are effective inhibitors of  $\beta$ -secretase activity demonstrate reduced cleavage of the substrate as compared to a control. In I, R1 is aryl, heterocycle; R2 is Ph, naphthyl, acenaphthyl, cyclohexyl, pyridyl, pyrimidinyl, pyrazinyl, oxopyridinyl, diazinyl, triazolyl, thienyl, oxazolyl, oxadiazolyl, thiazolyl, pyrrolyl, or furyl, optionally substituted. R3 is: H, hydroxy, lower-alkoxy, or lower-alkenyloxy; R4 is: H, lower-alkyl, lower-alkenyl, lower-alkoxy, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, benzyl, oxo, or where R3 and R4 together are a bond, or as specified in the claims. Q is: ethylene, or is absent; X is: a bond, -O-, -S-, -CH-R11- (R11 defined in claims), -CHOR9- (R9 defined in claims), -OCO-, -CO-, or CHNOR10- (R10 is carboxyalkyl, alkoxy-carbonylalkyl, alkyl or H, with the bond emanating from an O or S atom joining to a satd. C atom of group Z or to R1; W is: -O-, or -S-; Z is: lower-alkylene, lower-alkenyloxy, hydroxy-lower-alkylidene, -O-, -S-, -O-Alk- (Alk is a lower alkylene), -S-Alk-, -Alk-O-, or -Alk-S. N is: 1, or 0 or 1 when X is -O-CO-, and where m is 0 or 1; with provisos. [This abstr. record is one of 2 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.]  
IT 188861-51-OP, Quinazoline, 2-[[[4-(4-fluorophenyl)-3-piperidinyl]oxy]methyl]-4-methoxy-, trans- 188861-52-1P, Piperidine, 3-(benzo[b]thien-5-ylmethoxy)-4-(4-fluorophenyl)-, trans- 188861-55-4P, Isoquinoline, 6-[[[4-(4-fluorophenyl)-3-piperidinyl]oxy]methyl]-, trans- 188862-32-OP, Piperidine, 3-[(2,3-dihydro-1,4-benzodioxin-6-yl)methoxy]-4-(4-fluorophenyl)-, trans- 188862-34-2P, Piperidine, 3-(5-benzofuran-ylmethoxy)-4-(4-fluorophenyl)-, trans- 188862-46-6P, Piperidine, 3-(1,3-benzodioxol-5-ylmethoxy)-4-(4-chlorophenyl)-, trans-, methanesulfonate 188862-58-OP, Quinoline, 2-[[[4-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, trans- 188862-60-4P, Piperidine, 3-(2-benzofuran-ylmethoxy)-4-(4-chlorophenyl)-, hydrochloride, trans- 188862-62-6P, Piperidine, 3-(benzo[b]thien-2-ylmethoxy)-4-(4-chlorophenyl)-, hydrochloride, trans- 188866-50-4P, 1-Butanone, 4-[4-[3-(benzo[b]thien-5-ylmethoxy)-4-piperidinyl]phenoxy]-1-phenyl-, trans- 188866-74-2P, Benzenemethanol,  $\alpha$ -[3-[4-[3-(benzo[b]thien-5-ylmethoxy)-4-piperidinyl]phenoxy]propyl]-, (3 $\alpha$ ,4 $\beta$ )-[partial]- 188870-64-6P, Piperidine, 3-[(2,3-dihydro-1,4-benzodioxin-6-yl)methoxy]-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-, trans- 188873-04-3P, Pyridine, 3-[[[4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, trans- 188873-06-5P, Piperidine, 3-(1,3-benzodioxol-5-ylmethoxy)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-, hydrobromide, trans- 188875-89-OP, Quinoline, 7-[[[3-(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- 188875-90-3P, Quinoline, 1,2,3,4-tetrahydro-7-[[[3-(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- 188875-91-4P, Quinolinium,

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
1-methyl-7-[[[4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, chloride, trans- 188875-92-5P, Quinoline, 1,2,3,4-tetrahydro-1-methyl-7-[[[4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, trans- 188875-93-6P, Isoquinoline, 6-[[[4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, trans- 188875-94-7P, Isoquinoline, 1,2,3,4-tetrahydro-6-[[[4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, trans- 188875-95-8P, Quinoline, 7-[[[3-(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- 188875-96-9P, 1H-Benzimidazole, 5-[[[4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, trans- 188875-97-OP, Quinoline, 7-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, 1-oxide, trans- 188875-98-1P, 2(1H)-Quinolinone, 7-[[[3-(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- 188875-99-2P, Isoquinoline, 7-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, trans- 188876-00-8P, Quinoline, 1,2,3,4-tetrahydro-7-[[[3-(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- 188876-01-9P, Quinoxaline, 6-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, trans- 188881-02-9P, Quinoline, 7-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, (3R-trans)- 188881-08-5P, 2(1H)-Quinolinone, 7-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, (3R-trans)- 188881-09-6P, Isoquinoline, 7-[[[4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, (3R-trans)- 188881-10-9P, Quinoline, 1,2,3,4-tetrahydro-7-[[[3-(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, R1: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(methods of treating or preventing Alzheimer's and other diseases using 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes)  
RN 188861-51-0 CAPLUS  
CN Quinazoline, 2-[[[3-(3R,4R)-4-(4-fluorophenyl)-3-piperidinyl]oxy]methyl]-4-methoxy-, rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 188861-52-1 CAPLUS  
 CN Piperidine, 3-(benzo[b]thien-5-ylmethoxy)-4-(4-fluorophenyl)-,  
 (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 188861-55-4 CAPLUS  
 CN Isoquinoline, 6-[[[(3R,4R)-4-(4-fluorophenyl)-3-piperidinyl]oxy]methyl]-,  
 rel- (CA INDEX NAME)

Relative stereochemistry.



L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




CM 2

CRN 75-75-2  
 CMP C H4 O3 S



RN 188862-58-0 CAPLUS  
 CN Quinoline, 2-[[[(3R,4R)-4-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-,  
 rel- (CA INDEX NAME)

Relative stereochemistry.




RN 188862-60-4 CAPLUS  
 CN Piperidine, 3-(2-benzofuranylmethoxy)-4-(4-chlorophenyl)-, hydrochloride  
 (1:1), (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 188862-32-0 CAPLUS  
 CN Piperidine, 3-[(2,3-dihydro-1,4-benzodioxin-6-yl)methoxy]-4-(4-fluorophenyl)-, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188862-34-2 CAPLUS  
 CN Piperidine, 3-(5-benzofuranylmethoxy)-4-(4-fluorophenyl)-, (3R,4R)-rel-  
 (CA INDEX NAME)

Relative stereochemistry.




RN 188862-46-6 CAPLUS  
 CN Piperidine, 3-(1,3-benzodioxol-5-ylmethoxy)-4-(4-chlorophenyl)-,  
 (3R,4R)-rel-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 188862-45-5  
 CMP C19 H20 Cl N O3

Relative stereochemistry.


L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HCl

RN 188862-62-6 CAPLUS  
 CN Piperidine, 3-(benzo[b]thien-2-ylmethoxy)-4-(4-chlorophenyl)-,  
 hydrochloride (1:1), (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 188866-50-4 CAPLUS  
 CN 1-Butanone, 4-[4-[(3R,4R)-3-(benzo[b]thien-5-ylmethoxy)-4-piperidinyl]phenoxy]-1-phenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 188866-74-2 CAPLUS  
 CN Benzenemethanol, α-[3-[4-[(3R,4R)-3-(benzo[b]thien-5-ylmethoxy)-4-piperidinyl]phenoxy]propyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188870-64-6 CAPLUS  
 CN Piperidine, 3-[(2,3-dihydro-1,4-benzodioxin-6-yl)methoxy]-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-, (3R,4R)-rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 188873-04-3 CAPLUS  
 CN Pyridine, 3-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188873-06-5 CAPLUS  
 CN Piperidine, 3-(1,3-benzodioxol-5-ylmethoxy)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-, hydrobromide (1:1), (3R,4R)-rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 188875-89-0 CAPLUS  
 CN Quinoline, 7-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188875-90-3 CAPLUS  
 CN Quinoline, 1,2,3,4-tetrahydro-1-methyl-7-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 188875-91-4 CAPLUS  
 CN Quinolinium, 1-methyl-7-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, chloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188875-92-5 CAPLUS  
 CN Quinoline, 1,2,3,4-tetrahydro-1-methyl-7-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 188875-93-6 CAPLUS  
 CN Isoquinoline, 6-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 188875-94-7 CAPLUS  
 CN Isoquinoline, 1,2,3,4-tetrahydro-6-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188875-95-8 CAPLUS  
 CN Quinoline,  
 7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 188875-96-9 CAPLUS  
 CN 1H-Benzimidazole, 6-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188875-97-0 CAPLUS  
 CN Quinoline,  
 7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, 1-oxide, rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 188875-98-1 CAPLUS  
 CN 2(1H)-Quinolinone, 7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188875-99-2 CAPLUS  
 CN Isoquinoline, 7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 188876-00-8 CAPLUS  
 CN Quinoline, 1,2,3,4-tetrahydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188876-01-9 CAPLUS  
 CN Quinoxaline, 6-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 188881-02-9 CAPLUS  
CN Quinoline, 7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 188881-08-5 CAPLUS  
CN 2-(1H)-Quinolinone, 7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




IT 188862-45-5P, Piperidine, 3-(1,3-benzodioxol-5-ylmethoxy)-4-(4-chlorophenyl)-, trans-188862-59-1P, Piperidine, 3-(2-benzofuranylmethoxy)-4-(4-chlorophenyl)-, trans-188862-61-5P, Piperidine, 3-(benzo[b]thien-2-ylmethoxy)-4-(4-chlorophenyl)-, trans-188862-65-9P, Pyridine, 3-[[[(3R,4R)-4-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, rel-  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(methods of treating or preventing Alzheimer's and other diseases)

using 4-aryl-3-arylalkoxypiperidines and -azabicyclooctanes)

RN 188862-45-5 CAPLUS  
CN Piperidine, 3-(1,3-benzodioxol-5-ylmethoxy)-4-(4-chlorophenyl)-, (3R,4R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188862-59-1 CAPLUS  
CN Piperidine, 3-(2-benzofuranylmethoxy)-4-(4-chlorophenyl)-, (3R,4R)-rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 188881-09-6 CAPLUS  
CN Isoquinoline, 7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 188881-10-9 CAPLUS  
CN Quinoline, 1,2,3,4-tetrahydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 188862-61-5 CAPLUS  
CN Piperidine, 3-(benzo[b]thien-2-ylmethoxy)-4-(4-chlorophenyl)-, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188862-65-9 CAPLUS  
CN Pyridine, 3-[[[(3R,4R)-4-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



IT 188862-66-0P, Pyridine, 3-[[[4-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, dihydrochloride, trans-  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(methods of treating or preventing Alzheimer's and other diseases)

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 4-aryl-3-alkoxypiperidines and -azabicyclooctanes)  
 RN 188862-66-0 CAPLUS  
 CN Pyridine, 3-[[[(3R,4R)-4-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl


OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)  
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L11 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:516926 CAPLUS  
 DOCUMENT NUMBER: 135:313388  
 TITLE: Piperidine renin inhibitors: from leads to drug candidates  
 AUTHOR(S): Marki, H. P.; Binggeli, A.; Bittner, B.; Bohner-Lang, V.; Breu, V.; Bur, D.; Coassolo, Ph.; Clozel, J. P.; D'Arcy, A.; Doebeli, H.; Fischli, W.; Funk, Ch.; Foricher, J.; Giller, T.; Gruninger, F.; Guenzi, A.; Guller, R.; Hartung, T.; Hirth, G.; Jenny, Ch.; Kansy, M.; Klinkhammer, U.; Lave, T.; Lohri, B.; Luft, F. C.; Mervaala, E. M.; Muller, D. N.; Muller, M.; Montavon, F.; Oefner, Ch.; Qiu, C.; Reichel, A.; Sanwald-Ducray, P.; Scalone, M.; Schleimer, M.; Schmid, R.; Stadler, H.; Treiber, A.; Valdenaire, O.; Vieira, E.; Waldmeier, P.; Wiegand-Chou, R.; Wilhelm, M.; Wostl, W.; Zell, M.; Zell, R.  
 CORPORATE SOURCE: Pharma Research, F. Hoffmann-La Roche Ltd, Basel, CH-4070, Switz.  
 SOURCE: Farmaco (2001), 56(1-2), 21-27  
 CODEN: FMCE8; ISSN: 0014-827X  
 PUBLISHER: Elsevier Science S.A.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Non-peptidomimetic renin inhibitors of the piperidine type represent a novel structural class of compds. potentially free of the drawbacks seen with peptidomimetic compds. so far. Synthetic optimization in two structural series focusing on improvement of potency, as well as on physicochem. properties and metabolic stability, has led to the identification of two candidate compds. Both display potent and long-lasting blood pressure lowering effects in conscious sodium-depleted marmoset monkeys and double transgenic rats harboring both the human angiotensinogen and the human renin genes. In addition, one of compds. normalizes albuminuria and kidney tissue damage in these rats when given over a period of 4 wk. These data suggest that treatment of chronic renal failure patients with a renin inhibitor might result in a significant improvement of the disease status.  
 IT 304025-53-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (piperidine renin inhibitors: from leads to drug candidates)  
 RN 304025-53-4 CAPLUS  
 CN Acetamide, N-[2-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-quinolinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 188881-10-9 304025-56-7 304025-57-8  
 304025-62-5 304025-63-6 304025-70-5  
 304025-71-6 304025-73-8  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (piperidine renin inhibitors: from leads to drug candidates)  
 RN 188881-10-9 CAPLUS  
 CN Quinoline, 1,2,3,4-tetrahydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 304025-56-7 CAPLUS  
 CN 1(2H)-Quinolinepropanol, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-57-8 CAPLUS  
 CN 1(2H)-Quinolineethanol, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 304025-62-5 CAPLUS  
 CN 1(2H)-Quinolinepropanamine, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-63-6 CAPLUS  
 CN Acetamide, N-[3-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-quinolinyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 304025-70-5 CAPLUS  
 CN Methanesulfonamide, N-[2-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-quinolinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




OS.CITING REF COUNT: 36 THERE ARE 36 CAPLUS RECORDS THAT CITE THIS RECORD (36 CITINGS)  
 REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L11 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-71-6 CAPLUS  
 CN Sulfamide, N-[2-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-quinolinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 304025-73-8 CAPLUS  
 CN Urea, N-[2-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-quinolinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:772621 CAPLUS  
 DOCUMENT NUMBER: 133:335166  
 TITLE: 7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinoline  
 derivatives useful as renin inhibitors  
 INVENTOR(S): Brev, Volker; Bur, Daniel; Maerki, Hans-Peter; Vieira,  
 Eric; Westl, Wolfgang  
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.  
 SOURCE: PCT Int. Appl., 53 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064887	A1	20001102	WO 2000-EP3597	20000420
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6197959	B1	20010306	US 2000-542598	20000404
CA 2370244	A1	20001102	CA 2000-2370244	20000420
CA 2370244	C	20070327		
AU 2000047501	A	20001110	AU 2000-47501	20000420
AU 761392	B2	20030605		
BR 2000010076	A	20020115	BR 2000-10076	20000420
EP 1180103	A1	20020220	EP 2000-929401	20000420
EP 1180103	B1	20070530		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY			
TR 200103067	T2	20020521	TR 2001-3067	20000420
HU 2002000881	A2	20020828	HU 2002-881	20000420
HU 2002000881	A3	20030528		
JP 2002543072	T	20021217	JP 2000-614239	20000420
JP 3602449	B2	20041215		
AT 363478	T	20070615	AT 2000-929401	20000420
CN 1323079	C	20070627	CN 2000-806798	20000420
ES 2286021	T3	20071201	ES 2000-929401	20000420
ZA 2001008739	A	20030123	ZA 2001-8739	20011023
MX 2001010855	A	20020506	MX 2001-10855	20011025
PRIORITY APPLN. INFO.:			EP 1999-108200	A 19990427
			WO 2000-EP3597	W 20000420

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): MARPAT 133:335166  
 GI

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



AB The invention relates to title compds. I [R1 = (CH2)2-4NR3R4, (CH2)2-4OR3, (CH2)1-2R5, (CH2)1-3R6; R2 = cycloalkylalkyl, CH2CF3, (un)substituted Ph or CH2Ph (substituents = 1-3 halo, cyano, alkoxy, or NO2); R3 = H or alkyl; R4 = H, alkyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, alkylaminocarbonyl, alkylcarbamoyl, COCF3, SO2CF3, aminocarbonyl; R5 = alkoxy, carbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, or cyano; R6 = imidazolyl or triazolyl, with the proviso that (CH2)2-3 bears them when they are bound at N] and pharmaceutically acceptable salts thereof. The compds. are useful for the treatment of diseases which are associated with renin, e.g., restenosis, glaucoma, cardiac infarct, high blood pressure, and end organ damage, e.g., cardiac and kidney insufficiency. Examples include 24 syntheses of I and a bioassay of selected compds. For instance, (3R,4R)-3-hydroxy-4-(4-hydroxyphenyl)piperidine-1-carboxylic acid tert-Bu ester underwent a sequence of: (1) etherification with 1-[(3-chloropropoxy)methyl]-2-methoxybenzene, (2) a 2nd etherification with 1,2,3,4-tetrahydroquinolin-1-yl]propyl]methylamine HBr, (3) partial reduction of the quinoline ring using NiCl2 and NaBH4, (4) N-alkylation of the quinoline ring with N-(2-chloroethyl)acetamide, and (5) deprotection with ZnBr2, to give title compound II. This compound inhibited human renin in vitro with IC50 of 0.05 nM, and other compds. I gave 0.02-0.09 nM.

IT 304025-53-4P, (3R,4R)-N-[2-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]ethyl]acetamide 304025-54-5P, (3R,4R)-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]acetic acid ethyl ester 304025-55-6P, (3R,4R)-2-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]acetamide 304025-56-7P,

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


(3R,4R)-7-[[[4-[4-[3-(Cyclopropylmethoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-1,2,3,4-tetrahydroquinoline 304025-76-1P, (3R,4R)-3-[[1-(3-Methoxypropyl)-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]-4-[4-[3-(2,2,2-trifluoroethoxy)propoxy]phenyl]piperidine 304025-77-2P, (3R,4R)-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]acetic acid ethyl ester 304025-78-3P, (3R,4R)-2-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]acetamide 304025-79-4P, (3R,4R)-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]acetic acid methyl ester 304025-80-7P, (3R,4R)-3-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]propionic acid methyl ester 304025-81-8P, (3R,4R)-N-[3-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]propyl]methylamine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate, prep. of [(piperidinyl)oxy]methyl]tetrahydroquinoline derivs. useful as renin inhibitors)

RN 304025-53-4 CAPLUS

CN Acetamide, N-[2-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-quinolinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 304025-54-5 CAPLUS

CN 1(2H)-Quinolineacetic acid, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

(3R,4R)-3-[[[1-(3-Hydroxypropyl)-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine 304025-57-8P, (3R,4R)-2-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]ethanol 304025-58-9P, (3R,4R)-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]acetic acid methyl ester 304025-59-0P, (3R,4R)-3-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]propionic acid methyl ester 304025-60-3P, (3R,4R)-[3-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]propyl]methylamine 304025-61-4P,


(3R,4R)-N-[2-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]ethyl]methylamine 304025-62-5P, (3R,4R)-3-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]propylamine 304025-63-6P,

(3R,4R)-N-[3-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]propyl]acetamide 304025-64-7P, (3R,4R)-4-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]butylamine 304025-65-8P, (3R,4R)-1-(2-Imidazol-1-ylethyl)-7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinoline 304025-66-9P, (3R,4R)-4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]-3-[[[1-(3-Methoxypropyl)-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine 304025-67-0P, (3R,4R)-2-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]ethylamine 304025-68-1P, (3R,4R)-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]ethyl]dimethylamine 304025-69-2P, (3R,4R)-7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(2-methoxyethyl)-1,2,3,4-tetrahydroquinoline 304025-70-5P,

(3R,4R)-3-[[[1-(2-(Methanesulfonyl)amino)ethyl]-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine 304025-71-6P, (3R,4R)-N-[2-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]ethyl]sulfamide 304025-72-7P,

(3R,4R)-[2-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]ethyl]dimethylamine 304025-73-8P, (3R,4R)-N-[2-[7-[[[4-[4-[3-[(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]ethyl]urea 304025-74-9P, (3R,4R)-2,2,2-Trifluoro-N-[2-[7-[[[4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,2,3,4-tetrahydroquinolin-1-yl]ethyl]acetamide 304025-75-0P,


L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-55-6 CAPLUS

CN 1(2H)-Quinolineacetamide, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 304025-56-7 CAPLUS

CN 1(2H)-Quinolinepropanol, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-57-8 CAPLUS  
 CN 1(2H)-Quinolinetriethanol, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 304025-58-9 CAPLUS  
 CN 1(2H)-Quinolinetriethanol, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-59-0 CAPLUS  
 CN 1(2H)-Quinolinetriethanol, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 304025-60-3 CAPLUS  
 CN 1(2H)-Quinolinetriethanol, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-N-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-61-4 CAPLUS  
 CN 1(2H)-Quinolinetriethanol, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-N-methyl-, (CA INDEX NAME)


Absolute stereochemistry.



RN 304025-62-5 CAPLUS  
 CN 1(2H)-Quinolinetriethanol, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-63-6 CAPLUS  
 CN Acetamide, N-[3-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-quinolinyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 304025-64-7 CAPLUS  
 CN 1(2H)-Quinolinetriethanol, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-65-8 CAPLUS  
 CN Quinoline,  
 1,2,3,4-tetrahydro-1-[2-(1H-imidazol-1-yl)ethyl]-7-[[[(3R,4R)-4-  
 [4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 304025-66-9 CAPLUS  
 CN Quinoline,  
 1,2,3,4-tetrahydro-7-[[[(3R,4R)-4-[4-[3-[(2-  
 methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1-(3-  
 methoxypropyl)- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-69-2 CAPLUS  
 CN Quinoline,  
 1,2,3,4-tetrahydro-1-(2-methoxyethyl)-7-[[[(3R,4R)-4-[4-[3-[(2-  
 methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 304025-70-5 CAPLUS  
 CN Methanesulfonamide, N-[2-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-  
 methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-  
 quinolinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-67-0 CAPLUS  
 CN 1(2H)-Quinolinetanamine, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-  
 methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 304025-68-1 CAPLUS  
 CN 1(2H)-Quinolinetanamine, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-  
 methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA  
 INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-71-6 CAPLUS  
 CN Sulfamide, N-[2-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-  
 methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-  
 quinolinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 304025-72-7 CAPLUS  
 CN 1(2H)-Quinolinetanamine, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-  
 methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-N,N-  
 dimethyl- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-73-8 CAPLUS  
 CN Urea, N-[2-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-quinolinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 304025-74-9 CAPLUS  
 CN Acetamide, N-[2-[3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1(2H)-quinolinyl]ethyl]-2,2,2-trifluoro- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-77-2 CAPLUS  
 CN 1(2H)-Quinolineacetic acid, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 304025-78-3 CAPLUS  
 CN 1(2H)-Quinolineacetamide, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-75-0 CAPLUS  
 CN Quinoline, 7-[[[(3R,4R)-4-[4-[3-(cyclopropylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1,2,3,4-tetrahydro-1-(3-methoxypropyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 304025-76-1 CAPLUS  
 CN Quinoline, 1,2,3,4-tetrahydro-1-(3-methoxypropyl)-7-[[[(3R,4R)-4-[4-[3-(2,2,2-trifluoroethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-79-4 CAPLUS  
 CN 1(2H)-Quinolineacetic acid, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 304025-80-7 CAPLUS  
 CN 1(2H)-Quinolinepropanoic acid, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 304025-81-8 CAPLUS  
 CN 1(2H)-Quinolonepropanamine, 3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)  
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD  
 FORMAT

L11 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2000:116775 CAPLUS  
 DOCUMENT NUMBER: 132:151684  
 TITLE: Preparation of chiral substituted 3-hydroxypiperidines

INVENTOR(S): by hydroboration of 1,2,3,6-tetrahydropyridines  
 Lohri, Bruno; Schmid, Rudolf; Vieira, Eric  
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.; Speedel Pharma AG  
 SOURCE: Eur. Pat. Appl., 24 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 979819	A1	20000216	EP 1999-115243	19990802
EP 979819	B1	20080423		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
US 6274735	B1	20010814	US 1999-345917	19990701
AT 393144	T	20080515	AT 1999-115243	19990802
ES 2306493	T3	20081101	ES 1999-115243	19990802
CA 2279779	A1	20000210	CA 1999-2279779	19990806
CA 2279779	C	20050315		
JP 2000063355	A	20000229	JP 1999-224744	19990809
JP 3366289	B2	20030114		
CN 1245800	A	20000301	CN 1999-117531	19990809
CN 1161335	C	20040811		
KR 2000017192	A	20000325	KR 1999-32561	19990809
MX 9907329	A	20000930	MX 1999-7329	19990809
PRIORITY APPLN. INFO.:			EP 1998-114974	A 19980810
			EP 1999-115243	A 19990802

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): CASREACT 132:151684; MARPAT 132:151684  
 GI




AB Title compds. (I; A = arylene; R1 = C\*R3R4R5; R2 = alkoxy, cycloalkoxy, alkenyloxy, aryloxy, aralkoxy, aralkoxyalkoxy, alkylsulfonyloxy, arylsulfonyloxy, Cl, Br, iodo; R3 = H; R4 = aryl; R5 = alkyl, cycloalkyl, aryl, alkoxyalkyl, hydroxyalkyl; C\* = asym. C atom), were prepared by

L11 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 hydroboration of 1,2,3,6-tetrahydropyridines (II; variables as above).  
 Thus, (R)-4-(4-benzoyloxyphenyl)-1-(1-phenylethyl)-1,2,3,6-tetrahydropyridine (prepn. given) in dimethoxyethane was treated with NaBH4 and then with BF3.Et2O at 0-5° to give (3R,4R)-4-(4-benzoyloxyphenyl)-1-[(R)-1-phenylethyl]piperidin-3-ol.

IT 188881-10-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of chiral substituted 3-hydroxypiperidines by hydroboration of 1,2,3,6-tetrahydropyridines)

RN 188881-10-9 CAPLUS  
 CN Quinolone, 1,2,3,4-tetrahydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD  
 FORMAT

L11 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1999:348250 CAPLUS  
 DOCUMENT NUMBER: 131:124935  
 TITLE: Piperidine-renin inhibitors compounds with improved physicochemical properties

AUTHOR(S): Guller, Rolf; Bingsfeld, Alfred; Breu, Volker; Bur, Daniel; Fischli, Walter; Hirth, Georges; Jenny, Christian; Kansy, Manfred; Montavon, Francois;  
 Muller, Marcel; Oefner, Christian; Stadler, Heinz; Vieira, Eric; Wilhelm, Maurice; Wostl, Wolfgang; Marki, Hans Peter

CORPORATE SOURCE: Chemspeed Ltd., Augst, CH-4302, Switz.  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(10), 1403-1408  
 CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Piperidine renin inhibitors with heterocyclic core modifications or hydrophilic attachments show improved phys. properties (lower lipophilicity, improved solubility). Tetrahydroquinoline derivative with a mol.

weight of 517 and a log D(pH 7.4) of 1.9 displays potent and long lasting blood pressure lowering effects after oral administration to sodium depleted conscious marmosets.


IT 188875-89-0P 188875-90-3P 188875-95-8P  
 188875-98-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of piperidine-renin inhibitors compds. with improved physicochem. properties)

RN 188875-89-0 CAPLUS  
 CN Quinolone, 7-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188875-90-3 CAPLUS  
 CN Quinolone, 1,2,3,4-tetrahydro-7-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


L11 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 188875-95-8 CAPLUS  
CN Quinoline,  
7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-  
3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188875-98-1 CAPLUS  
CN 2(1H)-Quinolinone, 7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.


L11 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 188876-00-8P  
RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(preparation of piperidine-renin inhibitors compds. with improved  
physicochem. properties)

RN 188876-00-8 CAPLUS  
CN Quinoline, 1,2,3,4-tetrahydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 55 THERE ARE 55 CAPLUS RECORDS THAT CITE THIS  
RECORD (55 CITINGS)  
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR  
THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L11 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:191411 CAPLUS  
DOCUMENT NUMBER: 130:242312  
TITLE: Pharmaceutical preparations containing piperidine derivatives as antimalarials  
INVENTOR(S): Bur, Daniel; Fischli, Walter; Matile, Hugues; Ridley, Robert George; Mostl, Wolfgang  
PATENT ASSIGNEE(S): F.Hoffmann-La Roche A.-G., Switz.  
SOURCE: PCT Int. Appl., 48 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912532	A2	19990318	WO 1998-EP5570	19980902
WO 9912532	A3	19990729		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9897409	A	19990329	AU 1998-97409	19980902
PRIORITY APPLN. INFO.:			EP 1997-115510	A 19970908
			WO 1998-EP5570	W 19980902

AB Pharmaceutical prepn. containing piperidine derivs. are used against chloroquine-sensitive and chloroquine-resistant pathogens and in the production of corresponding medicaments; furthermore corresponding medicaments


and a method of treating malaria in a patient in need of such treatment comprises administering to said patient an effective amount of a corresponding compound or medicament. The IC50 of (3R,4R)-3-(naphthalen-2-ylmethoxy)-4-[4-(2-phenoxy-ethoxy)-phenyl]-piperidine (I) against chloroquine-resistant strains of Plasmodium falciparum was 0.6 nM. A tablet contained 1500, lactose 149, PVP 15, dioctyl sodium sulfosuccinate 1, sodium carboxymethyl starch 30, and magnesium stearate 5 mg.

IT 188862-65-9 221303-98-6  
RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);  
USES  
(Uses)  
(pharmaceutical prepn. containing piperidine derivs. as antimalarials)

RN 188862-65-9 CAPLUS  
CN Pyridine, 3-[[[(3R,4R)-4-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 221303-98-6 CAPLUS  
CN Isoquinoline, 1,2,3,4-tetrahydro-2-methyl-6-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS  
RECORD (10 CITINGS)  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1997:307688 CAPLUS  
 DOCUMENT NUMBER: 126:277402  
 ORIGINAL REFERENCE NO.: 126:53775a,53778a  
 TITLE: New 4-aryl-3-aralkoxypiperidines and  
 -azabicyclooctanes  
 INVENTOR(S): for treating heart and kidney insufficiency  
 Binggeli, Alfred; Breu, Volker; Bur, Daniel; Fischli,  
 Walter; Gueller, Rolf; Hirth, Georges; Maerki,  
 Hans-Peter; Mueller, Marcel; Oefner, Christian;  
 Stadler, Heinz; Vieira, Eric; Wilhelm, Maurice;  
 Westl, Wolfgang  
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.  
 SOURCE: PCT Int. Appl., 492 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9709311	A1	19970313	WO 1996-EP3803	19960829
W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, TR				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE IN 1996MA01426	A	20050304	IN 1996-MA1426	19960813
CA 2230931	A1	19970313	CA 1996-2230931	19960829
CA 2230931	C	20090519		
AU 9667432	A	19970327	AU 1996-67432	19960829
AU 708616	B2	19990805		
EP 863875	A1	19980916	EP 1996-927715	19960829
EP 863875	B1	20030604		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, FI				
CN 1202152	A	19981216	CN 1996-197674	19960829
CN 1256326	C	20060517		
JP 11500447	T	19990112	JP 1997-510837	19960829
JP 3648251	B2	20050518		
BR 9610385	A	19990706	BR 1996-10385	19960829
HU 9900926	A2	19990928	HU 1999-926	19960829
HU 9900926	A3	20021228		
NZ 315677	A	20000228	NZ 1996-315677	19960829
RU 2167865	C2	20010527	RU 1998-106388	19960829
AT 242213	T	20030615	AT 1996-927715	19960829
IL 123293	A	20030624	IL 1996-123293	19960829
CZ 292327	B6	20030917	CZ 1998-684	19960829
ES 2201192	T3	20040316	ES 1996-927715	19960829
PL 193686	B1	20070330	PL 1996-325425	19960829
ZA 9607424	A	19970307	ZA 1996-7424	19960902
TW 474932	B	20020201	TW 1996-85110684	19960902
NO 9800954	A	19980428	NO 1998-954	19980305
NO 310069	B1	20010514		
US 6051712	A	20000418	US 1999-255185	19990222


L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 HK 1016177 A1 20060901 HK 1999-101299 19990330  
 US 6150526 A 20001121 US 1999-456283 19991207  
 PRIORITY APPLN. INFO.: CH 1995-2548 A 19950907  
 CH 1996-1876 A 19960726  
 WO 1996-EP3803 W 19960829  
 US 1996-711339 A3 19960906  
 US 1999-255185 A1 19990222

OTHER SOURCE(S): MARPAT 126:277402  
 GI




AB New piperidine and azabicyclooctane derivs. (> 1000 compds.) are renin inhibitors for treatment of high blood pressure, heart and kidney insufficiency. Thus, the piperidine derivative I was prepared from 1-benzyl-3-propyl-4-piperidinone by reaction with 4-FC6H4Br, followed by 1-benzyl-3-chloromethylnaphthalene and deblocking. I had a renin-inhibiting IC50 of 0.317 μM.  
 IT 188875-95-8P 188875-98-1P 188875-99-2P  
 188876-00-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of piperidine and azabicyclooctane derivs. as renin inhibitors)  
 RN 188875-95-8 CAPLUS  
 CN Quinoline,  
 7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)  
 Relative stereochemistry.

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 188875-98-1 CAPLUS  
 CN 2(1H)-Quinolinone, 7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188875-99-2 CAPLUS  
 CN Isoquinoline, 7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 188876-00-8 CAPLUS  
 CN Quinoline, 1,2,3,4-tetrahydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



IT 188862-45-5P 188862-59-1P 188862-61-5P  
 188862-65-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of piperidine and azabicyclooctane derivs. as renin inhibitors)  
 RN 188862-45-5 CAPLUS  
 CN Piperidine, 3-(1,3-benzodioxol-5-ylmethoxy)-4-(4-chlorophenyl)-, (3R,4R)-rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 188862-59-1 CAPLUS  
 CN Piperidine, 3-(2-benzofuranylmethoxy)-4-(4-chlorophenyl)-, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188862-61-5 CAPLUS  
 CN Piperidine, 3-(benzo[b]thien-2-ylmethoxy)-4-(4-chlorophenyl)-, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 188862-65-9 CAPLUS  
 CN Pyridine, 3-[[[(3R,4R)-4-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 study); PREP (Preparation); USES (Uses)  
 (prepn. of piperidine and azabicyclooctane derivs. as renin


inhibitors)  
 RN 188861-51-0 CAPLUS  
 CN Quinoxaline, 2-[[[(3R,4R)-4-(4-fluorophenyl)-3-piperidinyl]oxy]methyl]-4-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188861-52-1 CAPLUS  
 CN Piperidine, 3-(benzo[b]thien-5-ylmethoxy)-4-(4-fluorophenyl)-, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 188861-55-4 CAPLUS  
 CN Isoquinoline, 6-[[[(3R,4R)-4-(4-fluorophenyl)-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 (CA INDEX NAME)


Relative stereochemistry.



IT 188862-66-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of piperidine and azabicyclooctane derivs. as renin inhibitors)

RN 188862-66-0 CAPLUS  
 CN Pyridine, 3-[[[(3R,4R)-4-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

IT	188861-51-0P	188861-52-1P	188861-55-4P
	188862-32-0P	188862-34-2P	188862-46-6P
	188862-58-0P	188862-60-4P	188862-62-6P
	188866-50-4P	188866-74-2P	188870-64-6P
	188873-04-3P	188873-06-5P	188875-89-0P
	188875-90-3P	188875-91-4P	188875-92-5P
	188875-93-6P	188875-94-7P	188875-96-9P
	188875-97-0P	188876-01-9P	188881-02-9P
	188881-08-5P	188881-09-6P	188881-10-9P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 188862-32-0 CAPLUS  
 CN Piperidine, 3-[(2,3-dihydro-1,4-benzodioxin-6-yl)methoxy]-4-(4-fluorophenyl)-, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188862-34-2 CAPLUS  
 CN Piperidine, 3-(5-benzofuranylmethoxy)-4-(4-fluorophenyl)-, (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 188862-46-6 CAPLUS  
 CN Piperidine, 3-(1,3-benzodioxol-5-ylmethoxy)-4-(4-chlorophenyl)-, (3R,4R)-rel-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 CRN 188862-45-5  
 CMF C19 H20 Cl N O3

Relative stereochemistry.




CM 2

CRN 75-75-2  
 CMF C H4 O3 S



RN 188862-58-0 CAPLUS  
 CN Quinoline, 2-[[[(3R,4R)-4-(4-chlorophenyl)-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188862-60-4 CAPLUS  
 CN Piperidine, 3-(2-benzofuranylmethoxy)-4-(4-chlorophenyl)-, hydrochloride (1:1), (3R,4R)-rel- (CA INDEX NAME)

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


Relative stereochemistry.



● HCl

RN 188862-62-6 CAPLUS  
 CN Piperidine, 3-(benzo[b]thien-2-ylmethoxy)-4-(4-chlorophenyl)-, hydrochloride (1:1), (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 188866-50-4 CAPLUS  
 CN 1-Butanone, 4-[[[(3R,4R)-3-(benzo[b]thien-5-ylmethoxy)-4-piperidinyl]phenoxy]-1-phenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 188866-74-2 CAPLUS  
 CN Benzenemethanol, α-[3-[4-[(3R,4R)-3-(benzo[b]thien-5-ylmethoxy)-4-piperidinyl]phenoxy]propyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188870-64-6 CAPLUS  
 CN Piperidine, 3-[(2,3-dihydro-1,4-benzodioxin-6-yl)methoxy]-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-, (3R,4R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188873-04-3 CAPLUS  
 CN Pyridine, 3-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-


L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 188873-06-5 CAPLUS  
 CN Piperidine, 3-(1,3-benzodioxol-5-ylmethoxy)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-, hydrobromide (1:1), (3R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.




● HBr

RN 188875-89-0 CAPLUS  
 CN Quinoline, 7-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 188875-90-3 CAPLUS  
 CN Quinoline, 1,2,3,4-tetrahydro-7-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188875-91-4 CAPLUS  
 CN Quinolinium, 1-methyl-7-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, chloride (1:1), rel- (CA INDEX NAME)


Relative stereochemistry.

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 188875-94-7 CAPLUS  
 CN Isoquinoline, 1,2,3,4-tetrahydro-6-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 188875-96-9 CAPLUS  
 CN 1H-Benzimidazole, 6-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188875-97-0 CAPLUS  
 CN Quinoline, 7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, 1-oxide, rel- (CA INDEX NAME)


Habt

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

● Cl<sup>-</sup>

RN 188875-92-5 CAPLUS  
 CN Quinoline, 1,2,3,4-tetrahydro-1-methyl-7-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 188875-93-6 CAPLUS  
 CN Isoquinoline, 6-[[[(3R,4R)-4-[4-[3-(phenylmethoxy)propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.


L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Relative stereochemistry.



RN 188876-01-9 CAPLUS  
 CN Quinoxaline, 6-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 188881-02-9 CAPLUS  
 CN Quinoline, 7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-, rel- (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 188881-08-5 CAPLUS  
 CN 2-((1H)-Quinolone, 7-[[[(3R,4R)-4-[[4-[[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1-methylpiperidine]]-1-methylpiperidine (CA INDEX NAME)


Absolute stereochemistry.



RN 188881-09-6 CAPLUS  
 CN Isoquinoline, 7-[[[(3R,4R)-4-[[4-[[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1-methylpiperidine]]-1-methylpiperidine (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 188881-10-9 CAPLUS  
 CN Quinolone, 1,2,3,4-tetrahydro-7-[[[(3R,4R)-4-[[4-[[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-1-methylpiperidine]]-1-methylpiperidine (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 45 THERE ARE 45 CAPLUS RECORDS THAT CITE THIS RECORD (50 CITINGS)  
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L11 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1986:618899 CAPLUS  
 DOCUMENT NUMBER: 105:218899  
 ORIGINAL REFERENCE NO.: 105:35162a  
 TITLE: Paroxetine for obesity therapy  
 PATENT ASSIGNEE(S): Aktiselskabet Ferrosan, Den.  
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61148121	A	19860705	JP 1985-271727	19851204
JP 05086763	B	19931214		
EP 188081	A2	19860723	EP 1985-308753	19851202
EP 188081	A3	19891011		
EP 188081	B1	19920311		
R: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
DK 8505625	A	19860605	DK 1985-5625	19851204
DK 158770	B	19900716		
DK 158770	C	19910107		
AU 8550749	A	19860612	AU 1985-50749	19851204
AU 580820	B2	19890202		
ZA 8509286	A	19861126	ZA 1985-9286	19851204
US 4745122	A	19880517	US 1985-804810	19851204
PRIORITY APPLN. INFO.:			GB 1984-30581	A 19841204

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Paroxetine or its salts at nontoxic levels are effective in treating obesity. Thus, group A rats were given Oxoid pellet diets only and group B rats were given Oxoid pellet diets in combination with paroxetine-HCl (50 mg/kg/day orally) at 11:00-13:00. The average body weight changed from 131 to 225 g on day 23 in group A and from 132 to 181 g in group B.  
 IT 105496-45-5  
 RL: BIOL (Biological study)  
 (obesity therapy with)  
 RN 105496-45-5 CAPLUS  
 CN Piperidine, 3-((1,3-benzodioxol-5-ylmethoxy)-4-(4-fluorophenyl)-, hydrobromide, trans-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

L11 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● HBr

OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

=> d sca 110



L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN  
 CC 27-16 (Heterocyclic Compounds (One Hetero Atom))  
 Section cross-reference(s): 1  
 TI Preparation of 4-(4-piperidinyl)phenols and related compounds as aspartic  
 protease inhibitors  
 ST piperidinylphenol prepn aspartic protease inhibition cathepsin D  
 IT Anti-AIDS agents  
 Anti-Alzheimer's agents  
 Antimalarials  
 Human  
 (preparation of 4-(4-piperidinyl)phenols and related compds. as  
 aspartic protease inhibitors)  
 IT AIDS (disease)  
 Alzheimer's disease  
 Malaria  
 (treatment of; preparation of 4-(4-piperidinyl)phenols and related  
 compds. as aspartic protease inhibitors)  
 IT 9025-26-7, Cathepsin D 78169-47-8, Aspartic protease 144114-21-6, Hiv  
 protease 158736-49-3,  $\beta$ -Secretase 159447-18-4, Plasmepsin II  
 R1: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibition of; preparation of 4-(4-piperidinyl)phenols and related  
 compds. as aspartic protease inhibitors)  
 IT 857271-92-2 857272-00-5 857272-04-9 857272-10-7  
 857272-11-8 857272-18-5 857272-24-3 857272-28-7  
 857272-32-3 857272-42-5 857272-44-7  
 857272-49-2 857272-55-0 857272-60-7  
 857272-66-3 857272-69-6 857272-75-4  
 857272-77-6 857272-82-3 857272-86-7  
 857272-89-0 857272-95-8 857272-99-2  
 857273-03-1 857273-07-5 857273-10-0 857273-11-1 857273-15-5  
 857273-17-7 857273-24-6 857273-26-8 857273-31-5  
 857273-35-9 857273-39-3 857273-43-9 857273-48-4 857273-53-1  
 857273-55-3 857273-57-5 857273-59-7 857273-61-1  
 857273-64-4 857273-73-5 857273-78-0  
 857273-80-4 857273-81-5 857273-82-6 857273-84-8  
 857273-86-0 857273-89-3 857273-92-8  
 857273-95-1 857273-99-5 857274-03-4 857274-07-8  
 857274-13-6 857274-14-7 857274-16-9 857274-18-1  
 857274-21-6 857274-29-4 857274-31-8 857274-32-9  
 857274-34-1 857274-36-3 857274-39-6 857274-43-2 857274-45-4  
 857274-47-6 857274-49-8 857274-51-2 857274-53-4  
 857274-57-8 857274-61-4 857274-63-6 857274-65-8  
 857274-70-5 857274-72-7 857274-74-9 857274-76-1  
 857274-78-3 857274-80-7 857274-82-9 857274-84-1  
 857274-86-3 857274-88-5 857274-90-9  
 857274-92-1 857274-95-4 857274-98-7  
 857275-00-4 857275-12-8 857275-14-0 857275-16-2  
 857275-22-0 857275-29-7 857275-31-1  
 857275-34-4 857275-35-5 857275-39-9 857275-42-4  
 857275-45-7 857275-51-5 857275-56-0 857275-58-2 857275-62-8  
 857275-66-2 857275-70-8 857275-73-1 857275-77-5 857275-80-0  
 857275-84-4 857275-88-8 857275-93-5 857275-95-7 857276-00-7

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 857276-10-9 857276-13-2 857276-17-6 857276-24-5  
 857276-29-0 857276-31-4 857276-35-8 857276-37-0  
 857276-42-7 857276-44-9 857276-52-9 857276-56-3 857276-62-1  
 857276-67-6 857276-69-8 857276-71-2 857276-73-4  
 857276-76-7 857276-80-3 857276-84-7  
 857276-88-1 857276-93-8 857276-97-2  
 857277-01-1 857277-05-5 857277-09-9  
 857277-14-6 857277-20-4 857277-23-7  
 857277-29-3 857277-33-9 857277-34-0 857277-38-4  
 857277-42-0 857277-46-4 857277-50-0  
 857277-54-4 857277-59-9 857277-63-5  
 857277-68-0 857277-73-7 857277-78-2  
 857277-82-8 857277-87-3 857277-95-3  
 857277-98-6 857277-99-7 857278-00-3  
 857278-01-4 857278-02-5 857278-03-6  
 857278-04-7 857278-05-8 857278-07-0 857278-09-2  
 857278-11-6 857278-13-8 857278-15-0 857278-18-3 857278-19-4  
 857278-20-7 857278-21-8 857278-27-4  
 857278-41-2 857278-42-3 857278-48-9  
 857278-49-0 857278-53-6 857278-54-7  
 857278-55-8 857278-56-9 857278-62-7  
 857278-63-8 857278-64-9 857278-65-0  
 857278-66-1 857278-67-2 857278-68-3  
 857278-69-4 857278-70-7 857278-71-8  
 857278-72-9 857278-73-0 857278-74-1  
 857278-75-2 857278-76-3 857278-77-4  
 857278-78-5 857278-79-6 857278-80-9  
 857278-81-0 857278-82-1 857278-83-2  
 857278-84-3 857278-91-2 857278-92-3  
 857278-99-0 857279-01-7 857279-02-8  
 857279-03-9 857279-04-0 857279-12-0 857279-13-1  
 857279-14-2 857279-15-3 857279-16-4 857279-26-6  
 857279-31-3 857279-35-7 857279-36-8  
 857279-37-9 857279-38-0 857279-45-9  
 857279-53-9 857279-54-0 857279-55-1  
 857279-56-2 857279-62-0 857279-64-2 857279-69-7  
 R1: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (prepn. of 4-(4-piperidinyl)phenols and related compds. as aspartic  
 protease inhibitors)  
 IT 857279-74-4 857279-76-6 857279-80-2  
 857279-82-4 857279-88-0 857279-91-5  
 857279-92-6 857279-93-7 857279-95-9  
 857279-96-0 857280-02-5 857280-07-0  
 857280-08-1 857280-13-8 857280-19-4  
 857280-22-9 857280-24-1 857280-25-2  
 857280-26-3 857280-27-4 857280-28-5  
 857280-29-6 857280-30-9 857280-31-0  
 857280-32-1 857280-33-2 857280-34-3  
 857280-35-4 857280-38-7 857280-42-3  
 857280-45-6 857280-46-7 857280-50-3  
 857280-54-7 857280-56-9 857280-61-6  
 857280-68-3 857280-69-4 857280-70-7  
 857280-73-0 857280-75-2 857280-78-5

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 857280-81-0 857280-82-1 857280-83-2  
 857280-84-3 857280-86-5 857280-87-6  
 857280-88-7 857280-89-8 857280-90-1  
 857280-91-2 857280-92-3 857280-93-4  
 857280-94-5 857280-95-6 857280-96-7  
 857281-00-6 857281-03-9 857281-04-0  
 857281-08-4 857281-10-8 857281-11-9  
 857281-12-0 857281-13-1 857281-14-2  
 857281-20-0 857281-21-1 857281-28-8  
 857281-30-2 857281-31-3 857281-33-5  
 857281-34-6 857281-35-7 857281-37-9  
 857281-38-0 857281-39-1 857281-41-5  
 857281-51-7 857281-53-9 857281-54-0  
 857281-55-1 857281-56-2 857281-57-3  
 857281-61-9 857281-64-2 857281-66-4  
 857281-69-7 857281-74-4 857281-77-7  
 857281-78-8 857281-80-2 857281-81-3  
 857281-82-4 857281-84-6 857281-85-7  
 857281-86-8 857281-87-9 857281-88-0  
 857281-89-1 857281-91-5 857281-92-6  
 857281-93-7 857281-97-1 857282-02-1  
 857282-08-7 857282-10-1 857282-12-3  
 857282-14-5 857282-15-6 857282-16-7  
 857282-17-8 857282-20-3 857282-22-5  
 857282-24-7 857282-27-0 857282-31-6  
 R1: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (prepn. of 4-(4-piperidinyl)phenols and related compds. as aspartic  
 protease inhibitors)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN  
 IC ICM C07D211-42  
 ICS C07D413-12; C07D401-12; A61K031-395  
 CC 27-16 (Heterocyclic Compounds (One Hetero Atom))  
 Section cross-reference(s): 1  
 TI Preparation of piperidines as renin inhibitors useful against  
 hypertension  
 and other disorders  
 ST piperidine prepn renin inhibitor antihypertensive; hypertension heart  
 failure infarction glaucoma restenosis piperidine drug prepn; kidney  
 failure piperidine drug prepn  
 IT Heart, disease  
 Kidney, disease  
 (failure; preparation of piperidines as renin inhibitors useful  
 against hypertension and other disorders)  
 IT Heart, disease  
 (infarction; preparation of piperidines as renin inhibitors useful  
 against hypertension and other disorders)  
 IT Antiglaucoma agents  
 Antihypertensives  
 Cardiovascular agents  
 Glaucoma (disease)  
 Human  
 Hypertension  
 (preparation of piperidines as renin inhibitors useful against  
 hypertension and other disorders)  
 IT Artery, disease  
 (restenosis; preparation of piperidines as renin inhibitors useful  
 against hypertension and other disorders)  
 IT 1044670-79-2 1044670-80-5 1044670-82-7  
 1044670-83-8 1044670-85-0 1044670-86-1  
 1044670-87-2 1044670-88-3 1044670-89-4  
 1044670-90-7 1044670-91-8 1044670-95-2  
 1044670-97-4 1044670-98-5 1044670-99-6 1044671-01-3  
 1044671-03-5 1044671-06-8 1044671-07-9  
 1044671-09-1 1044671-11-5 1044671-14-8  
 1044671-15-9 1044671-17-1 1044671-19-3  
 1044671-21-7 1044671-22-8 1044671-25-1  
 1044671-26-2 1044671-27-3 1044671-29-5  
 1044671-32-0 1044671-33-1 1044671-34-2  
 1044671-35-3 1044671-36-4 1044671-41-1  
 1044671-42-2 1044671-43-3 1044671-44-4  
 1044671-49-9 1044671-50-2 1044671-51-3 1044671-52-4  
 1044671-55-7 1044671-57-9 1044671-59-1  
 1044671-60-4 1044671-63-7 1044671-64-8  
 1044671-66-0 1044671-67-1 1044671-69-3  
 1044671-71-7 1044671-72-8 1044671-73-9  
 1044671-74-0 1044671-75-1 1044671-76-2  
 1044671-77-3 1044671-80-8 1044671-83-1  
 1044671-84-2 1044671-85-3 1044671-87-5  
 1044671-89-7 1044671-91-1 1044671-92-2  
 1044671-94-4 1044671-96-6 1044671-98-8  
 1044671-99-9 1044672-01-6 1044672-02-7  
 1044672-05-0 1044672-06-1 1044672-07-2  
 1044672-08-3 1044672-10-7 1044672-11-8

L10	2 ANSWERS	CAPLUS	COPYRIGHT	2009	ACS	on	STN	(Continued)
1044672-12-9		1044672-13-0		1044672-15-2		1044672-17-4		
1044672-19-6		1044672-20-9		1044672-23-2				
1044672-25-4		1044672-26-5		1044672-27-6				
1044672-29-8		1044672-30-1		1044672-32-3				
1044672-34-5		1044672-36-7		1044672-37-8				
1044672-39-0		1044672-41-4		1044672-43-6				
1044672-44-7		1044672-46-9		1044672-47-0				
1044672-49-2		1044672-50-5		1044672-51-6				
1044672-52-7		1044672-53-8		1044672-54-9				
1044672-55-0		1044672-56-1		1044672-57-2				
1044672-58-3		1044672-59-4		1044672-60-7				
1044672-61-8		1044672-62-9		1044672-63-0				
1044672-64-1		1044672-65-2		1044672-66-3				
1044672-67-4		1044672-68-5		1044672-69-6				
1044672-70-9		1044672-71-0		1044672-72-1				
1044672-73-5		1044672-74-3		1044672-75-4				
1044672-76-2		1044672-77-6		1044672-78-7				
1044672-79-8		1044672-80-1		1044672-81-2				
1044672-82-3		1044672-83-4		1044672-84-5				
1044672-85-6		1044672-86-7		1044672-87-8				
1044672-88-9		1044672-89-0		1044672-90-3				
1044672-91-4		1044672-92-5		1044672-93-6				
1044672-94-7		1044672-95-8		1044672-96-9				
1044672-97-0		1044672-98-1		1044672-99-2				
1044673-00-8		1044673-01-9		1044673-02-0				
1044673-03-1		1044673-04-2		1044673-05-3				
1044673-06-4		1044673-07-5		1044673-08-6				
1044673-09-7		1044673-10-0		1044673-11-1				
1044673-12-2		1044673-13-3		1044673-14-4				
1044673-15-5		1044673-16-6		1044673-17-7				
1044673-18-8		1044673-19-9		1044673-20-2				
1044673-21-3		1044673-22-4		1044673-23-5				
1044673-24-6		1044673-25-7		1044673-26-8				
1044673-27-9		1044673-28-0		1044673-29-1				
1044673-30-4		1044673-31-5		1044673-32-6		1044673-33-7		
1044673-34-8		1044673-35-9		1044673-36-0				
1044673-37-1		1044673-38-2		1044673-39-3				
1044673-40-6		1044673-41-7		1044673-42-8				
1044673-43-9		1044673-44-0		1044673-45-1				
1044673-46-2		1044673-47-3		1044673-48-4				
1044673-49-5		1044673-50-8		1044673-51-9				
1044673-52-0		1044673-53-1		1044673-54-2		1044673-55-3		
1044673-56-4		1044673-57-5		1044673-58-6				
1044673-59-7		1044673-60-0		1044673-61-1				
1044673-62-2		1044673-63-3		1044673-64-4		1044673-65-5		
1044673-66-6		1044673-67-7		1044673-68-8				
1044673-69-9		1044673-70-2		1044673-71-3		1044673-72-4		
1044673-73-5		1044673-74-6		1044673-75-7				
1044673-76-8		1044673-77-9		1044673-78-0				
1044673-79-1		1044673-80-4		1044673-81-5				
1044673-82-6		1044673-83-7		1044673-84-8				
1044673-85-9								
RL: PREPH (Prophetic)								
[Prepn. of piperidines as renin inhibitors useful against hypertension]								

10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

4-2-[[3-(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]butyrate 857278-92-3P,  
7-[[[(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,3-dimethyl-1,3-dihydroindol-2-one 857279-82-4P,  
Methyl

7-[[[(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1H-benzimidazole-2-carboxylate 857279-93-7P,  
7-[[[(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1,3,3-trimethyl-1,3-dihydroindol-2-one 857281-69-7P,  
6-[[[(3R,4R)-4-[[4-Methoxyphenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one 857281-91-5P,  
6-[[[(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one 857281-91-5P,  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); AG (Agriculture use); HAZ (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; prepn. of piperidines as renin inhibitors useful against hypertension and other disorders)

IT 857271-92-2P, (3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]-3-[[3-methoxy-5-(3-methoxypropoxy)benzoyloxy]piperidine 857272-04-9P,

2-[[[(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]N-(2-methoxybenzoyloxy)phenyl]propionamide 857272-07-7P,  
6-[[[(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857272-11-8P,  
5-[[[(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3-(3-methoxypropyl)benzoxazol-2(3H)-one 857272-18-5P,  
(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]-[[7-(3-methoxypropoxy)benzofuran-2-yl]methyl]piperidine 857272-24-3P,  
N-[5-[[[(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-methylphenyl]-N-(3-methoxypropyl)acetamide 857272-28-7P,  
N-[3-[[[(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]phenyl]-N-(3-methoxypropyl)acetamide 857272-32-3P,  
6-[[[(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-1H-indole 857272-42-5P  
857272-44-7P,

(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]-3-[[3-(3-methoxypropoxy)-4-methylbenzoyloxy]piperidine 857272-49-2P,  
7-[[[(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857272-55-0P,  
N-[2-[[2-[[2-[[[(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]acetamide 857272-60-7P,  
7-[[[(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-1H-quinolin-2-one 857272-66-3P,  
7-[[[(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-(3-methoxypropyl)quinoline 857272-75-4P,  
(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]-3-[[7-(3-methoxypropoxy)-2,3-dihydrobenzofuran-2-yl]methyl]piperidine 857272-77-6P,

(3R,4R)-3-[[4-Fluoro-3-(3-methoxypropoxy)benzoyloxy]-4-[[4-[[3-(2-methoxybenzoyloxy)propoxy]phenyl]piperidine 857272-82-3P,  
6-[[[(3R,4R)-4-[[4-[[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3-methyl-1H-indole

L10	2 ANSWERS	CAPLUS	COPYRIGHT 2009 ACS on STN	(Continued)
	and other disorders)			
IT	1044673-86-0	1044673-87-1	1044673-89-3	
	1044673-90-6	1044673-91-7	1044673-92-8	1044673-93-9
	1044673-94-0	1044673-95-1	1044673-97-3	
	1044673-99-5	1044674-00-1	1044674-02-3	
	1044674-03-4	1044674-05-6	1044674-07-8	
	1044674-08-3	1044674-10-3	1044674-11-5	1044674-12-5
	1044674-13-6	1044674-17-0	1044674-18-1	1044674-19-2
	1044674-20-5	1044674-23-8	1044674-25-0	
	1044674-26-1	1044674-28-3	1044674-31-8	
	1044674-32-9	1044674-33-0	1044674-36-3	
	1044674-39-6	1044674-40-9	1044674-41-0	
	1044674-42-1	1044674-47-6	1044674-48-7	
	1044674-49-8	1044674-50-1	1044674-55-6	
	1044674-56-7	1044674-57-8	1044674-58-9	
	1044674-61-4	1044674-62-5	1044674-63-6	1044674-65-8
	1044674-66-9	1044674-67-0	1044674-68-1	
	1044674-69-2	1044674-70-5	1044674-71-6	
	1044674-72-7	1044674-73-8	1044674-74-9	
	1044674-75-0	1044674-76-1	1044674-77-2	1044674-79-4
	1044674-80-7	1044674-81-8	1044674-82-9	1044674-83-0
	1044674-84-1	1044674-85-2	1044674-86-3	
	1044674-87-4	1044674-88-5	1044674-89-6	
	1044674-90-9	1044674-92-1	1044674-93-2	
	1044674-95-4	1044674-97-6	1044674-98-7	
	1044674-99-8	1044675-00-4	1044675-02-6	
	1044675-03-7	1044675-04-8	1044675-05-9	
	1044675-07-1	1044675-08-2	1044675-10-6	
	1044675-11-7	1044675-12-8	1044675-13-9	
	1044675-14-0			
	RL: FRPH (Prophetic)			
	(Preparation of piperidines as renin inhibitors useful against hypertension and other disorders)			
IT	773873-09-9P			
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)			
	(Preparation of piperidines as renin inhibitors useful against hypertension and other disorders)			
IT	857272-00-5P, 6-[[[[(3R,4R)-4-{4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one 857272-69-6P, 6-[[[[(3R,4R)-4-{4-[3-(2-Methoxybenzyloxy)propoxy]methyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)spiro[cyclopropane-1,3'-[3H]indol]-2'(1'H)-one 857273-11-1P, Methyl 4-[[[[(3R,4R)-4-{4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-(3-methoxypropoxy)benzoate 857273-73-5P, 7-[[[[(3R,4R)-4-{4-[2-(2-Methoxyphenyl)ethoxy]ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857273-81-5P, 8-[[[[(3R,4R)-4-{4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]propionate 857276-71-2P, Methyl			

L10 2 ANSWERS CPLUS COPYRIGHT 2009 ACS ON STN (Continued)  
 857272-86-7P, 6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-2-methyl-1H-indole 857272-89-0P,  
 6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-1H-indazole 857272-95-8P,  
 6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-(3-methoxypropyl)-2H-indazole 857272-99-2P,  
 7-[[[(3R,4R)-4-[4-[4-(2-Methoxyphenoxy)butoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one  
 857273-03-1P,  
 (3R,4R)-4-[4-[3-(2-Methoxybenzoyloxy)propoxy]phenyl]-3-[2-[2-  
 2-[(1,2,4-triazol-1-yl)ethyl]phenoxy]ethoxy]piperidine 857273-07-5P,  
 (3R,4R)-4-[4-[3-(2-Methoxybenzoyloxy)propoxy]phenyl]-3-[2-[2-(tetrazol-1-yl)ethyl]phenoxy]ethoxy]piperidine 857273-10-0P 857273-15-5P,  
 N-[2-[2-[2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]-N-methylacetamide 857273-17-7P,  
 (3R,4R)-3-[[[4-Chloro-3-(3-methoxypropoxy)benzyl]oxy]-4-[4-[3-[(2-methoxybenzoyloxy)propoxy]phenyl]piperidine 857273-24-6P,  
 2-[2-[2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl methyl carbonate 857273-26-8P,  
 2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3-(3-methoxypropyl)-1H-indole 857273-31-5P,  
 N-[2-(2-Acetylaminoethyl)phenyl]-2-[[[(3R,4R)-4-[4-[3-(2-methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]acetamide  
 857273-35-9P,  
 N-[2-(2-Acetylaminoethyl)phenyl]-2(S)-[[[(3R,4R)-4-[4-[3-(2-methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]propionamide  
 857273-39-3P,  
 N-[2-(2-Acetylaminoethyl)phenyl]-2(R)-[[[(3R,4R)-4-[4-[3-(2-methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]propionamide  
 857273-43-9P, N-[2-[2-[[[(3R,4R)-4-(4-Methoxyphenyl)piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]acetamide 857273-48-4P,  
 N-[2-[2-[2-[[[(3R,4R)-4-[4-[4-(2-Methoxyphenoxy)butoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]acetamide 857273-53-1P,  
 1-[2-[2-[2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]pyrrolidin-2-one 857273-55-3P,  
 (3R,4R)-3-[2-[2-[2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]acetamide 857273-55-5P,  
 3-[2-[2-[2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]propionitrile 857273-59-7P,  
 3-[2-[2-[2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]oxazolidin-2-one 857273-61-1P,  
 (3R,4R)-3-[[[4-Ethyl-3-(3-methoxypropoxy)benzyl]oxy]-4-[4-[3-[(2-methoxybenzoyloxy)propoxy]phenyl]piperidine 857273-64-4P  
 857273-78-0P, 7-[[[(3R,4R)-4-[4-[3-Hydroxypropoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one  
 857273-80-4P, 3-[2-[2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzoyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]propionic  
 acid 857273-82-6P, 1-(3-Methoxypropyl)-7-[[[(3R,4R)-4-[4-[4-(6-tolyloxy)butoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-1H-quinolin-  
 2-one 857273-84-8P, 7-[[[(3R,4R)-4-[4-[4-(2-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
3,4-dihydro-1H-quinolin-2-one 857273-86-0P,  
7-[[[(3R,4R)-4-[4-[4-[(2-Ethylphenyl)oxy]butoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one  
857273-89-3P, 2-[4-[4-[(3R,4R)-3-[1-(3-Methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-ylmethoxy]piperidin-4-yl]phenoxy]butoxy]benzonitrile 857273-92-8P,  
1-(3-Methoxypropyl)-7-[[[(3R,4R)-4-[4-[4-(3-methylindol-1-yl)butoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-1H-quinolin-2-one  
857273-95-1P, 4-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]butyronitrile 857273-99-5P,  
N-[2-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]methanesulfonamide 857274-03-4P,  
4-Methoxy-N-[2-[[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]phenyl]butyramide 857274-07-8P,  
6-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,3-dimethyl-1,3-dihydroindol-2-one  
857274-13-6P, 2',3'-Dihydro-6'-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1'-(3-methoxypropyl)spiro[cyclopropane-1,3'-1H-indol] 857274-14-7P,  
6-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,3-dimethyl-2,3-dihydro-1H-indole  
857274-16-9P, 4-Methoxy-N-[2-[[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]phenyl]-N-methylbutyramide 857274-18-1P, 2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]-N-(3-methoxypropyl)-N-phenylacetamide 857274-21-6P,  
N-[2-[2-[[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]benzofuran-7-yl]ethyl]acetamide 857274-29-4P, Methyl  
2-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]acetamide 857274-31-8P,  
4-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-(3-methoxypropoxy)benzoic acid 857274-32-9P,  
[3-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]propyl]dimethylamine 857274-34-1P,  
4-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-(3-methoxypropoxy)benzonitrile 857274-36-3P,  
(3R,4R)-3-[2-[2-[3-(Methylsulfonylpropyl)phenoxy]ethoxy]-4-[4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]piperidine 857274-39-6P,  
4-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-(3-methoxypropoxy)benzamide 857274-43-2P,  
4-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-(3-methoxypropoxy)-N-methylbenzamide 857274-45-4P,  
4-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-(3-methoxypropoxy)-N,N-dimethylbenzamide 857274-47-6P,  
3-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]-N-methylpropionamide 857274-49-8P,  
N-[2-[2-[[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
857274-98-7P, 7-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857275-00-4P,  
N-[2-[6-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,3-dimethyl-2,3-dihydroindol-1-yl]ethyl]acetamide  
857275-12-8P, 2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]-N-[2-(3-methoxypropyl)phenyl]-N-methylacetamide 857275-14-0P,  
2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]-N-[2-(4-methoxybutyl)phenyl]-N-methylacetamide 857275-16-2P,  
N-[2-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]acetamide 857275-22-0P,  
N-[[[(3R)-1-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]phenyl]pyrrolidin-3-yl]methyl]acetamide  
857275-29-7P, 1-[2-[6-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3-methylindol-1-yl]ethyl]-3-methylurea 857275-31-1P,  
6-[[[(3R,4R)-4-[4-[4-[2-[2-(2-Methoxyphenyl)ethoxy]ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857275-34-4P, 7-[[[(3R,4R)-4-[4-[4-[2-[2-(2-Methoxyphenyl)ethoxy]ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-1,2,3,4-tetrahydroquinoline 857275-35-5P,  
1-(3-Methoxypropyl)-7-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-1H-quinolin-2-one 857275-39-9P, (3R,4R)-3-[[4-(Furan-2-yl)-3-(3-methoxypropoxy)benzyl]oxy]-4-[4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine 857275-42-4P,  
N-[4-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-(3-methoxypropoxy)phenyl]acetamide 857275-45-7P,  
N-[2-(2-Acetylaminophenyl)phenyl]-2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]-N-methylacetamide  
857275-51-5P, 3-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-N-(2-methoxyethyl)benzamide 857275-56-0P,  
3-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-N-(2-methoxyethyl)benzamide 857275-58-2P,  
N-[2-[3-Fluoro-2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]acetamide 857275-62-8P,  
N-[2-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]-6-methylphenyl]ethyl]acetamide 857275-66-2P,  
N-[2-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]-3-methylphenyl]ethyl]acetamide 857275-70-8P,  
N-[2-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]-5-methylphenyl]ethyl]acetamide 857275-73-1P,  
N-[2-[4-Fluoro-2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
yl]oxy]methyl]-2,3-dihydrobenzofuran-7-yl]ethyl]acetamide 857274-51-2P,  
2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]-N-[2-(3-methoxypropyl)phenyl]acetamide 857274-53-4P,  
2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]-N-[2-(4-methoxybutyl)phenyl]acetamide 857274-57-8P,  
N-[2-[6-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3-methylindol-1-yl]ethyl]acetamide 857274-61-4P,  
N-[2-[1-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethyl]-1H-indol-3-yl]ethyl]acetamide 857274-63-6P,  
2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]-N-(4-methoxybutyl)-N-phenylacetamide 857274-65-8P,  
(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]-3-[[[3-(3-methoxypropoxy)-4-(pyrrolidin-1-yl)benzyl]oxy]piperidine 857274-70-5P,  
4-[4-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-(3-methoxypropoxy)phenyl]morpholine 857274-72-7P, N-[2-[6-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3-methylindol-1-yl]ethyl]cyclopropanecarboxamide 857274-74-9P,  
N-[2-[6-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3-methylindol-1-yl]ethyl]propionamide 857274-76-1P,  
N-[2-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]propionamide 857274-78-3P,  
N-[2-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]cyclopropanecarboxamide 857274-80-7P,  
1-[2-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]-3-methylurea 857274-82-9P,  
7-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857274-84-1P, 7-[[[(3R,4R)-4-[4-[4-[2-(6-Dimethoxyphenoxy)butoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857274-86-3P,  
7-[[[(3R,4R)-4-[4-[4-[3-(2-Chlorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857274-88-5P, 2-[3-[4-[(3R,4R)-3-[[1-(3-Methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidin-4-yl]phenoxy]propoxy]benzonitrile 857274-90-9P,  
7-[[[(3R,4R)-4-[4-[4-[2-(Chlorophenoxy)butoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857274-92-1P, 7-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxy-6-methylphenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857274-95-4P,  
7-[[[(3R,4R)-4-[4-[4-[4-(2-Methoxy-6-methylphenoxy)butoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857275-77-5P,  
N-[2-[5-Fluoro-2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]acetamide 857275-80-0P,  
N-[2-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]-4-methylphenyl]ethyl]acetamide 857275-84-4P,  
N-[2-[2-Fluoro-6-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]acetamide 857275-88-8P,  
4-Methoxy-N-[2-[[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-5-methylphenyl]-N-methylbutyramide 857275-93-5P,  
(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]-3-[2-[2-[3-(1H-tetrazol-5-yl)propyl]phenoxy]ethoxy]piperidine 857275-95-7P,  
3-Methoxy-N-[3-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]phenyl]-N-methylpropionamide 857276-00-7P,  
N-[2-[5-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-methylphenyl]oxy]ethyl]acetamide 857276-10-9P,  
4-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]-N-methylbutyramide 857276-13-2P,  
6-[[[(3R,4R)-4-[4-[4-[3-(2-Chlorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857276-17-6P, N-[2-[4-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]-2-methylpyrimidin-5-yl]ethyl]acetamide 857276-24-5P,  
N-[2-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Chlorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]-4-fluorophenyl]ethyl]acetamide 857276-29-0P,  
N-[2-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-Chlorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]acetamide 857276-31-4P,  
1-(3-Methoxypropyl)-7-[[[(3R,4R)-4-[4-[4-[5-methoxypyrimidin-4-yl]amino]butoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-1H-quinolin-2-one 857276-35-8P, 1-(3-Methoxypropyl)-7-[[[(3R,4R)-4-[4-[4-[3-(3-methoxypyridin-2-yl)amino]butoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-1H-quinolin-2-one 857276-37-0P,  
5-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-N-(2-methoxyethyl)-2-methyl-N-methylbenzamide 857276-42-7P, 5-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-N-(2-methoxyethyl)-2-methylbenzamide 857276-44-9P,  
3-Methoxy-N-[5-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-methylphenyl]-N-methylpropionamide 857276-52-9P,  
N-Isopropyl-3-methoxy-N-[3-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]phenyl]propionamide 857276-56-3P,  
N-[4-Fluoro-2-[[[(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]phenyl]-4-methoxy-N-methylbutyramide 857276-62-1P,  
(3R,4R)-4-[4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]-3-[[[3-(1-(3-methoxypropyl)-1H-imidazol-2-yl]benzyl]oxy]piperidine 857276-67-6P,  
3-Methoxy-N-[2-[2-[[[(3R,4R)-4-[4-[4-[3-(2-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)  
methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]propionamide 857276-69-8P,  
2-[2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]-N-(2-methoxyethyl)benzamide 857276-73-4P,  
3-Ethoxy-N-[3-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]phenyl]-N-methylpropionamide 857276-76-7P,  
6-[[[(3R,4R)-4-[4-[3-(3-Methoxyphenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857276-80-3P, 6-[[[(3R,4R)-4-[4-[3-(3-Fluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857276-84-7P, 6-[[[(3R,4R)-4-[4-[3-(2-Fluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857276-88-1P, 6-[[[(3R,4R)-4-[4-[3-(2,5-Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857276-93-8P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[3-(4-tolyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857276-97-2P  
, 6-[[[(3R,4R)-4-[4-[3-(2-Methoxyphenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-01-1P, 6-[[[(3R,4R)-4-[4-[3-(3-Chlorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-05-5P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[3-(3-m-tolyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857277-09-9P, (3R,4R)-3-[4-Ethoxy-3-(3-methoxypropoxy)benzyl]oxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine 857277-14-6P, 4-Methoxy-1-[(2R)-2-[[[(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2,3-dihydrobenzo[1,4]oxazin-4-yl]butan-1-one 857277-20-4P, N-[2-[4-Chloro-2-[2-[[[(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2,3-dihydrobenzo[1,4]oxazin-4-yl]butan-1-one 857277-23-7P, 4-Methoxy-1-(2S)-2-[[[(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2,3-dihydrobenzo[1,4]oxazin-4-yl]butan-1-one 857277-29-3P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[3-(3-phenoxypropoxy)phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857277-33-9P, 4-[2-[2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]butyric acid 857277-34-0P, (3R,4R)-4-[4-[3-(2-Methoxybenzyl)oxy]propoxy]phenyl]-3-[[3-methoxy-2-(2-methoxybenzyl)benzyl]oxy]piperidine 857277-38-4P, (3R,4R)-4-[4-[3-(2-Methoxybenzyl)oxy]propoxy]phenyl]-3-[[3-methoxy-2-(3-methoxypropoxy)benzyl]oxy]piperidine 857277-42-0P, N-Hydroxy-3-[2-[2-[[[(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]-N-methylpropionamide 857277-46-4P, 6-[[[(3R,4R)-4-[4-[3-[(Benzodioxol-5-yl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-50-0P, 6-[[[(3R,4R)-4-[4-[3-(2,4-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)  
[4-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-(3-methoxypropoxy)phenyl]methylaniline 857278-15-0P, Methyl N-[2-[4-fluoro-2-[2-[[[(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]carbamate 857278-18-3P, Methyl [2-[3-fluoro-2-[2-[[[(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]carbamate 857278-19-4P, Methyl [2-[5-fluoro-2-[2-[[[(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]carbamate 857278-20-7P, Methyl [2-[2-fluoro-6-[2-[[[(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]phenyl]ethyl]carbamate 857278-21-8P, 3-Fluoro-N-[2-[4-[[[(3R,4R)-3-[4-[3-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy]ethyl]benzamide 857278-27-4P, N-[2-[6-[[[(3R,4R)-4-[4-[3-(2,5-Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2,3-dihydrobenzo[1,4]oxazin-4-yl]ethyl]acetamide 857278-41-2P, Methyl [2-[6-[[[(3R,4R)-4-[4-[3-(2,5-difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2,3-dihydrobenzo[1,4]oxazin-4-yl]ethyl]carbamate 857278-42-3P, 6-[[[(3R,4R)-4-[4-[3-(2,5-Difluorophenoxy)ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-48-9P, 6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyl)oxy]ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-49-0P,  
2-Cyclopropyl-1-[(3S)-3-[4-[(3R,4R)-3-[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy]pyrrolidin-1-yl]ethanone 857278-53-6P, Cyclohexyl[(3S)-3-[4-[(3R,4R)-3-[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy]pyrrolidin-1-yl]methanone 857278-54-7P, [(3S)-3-[4-[(3R,4R)-3-[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy]pyrrolidin-1-yl] (tetrahydropryan-4-yl)methanone 857278-55-8P, [3-[4-[(3R,4R)-3-[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy]azetidin-1-yl]Phenylmethanone 857278-56-9P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[(3S)-1-phenylpyrrolidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857278-62-7P, 6-[[[(3R,4R)-4-[4-[(3S)-1-(2-Fluorophenyl)pyrrolidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-63-8P, 6-[[[(3R,4R)-4-[4-[(3S)-1-(4-Fluorophenyl)pyrrolidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-64-9P, 6-[[[(3R,4R)-4-[4-[(3S)-1-(3-Fluorophenyl)pyrrolidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-65-0P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[(1-phenylazetidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857278-66-1P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[(1-phenylpiperidin-4-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857278-67-2P,

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)  
Difluorophenoxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-54-4P, 6-[[[(3R,4R)-4-[4-[3-(2,3-Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-59-9P, 6-[[[(3R,4R)-4-[4-[3-(4-Fluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-68-0P, 6-[[[(3R,4R)-4-[4-[3-(3,4-Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-73-7P, 6-[[[(3R,4R)-4-[4-[3-(3,5-Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-78-2P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[3-[(3-trifluoromethylphenyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857277-82-8P, 6-[[[(3R,4R)-4-[4-[3-(Cyclohexyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-87-3P, 6-[[[(3R,4R)-4-[4-[2(R)-Methoxy-3-phenoxypropoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-95-3P,  
1-[[2-[2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]ethoxy]benzyl]oxy]propan-2(S)-ol 857277-98-6P, 1-[4-[[[(3R,4R)-3-[4-[(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy]-3-phenoxypropan-2(R)-ol 857277-99-7P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-(2(R)-Methyl-3-phenoxypropoxy)phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857278-00-3P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[3-[(piperidin-4-yl]oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857278-01-4P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[3-[(tetrahydropryan-4-yl]oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857278-02-5P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[3-[(pyridin-2-yl]oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857278-03-6P,  
3-[3-[4-[(3R,4R)-3-[4-[(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy]propoxy]phenol 857278-04-7P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[2-[(1-phenylcyclopropylmethoxy)ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857278-05-8P, 6-[[[(3R,4R)-4-[4-[3-(3-Methoxyphenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-07-0P,  
(3R,4R)-4-[4-[3-(3-Fluorophenoxy)propoxy]phenyl]-3-[[3-(3-methoxypropoxy)-(4-pyrrolidin-1-yl)benzyl]oxy]piperidine 857278-09-2P, [4-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-(3-methoxypropoxy)phenyl]dimethylamine 857278-11-6P, 1-[4-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-(3-methoxypropoxy)phenyl]pyrrolidin-2-one 857278-13-8P,  
L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)  
6-[[[(3R,4R)-4-[4-[(3S)-1-(3-Methoxyphenyl)pyrrolidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-68-3P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[(3S)-1-(pyridin-2-yl)pyrrolidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857278-69-4P, 6-[[[(3R,4R)-4-[4-[(3S)-1-(3-Chlorophenyl)pyrrolidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-70-7P, 6-[[[(3R,4R)-4-[4-[(3S)-1-(2-Chlorophenyl)pyrrolidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-71-8P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[(3S,5S)-5-methyl-1-phenylpyrrolidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine  
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; prepn. of piperidines as renin inhibitors useful against hypertension and other disorders)  
IT 857278-72-9P, 6-[[[(3R,4R)-4-[4-[(3S)-1-(2-Methoxyphenyl)pyrrolidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-73-0P, 6-[[[(3R,4R)-4-[4-[(3S)-1-(Benzodioxol-5-yl)pyrrolidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-74-1P, 6-[[[(3R,4R)-4-[4-[1-(2-Fluorophenyl)azetidin-3-yloxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-75-2P, 6-[[[(3R,4R)-4-[4-[1-(3-Fluorophenyl)azetidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-76-3P,  
6-[[[(3R,4R)-4-[4-[1-(4-Fluorophenyl)azetidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-77-4P, 6-[[[(3R,4R)-4-[4-[1-(1-Benzodioxol-5-yl)azetidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-78-5P,  
6-[[[(3R,4R)-4-[4-[1-(2,5-Difluorophenyl)azetidin-3-yloxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-79-6P, 6-[[[(3R,4R)-4-[4-[1-(3,4-Difluorophenyl)azetidin-3-yloxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-80-9P,  
6-[[[(3R,4R)-4-[4-[1-(3,5-Difluorophenyl)azetidin-3-yloxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-81-0P, 6-[[[(3R,4R)-4-[4-[1-(4-Methoxyphenyl)azetidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-82-1P,  
6-[[[(3R,4R)-4-[4-[1-(3-Methoxyphenyl)azetidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-83-2P, 6-[[[(3R,4R)-4-[4-[1-(2-Methoxyphenyl)azetidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-84-3P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[(4-phenylpiperidin-1-

10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

yl)oxy)methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-27-4P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-  
[[[tetrahydrofuran-3-yl]oxy)methyl]phenyl]piperidin-3-yl]oxy)methyl]-3,4-  
dihydro-2H-benzo[1,4]oxazine 857280-28-5P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[tetrahydropyran-4-  
yl]oxy)methyl]phenyl]piperidin-3-yl]oxy)methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857280-29-6P,  
6-[[[(3R,4R)-4-[4-(Cyclopropylmethoxy)methyl]phenyl]piperidin-3-  
yl]oxy)methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-30-9P, 6-[[[(3R,4R)-4-[4-(2-  
Cyclopropylethoxymethyl)phenyl]piperidin-3-yl]oxy)methyl]-4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-31-0P,  
6-[[[(3R,4R)-4-[4-(2-Methoxyethoxymethyl)phenyl]piperidin-3-yl]oxy)methyl]-  
3-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-32-1P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-  
propoxymethyl]phenyl]piperidin-3-yl]oxy)methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857280-33-2P,  
6-[[[(3R,4R)-4-(4-Butoxymethyl)phenyl]piperidin-3-yl]oxy)methyl]-4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-34-3P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(3S)-1-(thiazol-2-yl)pyrrolidin-3-  
yl]oxy]phenyl]piperidin-3-yl]oxy)methyl]-3,4-dihydro-2H-benzo[1,4]oxazin-  
857280-35-4P, [(1S)-1-[(4-(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-  
dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy)methyl]-3-  
phenyl]propyl]amine 857280-38-7P,  
6-[[[(3R,4R)-4-[4-(2-(3-Methoxyphenoxy)ethoxy]phenyl]piperidin-3-  
yl]oxy)methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-42-3P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-(pyrrolidin-1-  
yl)phenyl]piperidin-3-yl]oxy)methyl]-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-45-6P, 6-[[[(3R,4R)-4-[4-(Azetidin-1-yl)phenyl]piperidin-3-  
yl]oxy)methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-46-7P, 6-[[[(3R,4R)-4-[4-[2-(3-  
Ethoxyphenoxy)ethoxy]phenyl]piperidin-3-yl]oxy)methyl]-4-(3-methoxypropyl)-  
3,4-dihydro-2H-benzo[1,4]oxazine 857280-50-3P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(1-phenylazetidin-3-  
yl]oxy)methyl]phenyl]piperidin-3-yl]oxy)methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857280-54-7P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[(3-phenylpyrrolidin-1-  
yl)methyl]phenyl]piperidin-3-yl]oxy)methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857280-56-9P,  
6-[[[(3R,4R)-4-[4-[2-(2,5-Difluorophenoxy)ethoxy]methyl]phenyl]piperidin-  
3-yl]oxy)methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-61-4P, 857280-63-3P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[(1R)-3-phenoxypyrrolidin-1-  
yl)methyl]phenyl]piperidin-3-yl]oxy)methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857280-69-4P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[(3-phenylazetidin-1-  
yl)methyl]phenyl]piperidin-3-yl]oxy)methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857280-70-7P,  
6-[[[(3R,4R)-4-[4-[3-(2-Fluorobenzoyloxy)phenoxy]phenyl]piperidin-3-  
yl]oxy)methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-73-0P, [2-(4-Fluorobenzoyloxy)phenyl] [2-[4-[(3R,4R)-3-[[4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-  
yl]phenoxy]ethyl]amine 857280-75-2P,

10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

6-[[[(3R,4R)-4-[[4-[[1-(Benzothiazol-2-yl)azetidin-3-yl]oxy]phenyl]piperidin-3-yl]oxy]methyl]-4-[(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-78-5P,  
[2-(2-Fluorophenyl)ethyl]-2-[4-[(3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy]ethoxy]amine 857280-81-0P,  
6-[[[(3R,4R)-4-[[4-[[2-(3-Fluorobenzyloxy)ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-[(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-82-1P, 6-[[[(3R,4R)-4-[[4-[[2-(2-Fluorobenzyloxy)ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-[(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-83-2P,  
6-[[[(3R,4R)-4-[[4-[[2-(3,5-Difluorobenzyloxy)ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-[(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-84-3P, 6-[[[(3R,4R)-4-[[4-[[2-(3-  
Chlorophenoxy)ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-[(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-86-5P,  
6-[[[(3R,4R)-4-[[4-[[2-[(4-Fluorophenyl)ethoxy]ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-[(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-87-6P, 6-[[[(3R,4R)-4-[[4-[[2-(3-Fluorophenyl)ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-[(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-88-7P,  
6-[[[(3R,4R)-4-[[4-[[2-[(2-Fluorophenyl)ethoxy]ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-[(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-89-8P, 6-[[[(3R,4R)-4-[[4-[[2-(4-  
Fluorophenoxy)ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-[(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-90-1P,  
6-[[[(3R,4R)-4-[[4-[[2-[(Benz-1,3]dioxol-5-yl)oxy]ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-[(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-91-2P, 4-[(3-Methoxypropyl)-6-[[[(3R,4R)-4-[[4-[[2-(m-tolyloxy)ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857280-92-3P,  
3-[[2-[4-[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy]ethoxy]benzonitrile 857280-93-4P, 6-[[[(3R,4R)-4-[[4-[[2-(2-  
Fluorophenoxy)ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-[(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-94-5P,  
6-[[[(3R,4R)-4-[[4-[[2-(3-Fluorophenoxy)ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-[(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-95-6P, 2-[4-[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenyl]-1-(3-phenylpyrrolidin-1-yl)ethanone 857280-96-7P,  
1-(3,4-Dihydro-2H-quinolin-1-yl)-2-[4-[(3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenyl]ethanone 857281-00-6P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[[4-[[2-(3-phenylpyrrolidin-1-yl)ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857281-03-5P,  
6-[[[(3R,4R)-4-[[4-[[2-(3,4-Dihydro-1H-isooquinolin-2-yl)ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-[(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857281-04-0P,  
[3-[2,5-Difluorophenoxy]propyl]-4-[(3R,4R)-3-[[4-(3-methoxypropyl)-3,4-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
dihydro-2H-benzo[1,4]oxazin-6-yl[methoxy]piperidin-4-yl]phenyl]amine  
857281-08-4P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-(4-  
propoxyphenyl)piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine  
857281-10-8P 857281-11-9P,  
6-[[[(3R,4R)-4-(4-(Cyclopropylmethoxy)phenyl)piperidin-3-yl]oxy]methyl]-4-(  
3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857281-12-0P  
6-[[[(3R,4R)-4-(4-(3-Methoxypropoxy)phenyl)piperidin-3-yl]oxy]methyl]-4-(  
3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857281-13-1P  
6-[[[(3R,4R)-4-(4-Isobutoxyphenyl)piperidin-3-yl]oxy]methyl]-4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857281-14-2P,  
1-Ethyl-4-[[[(3R,4R)-4-(4-(3-(2-methoxybenzyloxy)propoxy)phenyl)piperidin-  
3-yl]oxy]methyl]benzimidazol-2(3H)-one 857281-20-0P,  
[2-(3-Fluorophenyl)ethyl]-2-[4-[(3R,4R)-3-[[4-(3-methoxypropyl)-3,4-  
dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-  
yl]phenoxy]ethyl]amine 857281-21-1P,  
6-[1(R)-[[[(3R,4R)-4-(4-Methoxyphenyl)piperidin-3-yl]oxy]ethyl]-4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857281-28-8P,  
6-[1(S)-[[[(3R,4R)-4-(4-Methoxyphenyl)piperidin-3-yl]oxy]ethyl]-4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857281-30-2P,  
4-(3-Ethoxypropyl)-6-[[[(3R,4R)-4-(4-[3-(2-  
methoxybenzyl)oxy]propoxy)phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857281-31-3P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-(4-[(tetrahydrofuran-3-  
yl)oxy]phenyl)piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine  
857281-33-5P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-(4-  
[(tetrahydrofuran-4-yl)oxy]phenyl)piperidin-3-yl]oxy]methyl]-3,4-dihydro-  
2H-benzo[1,4]oxazine 857281-34-6P,  
6-[[[(3R,4R)-4-(4-(Cyclohexyloxy)phenyl)piperidin-3-yl]oxy]methyl]-4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857281-35-7P  
857281-37-9P, 6-[[[(3R,4R)-4-(4-(Cyclopentyloxy)phenyl)piperidin-3-  
yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857281-38-0P, 6-[[[(3R,4R)-4-(4-Ethoxyphenyl)piperidin-3-  
yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857281-39-1P, 6-[[[(3R,4R)-4-(4-[imidazol-1-  
ylmethyl]phenyl)piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazine 857281-41-5P,  
[4-[6-[[[(3R,4R)-4-(4-[3-(2-Methoxybenzyloxy)propoxy]phenyl)piperidin-3-  
yl]oxy]methyl]-2,3-dihydrobenzo[1,4]oxazin-4-yl]butyl]amine  
857281-51-7P, 6-[[[(3R,4R)-4-(4-Ethoxymethylphenyl)piperidin-3-  
yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857281-53-9P, 6-[1(R)-[[[(3R,4R)-4-(4-[3-(2-  
Methoxybenzyloxy)propoxy]phenyl)piperidin-3-yl]oxy]ethyl]-4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857281-54-0P,  
6-[1(S)-[[[(3R,4R)-4-(4-[3-(2-Methoxybenzyloxy)propoxy]phenyl)piperidin-3-  
yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857281-55-1P, 6-[1(R)-[[[(3R,4R)-4-(4-Methoxyphenyl)piperidin-3-  
yl]oxy]propyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857281-56-2P, 6-[1(S)-[[[(3R,4R)-4-(4-Methoxyphenyl)piperidin-3-  
yl]oxy]propyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857281-57-3P,  
L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
857282-10-1P, 3-[4-[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-  
benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy]propan-1-ol  
857282-12-3P, 6-[[[(3R,4R)-4-(4-[(1H-Indol-4-  
yloxy)methyl]phenyl)piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-  
dihydro-2H-benzo[1,4]oxazine 857282-14-5P,  
N-[3-[[4-[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-  
6-yl]methoxy]piperidin-4-yl]benzyl]oxy]phenyl]acetamide  
857282-15-6P, 5-[[4-[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]benzyl]oxy]-3,4-dihydro-1H-  
quinolin-2-one 857282-16-7P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(3-methyl-1H-indol-4-  
yl)oxy]methyl]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857282-17-8P,  
2-[3-[[4-[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-  
6-yl]methoxy]piperidin-4-yl]benzyl]oxy]phenyl]-N-methylacetamide  
857282-20-3P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(1-methyl-1H-  
indol-4-yl)oxy]methyl]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857282-22-5P,  
2-[3-[[4-[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-  
6-yl]methoxy]piperidin-4-yl]benzyl]oxy]phenyl]acetamide  
857282-24-7P, 6-[[[(3R,4R)-4-[4-[(3-1H-Imidazol-4-  
yl)phenoxy]methyl]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-  
3,4-dihydro-2H-benzo[1,4]oxazine 857282-27-0P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-(4-phenoxyphenyl)piperidin-3-  
yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857282-31-6P,  
N-Methyl-5-[4-[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-  
benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenyl]pentanamide  
RL: PKC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(drug candidate; prepn. of piperidines as renin inhibitors useful  
against hypertension and other disorders)  
IT 9015-94-5, Renin, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Inhibitors; preparation of piperidines as renin inhibitors useful  
against hypertension and other disorders)  
IT 57-57-8, Propiolactone 62-53-3, Aniline, reactions 67-63-0,  
2-Propanol, reactions 75-30-9, 2-Iodopropane 75-31-0, Isopropylamine,  
reactions 76-83-5, Trityl chloride 83-34-1, 3-Methylindole 88-75-5,  
2-Nitrophenol 90-00-6, 2-Ethylphenol 90-01-7, 2-Hydroxymethylphenol  
90-05-1 91-21-4 92-54-6 95-48-7, reactions 96-21-9 96-33-3,  
Methyl acrylate 98-80-6, Phenylboronic acid 100-39-0, Benzyl bromide  
100-44-7, Benzyl chloride, reactions 104-57-4, Benzyl formate  
105-39-5, Ethyl chloroacetate 106-44-5, reactions 106-95-6, Allyl  
bromide, reactions 106-96-7, Propargyl bromide 107-08-4,  
1-Iodopropane 108-39-4, reactions 108-46-3, 1,3-Benzenediol, reactions 108-86-1,  
Bromobenzene, reactions 108-94-1, Cyclohexanone, reactions 108-95-2,  
Phenol, reactions 109-64-8, 1,3-Dibromopropane 109-85-3,  
2-Methoxyethylamine 110-52-1, 1,4-Dibromobutane 110-87-2,  
3,4-Dihydro-2H-pyran 110-91-8, Morpholine, reactions 123-62-6,  
Propionic anhydride 123-75-1, Pyrrolidine, reactions 134-20-3, Methyl  
2-aminobenzoate 142-08-5, 2(1H)-Pyridinone 150-19-6, 3-Methoxyphenol

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
857281-57-3P, (2,5-Difluorophenyl)[3-[4-[(3R,4R)-3-[[4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-  
yl]phenoxy]propyl]amine 857281-61-9P,  
(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]-3-[[2-(3-  
methoxypropoxy)benzyl]oxy]piperidine 857281-64-2P,  
6-[[[(3R,4R)-4-(4-Benzyloxyphenyl)piperidin-3-yl]oxy]methyl]-4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857281-66-4P,  
[2-[4-[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-  
yl]methoxy]piperidin-4-yl]phenoxy]ethyl]dimethylamine  
857281-74-4P, [3-[4-[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-  
yl]phenoxy]propyl]dimethylamine 857281-77-7P,  
6-[[[(3R,4R)-4-(4-Methoxyphenyl)piperidin-3-yl]oxy]methyl]-4-(3-  
methoxypropyl)-2,2-dimethyl-2H-benzo[1,4]oxazine 857281-78-8P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-(4-phenoxy)methylphenyl]piperidin-3-  
yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857281-80-2P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-(o-tolyl)oxy]methyl]phenyl]piperidin-  
3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857281-81-3P  
6-[[[(3R,4R)-4-[4-[(3-Fluorophenoxy)methyl]phenyl]piperidin-3-  
yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857281-82-4P, 6-[[[(3R,4R)-4-[4-[(2-  
Fluorophenoxy)methyl]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-  
3,4-dihydro-2H-benzo[1,4]oxazine 857281-84-6P  
6-[[[(3R,4R)-4-[4-[(4-Fluorophenoxy)methyl]phenyl]piperidin-3-yl]oxy]methyl]-  
4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857281-85-7P,  
6-[[[(3R,4R)-4-[4-[(2,4-  
Difluorophenoxy)methyl]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857281-86-8P,  
6-[[[(3R,4R)-4-[4-[(2-Methoxyphenyl)methyl]phenyl]piperidin-3-  
yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857281-87-9P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[(m-  
tolyl)oxy]methyl]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857281-88-0P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[(p-tolyl)oxy]methyl]phenyl]piperidin-  
3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857281-89-1P  
6-[[[(3R,4R)-4-(4-Isopropoxymethylphenyl)piperidin-3-yl]oxy]methyl]-4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857281-92-6P,  
3,4-Dihydro-6-[[[(3R,4R)-4-[4-[(3-2-  
methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-  
methoxypropyl)-2,2-dimethyl-2H-benzo[1,4]oxazine 857281-93-7P,  
[4-[6-[[[(3R,4R)-4-[4-[(3-2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-  
yl]oxy]methyl]-2,3-dihydrobenzo[1,4]oxazin-4-yl]butyl]methylamine  
857281-97-1P, 6-[[[(3R,4R)-4-(3-Fluoro-4-methoxyphenyl)piperidin-3-  
yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857282-02-1P, 8-[[[(3R,4R)-4-[4-[(3-2-  
Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4,4-dimethyl-  
1,4-dihydrobenzo[d][1,3]oxazin-2-one 857282-08-7P,  
6-[[[(3R,4R)-4-[4-[(Benzodioxol-5-yl)oxy]methyl]phenyl]piperidin-3-  
yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857281-98-0P,  
L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
288-32-4, 1H-Imidazole, reactions 331-25-9 345-29-9,  
4-Fluoro-2-hydroxybenzoic acid 348-52-7 352-34-1 367-12-4  
367-27-1  
367-30-6, 2,5-Difluoroaniline 371-41-5 372-20-3 428-63-7,  
2,2-Difluoropropane-1,3-diol 446-48-0 446-58-2,  
2-Fluoro-6-hydroxymethylphenol 451-82-1, 2-Fluorophenylacetic acid  
453-20-3 455-38-9, 3-Fluorobenzoic acid 456-41-7 497-25-6,  
2-Oxazolidinone 501-53-1, Benzyl chloroformate 503-29-7, Azetidine  
504-63-2, 1,3-Propanediol 529-28-2 530-62-1,  
Bis(imidazol-1-yl)methanone 533-31-3, 1,3-Benzodioxol-5-ol 535-11-5,  
Ethyl 2-bromopropionate 579-74-8 586-30-1, 3-Hydroxy-4-methylbenzoic  
acid 588-63-6, (3-Bromopropoxy)benzene 591-50-4, Iodobenzene  
615-18-9, 2-Chlorobenzoazole 615-20-3, 2-Chlorobenzothiazole  
615-41-8  
616-45-5, 2-Pyrrolidinone 619-23-8, 3-Nitrobenzyl chloride 621-34-1,  
3-Ethoxyphenol 621-42-1 625-99-0 627-18-9, 3-Bromopropan-1-ol  
635-46-1, 1,2,3,4-Tetrahydroquinoline 695-85-2,  
4-Chloro-5-methoxypyrimidine 696-62-8 766-85-8 771-99-3,  
4-Phenylpiperidine 823-78-9, 3-Bromobenzyl bromide 873-62-1  
936-44-7, 3-Phenylpyrrolidine 953-91-3 1016-47-3,  
N-[2-(1H-Indol-3-yl)ethyl]acetamide 1072-53-3 1121-86-4 1125-31-1  
1129-28-8, Methyl 3-(bromomethyl)benzoate 1129-78-8,  
1-(3-Bromopropoxy)-4-fluorobenzene 1450-72-2,  
1-(2-Hydroxy-5-methylphenyl)ethanone 1481-92-1,  
2-(3-Hydroxypropyl)phenol 1556-18-9 1736-67-0,  
2-(4-Fluorophenyl)acetaldehyde 1758-46-9, 2-Phenoxyethylamine  
1877-77-6, (3-Aminophenyl)methanol 2033-82-1,  
1-(4-Bromobutoxy)-2-methylbenzene 2043-61-0, Cyclohexanecarboxaldehyde  
2081-44-9 2265-91-0 2265-92-1 2302-25-2, 4-Bromimidazole  
2375-33-7, 4-Fluoro-2-hydroxymethylphenol 2380-94-1, 4-Hydroxyindole  
2516-33-8, Cyclopropanemethanol 2566-44-1, Cyclopropanemethanol  
2646-90-4 2713-31-7, 2,5-Difluorophenol 2713-33-9, 3,4-Difluorophenol  
2713-34-0, 3,5-Difluorophenol 2719-27-9, Cyclohexanecarbonyl chloride  
2896-67-5, 2-Methoxy-6-methylphenol 3011-34-5,  
4-Hydroxy-3-nitrobenzaldehyde 3034-53-5, 2-Bromothiazole 3041-17-6,  
4,5-Dihydro-3H-benzo[b]oxepin-2-one 3245-40-7,  
1-(3-Bromopropoxy)-3-methoxybenzene 3245-57-6,  
2-(3-Bromopropoxy)-1,3-dimethoxybenzene 3257-51-0,  
1-(4-Bromobutoxy)-2-methoxybenzene 3350-78-5, 3-Methylbut-2-enoyl  
chloride 3351-52-8, 1-(3-Bromopropoxy)-3-trifluoromethylbenzene  
3493-80-5, 2-Bromobenzyl bromide 4023-34-1, Cyclopropanecarbonyl  
chloride 4229-44-1 4244-59-1, 3-Methoxypropionyl chloride 4296-15-5  
4363-13-7 4383-05-5, 2-Hydroxymethyl-6-methoxyphenol 4670-56-8,  
Methyl  
2-hydroxy-4-methylbenzoate 5029-67-4 5332-06-9, 4-Bromobutyronitrile  
5382-16-1, 4-Piperidinol 5469-66-9, 1,3-Propanediol  
di-p-toluenesulfonate 5663-39-8, 2-(o-Tolyl)-[1,3]dioxane 5876-51-7  
6291-74-3, 1-(3-Bromopropoxy)-3-methylbenzene 6315-52-2, Ethylene  
di(p-toluenesulfonate) 6418-38-8, 2,3-Difluorophenol 6482-24-2,  
2-Bromomethyl methyl ether 7230-41-3,  
N-(2-Fluorophenyl)-4-methylbenzenesulfonamide 7405-12-1,  
2-Hydroxymethyl-5-methylphenol 7417-18-7, 2-(2-Methoxyphenyl)ethanol  
7768-28-2, 2-(2-Hydroxyethyl)phenol 13161-32-5,  
4-Hydroxy-3H-isobenzofuran-1-one 13291-18-4, Isopropenylmagnesium  
bromide 13331-23-2, Furan-2-ylboronic acid 13694-84-3,  
Tetrahydrofuran-3-yl toluene-4-sulfonate 14092-04-7,  
1-Propenylmagnesium  
bromide 14847-51-9, 2-Bromo-5-methylphenol 16088-62-3,

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
(S)-(-)-Propylene oxide, reactions 17349-64-3,  
7-Methylbenzofuran-2-carboxylic acid 17913-18-7,  
1-Chloro-4-methoxybutane 18342-66-0 18621-18-6, 3-Hydroxyazetidine  
hydrochloride 19190-68-2, 4-Methyl-1,3-dihydrobenzimidazol-2-one  
19501-89-4, 3,3,7-Trimethyl-1,3-dihydroindol-2-one 20349-89-7, Methyl  
3-(2-hydroxyphenyl)propionate 22446-38-4, Ethyl  
2-(3-hydroxyphenyl)acetate 22470-99-1, 2-Hydroxymethyl-6-methylphenol  
23468-00-0, 1-(4-Bromobutoxy)-2-chlorobenzene 23529-80-8,  
1-(4-Bromobutoxy)-3-chlorobenzene 24100-18-3, 2-Bromo-3-methoxypyridine  
24677-78-9, 2,3-Dihydroxybenzaldehyde 26690-80-2, tert-Butyl  
(2-hydroxyethyl)carbamate 28148-04-1 28177-48-2, 2,6-Difluorophenol  
29006-02-8, 4-Methoxybutyric acid 29922-52-9,  
2-Hydroxymethyl-3-methylphenol 30389-33-4 30697-26-8 30891-29-3,  
3-Hydroxymethyl-5-methoxyphenol 31729-66-5 33567-59-8 33574-02-6  
33756-81-9 34113-69-4, 4-Chloro-3-hydroxybenzoic acid 34368-52-0,  
3-(S)-Hydroxypyrrrolidin-2-one 35387-19-0, 4-(2-Hydroxyphenyl)butyric  
acid 36215-07-3, 1-Chloro-3-methoxypropane 36865-38-0,  
1-Chloro-3-methoxypropan-1-ol 37432-42-4, 1-(3-Bromopropoxy)-3-chlorobenzene  
38256-93-8, 2-Methoxy-N-methylthyamine 40191-32-0 40870-59-5,  
4-Methyl-3-nitrobenzyl alcohol 41253-21-8 49775-37-3,  
3-Ethoxypropionyl chloride 50912-59-9,  
1-(3-Bromopropoxy)-2-chlorobenzene 50912-60-2,  
1-(3-Bromopropoxy)-2-methylbenzene 51446-31-2,  
4-Fluoro-3-hydroxybenzoic  
acid 51594-55-9, (R)-(-)-Epichlorohydrin, reactions 52289-93-7  
53078-85-6, (2-Bromo-5-methylphenyl)amine 54322-65-5, Cyclopropylacetyl  
chloride 56219-51-3, 5-(3-Bromopropoxy)benzo[1,3]dioxole 57113-91-4,  
Methyl 2-amino-3-nitrobenzoate 58885-58-8, 3-(Boc-amino)-1-propanol  
59689-18-8, 2-(2-Amino-3-methylphenyl)propan-2-ol 61542-10-7,  
61882-39-1, 4-Methoxybutyl chloride 64248-58-4 67021-83-4,  
3H-Benzimidazol-4-ol 67531-86-6, 2-Fluoro-6-hydroxybenzoic acid  
67563-72-8, 1-(3-Bromopropoxy)-2-methoxybenzene 67843-74-7,  
(S)-(+)-Epichlorohydrin, reactions 71031-03-3,  
2-(S)-Phenoxydimethylsilane 72985-24-1, Methyl  
5-hydroxymethyl-2-methylbenzoate 73183-34-3 75322-09-7,  
3-(Cyclohexyloxy)propan-1-ol 76513-69-4,  
[2-(Trimethylsilyl)ethoxy]methyl chloride 76570-20-2 77635-17-7,  
8-Oxo-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid 78555-40-5,  
2-(3-Bromopropoxy)benzonitrile 81863-45-8,  
(3-Amino-4-methylphenyl)methanol 82617-49-0,  
2-Bromo-1-bromomethyl-3-nitrobenzene 84028-88-6, Ethyl  
2-(S)-trifluoromethylsulfonfylpropionate 84028-89-7, Ethyl  
2-(R)-trifluoromethylsulfonfylpropionate 85117-99-3,  
2,5-Difluorobenzyl bromide 87199-18-6, 3-Hydroxyphenylboronic acid  
87836-36-0 92550-77-7, 4-(Iodoethoxy)trisopropylsilane 97986-34-0  
105294-45-9, N-(2-Hydroxyphenyl)-3-methoxypropionamide 106558-68-3,  
1-(4-Bromobutoxy)-2-fluorobenzene 106899-00-7,  
2-(2-Methylaminophenyl)ethanol 111762-13-1,  
N-[2-(2-Hydroxyphenyl)ethyl]acetamide 116183-80-3,  
(S)-1-Benzylpyrrolidin-3-yl toluene-4-sulfonate 116547-92-3,  
N-(2-Iodophenyl)methanesulfonamide 118811-07-7 122536-94-1,  
(S)-3-Pyrrolidinol hydrochloride 131529-85-6, N-Methyl-4-pentynamide  
136472-28-1, Ethyl 4-[2-chloro-2-(methoxycarbonyl)ethyl]-3-nitrobenzoate  
136472-36-1, Ethyl 2-oxo-1,2-dihydroquinoline-7-carboxylate  
139986-03-1,

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
tolylsulfonfyl)oxy]ethoxy]phenyl]piperidine-1-carboxylate 873945-77-8  
1048686-01-6 1048687-36-0 1048687-73-5 1048687-96-2  
1048688-50-1 1048688-89-6 1048689-32-2 1048689-80-0  
RI: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. of piperidines as renin inhibitors useful against hypertension  
and other disorders)  
IT 79-30-1P, Isobutyryl chloride 2563-04-4P, 2-Ethoxy-5-methylphenol  
4383-07-7P, 2-Hydroxymethyl-4-methylphenol 16375-94-3P,  
N-(3-Hydroxymethylphenyl)acetamide 37619-25-3P, Methyl  
3H-benzimidazole-4-carboxylate 71557-11-4P, Methyl  
8-oxo-5,6,7,8-tetrahydronaphthalene-1-carboxylate 87941-55-7P,  
4-Bromo-1-trityl-1H-imidazole 107582-20-7P, Methyl 2,3-diaminobenzoate  
125872-98-2P, 4-Allyloxy-3-nitrobenzaldehyde 127506-02-9P,  
N-(5-Hydroxymethyl-2-methyl-2-phenyl)acetamide 142677-42-7P,  
3-(1H-Imidazol-4-yl)phenol 229323-04-0P,  
(R)-1-Benzylpyrrolidin-3-yl)methylamine 615568-17-7P,  
6-Hydroxymethyl-4H-benzo[1,4]oxazin-3-one 660390-77-2P,  
3-Fluoro-2-hydroxymethylphenol 672957-91-4P, Methyl  
1-methyl-1H-benzimidazole-4-carboxylate 697306-33-5P, Ethyl  
2-oxo-1,2,3,4-tetrahydroquinoline-7-carboxylate 709025-81-0P,  
(5-Fluoro-2-hydroxyphenyl)acetoneitrile 853643-71-7P,  
(3-Methoxypropoxy)phenyl]methanol 856840-79-4P,  
1-Methyl-1H-benzimidazole-4-yl)methanol 856840-83-0P,  
4-Chloromethyl-1-methyl-1H-benzimidazole 857271-94-4P 857271-96-6P,  
1-Chloromethyl-3-methoxy-5-(3-methoxypropoxy)benzene 857271-97-7P,  
[3-Methoxy-5-(3-methoxypropoxy)phenyl]methanol 857272-01-6P, tert-Butyl  
(3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[4-[3-(3-  
methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-  
yl]methoxy]piperidine-1-carboxylate 857272-02-7P,  
6-Chloromethyl-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
857272-03-8P, 6-Hydroxymethyl-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-  
one 857272-05-0P, tert-Butyl (3R,4R)-4-[4-[3-(2-  
methoxybenzyloxy)propoxy]phenyl]-3-[1-[(2-(3-  
methoxypropoxy)phenyl]carbamoyl]ethoxy]piperidine-1-carboxylate  
857272-06-1P, tert-Butyl (3R,4R)-3-(1-carboxyethoxy)-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-07-2P,  
2-(3-Methoxypropoxy)phenylamine 857272-08-3P, tert-Butyl  
(3R,4R)-3-(1-ethoxycarbonyl)ethoxy)-4-[4-[3-(2-  
methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857272-09-4P,  
1-(3-Methoxypropoxy)-2-nitrobenzene 857272-12-9P, tert-Butyl  
(3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[4-[3-(3-  
methoxypropyl)-2-oxo-2,3-dihydrobenzoxazol-5-yl]methoxy]piperidine-1-  
carboxylate 857272-13-0P, tert-Butyl  
(3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[2-(2-oxo-2,3-  
dihydrobenzoxazol-5-yl)methoxy]piperidine-1-carboxylate 857272-14-1P,  
tert-Butyl (3R,4R)-3-(3-amino-4-hydroxybenzyloxy)-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-15-2P,  
tert-Butyl (3R,4R)-3-(4-allyloxy-3-nitrobenzyloxy)-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-16-3P,  
1-Allyloxy-4-chloromethyl-2-nitrobenzene 857272-17-4P,  
(4-Allyloxy-3-nitrophenyl)methanol 857272-19-6P, tert-Butyl  
(3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[7-[(3-  
methoxypropoxy)benzofuran-2-yl]methoxy]piperidine-1-carboxylate  
857272-20-9P, 2-Chloromethyl-7-(3-methoxypropoxy)benzofuran  
857272-21-0P, [7-(3-Methoxypropoxy)benzofuran-2-yl]methanol  
857272-22-1P, Ethyl 7-(3-methoxypropoxy)benzofuran-2-carboxylate  
857272-23-2P, 2-Hydroxy-3-(3-methoxypropoxy)benzaldehyde 857272-25-4P,  
tert-Butyl (3R,4R)-3-[3-[(acetyl) (3-methoxypropyl)amino]-4-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
tert-Butyl 3-(R)-[(4-tolylsulfonfyl)oxy]pyrrolidine-1-carboxylate  
141776-91-2 142228-52-2, Methyl 2-(4,6-dichloro-2-methylpyrimidin-5-  
yl)acetate 145943-76-6, 1-(3-Bromopropoxy)-2-fluorobenzene  
RI: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. of piperidines as renin inhibitors useful against hypertension  
and other disorders)  
IT 147542-02-7, 2-Bromo-1-chloromethyl-4-methylbenzene 163618-94-8,  
2-Hydroxy-N-(2-methoxyethyl)benzamide 169286-55-9,  
1-(3-Bromopropoxy)-2,4-difluorobenzene 170487-40-8, Methyl  
1H-indazole-6-carboxylate 179950-75-5, Methyl  
2,2-dimethyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate  
188174-51-8, 2-(4-Bromobutoxy)-1,3-dimethoxybenzene 188614-01-9, Methyl  
3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxylate 193356-97-7,  
1-(3-Bromopropoxy)-3-fluorobenzene 202195-67-3, Methyl  
3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate 202865-66-5,  
(2-Bromo-5-fluorophenyl)methanol 209967-16-8,  
4-(2-Nitrophenyl)-3-butyn-1-ol 257938-67-3, tert-Butyl  
(3R,4R)-3-hydroxy-4-(4-hydroxyphenyl)piperidine-1-carboxylate  
257938-68-4, tert-Butyl (3R,4R)-3-hydroxy-4-[4-[3-(2-  
methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 307950-18-1,  
3-(2-Hydroxyphenyl)-N-methylpropionamide 315663-43-5,  
N-[2-(2-Nitrophenyl)ethyl]acetamide 326595-66-8,  
1-Bromo-4-bromomethyl-2-nitrobenzene 339364-79-3,  
2-(3-Methoxypropyl)phenylamine 340824-87-5 359443-15-5, tert-Butyl  
(3R,4R)-4-(4-allyloxyphenyl)-3-hydroxypropylidene-1-carboxylate  
371240-55-0, tert-Butyl (S)-3-[(4-tolylsulfonfyl)oxy]pyrrolidine-1-  
carboxylate 484676-64-4, 2-(4-Bromobutoxy)benzonitrile 538342-36-8,  
[4-Chloro-2-hydroxyphenyl]acetoneitrile 605655-08-1, tert-Butyl  
3-(4-toluenesulfonfyl)azetidine-1-carboxylate 611209-87-1, Benzyl  
(S)-1-hydroxymethyl-3-phenylpropyl)carbamate 857272-91-4,  
6-Chloromethyl-1-(3-methoxypropyl)-1H-indazole 857274-15-8, tert-Butyl  
(3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[1-[(3-  
methoxypropyl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl]methoxy]piperidine-1-  
carboxylate 857276-70-1, tert-Butyl  
(3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[2-[2-(2-  
methoxyethylcarbamoyl)phenoxy]ethoxy]piperidine-1-carboxylate  
857277-41-9, [3-Methoxy-2-(3-methoxypropoxy)phenyl]methanol  
857278-52-5,  
Benzyl (3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-  
yl]methoxy]-4-[4-[(S)-pyrrolidin-3-yl]oxy]phenyl]piperidine-1-carboxylate  
857279-71-1, Benzyl (3R,4R)-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-  
benzo[1,4]oxazin-6-yl]methoxy]-4-[4-  
[(trifluoromethylsulfonfyl)oxy]phenyl]piperidine-1-carboxylate  
857280-85-4, Benzyl  
(3R,4R)-4-[4-[2-(3-chlorophenoxy)ethoxy]phenyl]-3-[4-[(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-  
carboxylate 857281-02-8, 3-Phenylpyrrolidine hydrochloride  
857281-26-6, Benzyl (3R,4R)-3-hydroxy-4-(4-methoxyphenyl)piperidine-1-  
carboxylate 857281-50-6, (4-Bromobutoxy)trisopropylsilane  
857281-68-6, Benzyl (3R,4R)-3-[4-(3-methoxypropyl)-3,4-dihydro-2H-  
benzo[1,4]oxazin-6-yl]methoxy]-4-[4-[2-[(4-  
methyl-1H-imidazol-4-yl)methoxy]phenyl]piperidine-1-carboxylate 857272-27-6P,  
N-(5-Hydroxymethyl-2-methylphenyl)-N-(3-methoxypropyl)acetamide  
857272-29-8P, tert-Butyl (3R,4R)-3-[[3-[(acetyl) (3-  
methoxypropyl)amino]phenyl]methoxy]oxy]-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-30-1P,  
N-(3-Chloromethylphenyl)-N-(3-methoxypropyl)acetamide 857272-31-2P,  
N-(3-Hydroxymethylphenyl)-N-(3-methoxypropyl)acetamide 857272-33-4P,  
Benzyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[1-[(3-  
methoxypropyl)-1H-indol-6-yl]methoxy]piperidine-1-carboxylate  
857272-34-5P, Benzyl (3R,4R)-3-(1H-indol-6-yl)methoxy)-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-35-6P,  
Benzyl (3R,4R)-3-(1H-indol-4-yl)methoxy)-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-36-7P,  
Benzyl (3R,4R)-3-[(1-acetyl-1H-indol-6-yl)methoxy]-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-37-8P,  
Benzyl (3R,4R)-3-[(1-acetyl-1H-indol-4-yl)methoxy]-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-38-9P,  
Benzyl (3R,4R)-3-[3-(acetylhydroxyamino)benzyloxy]-4-[4-[3-(2-  
methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857272-39-0P,  
Benzyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[1-[(3-  
nitrobenzyl)oxy]piperidine-1-carboxylate 857272-40-3P, Benzyl  
(3R,4R)-3-hydroxy-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-  
carboxylate 857272-41-4P, (3R,4R)-4-[4-[3-(2-  
Methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857272-43-6P, Benzyl  
(3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[1-[(3-  
methoxypropyl)-1H-indol-4-yl]methoxy]piperidine-1-carboxylate  
857272-45-8P, tert-Butyl (3R,4R)-4-[4-[3-(2-  
methoxybenzyloxy)propoxy]phenyl]-3-[1-[(3-methoxypropoxy)-4-  
methoxybenzyl]oxy]piperidine-1-carboxylate 857272-46-9P,  
4-Chloromethyl-2-(3-methoxypropoxy)-1-methylbenzene 857272-47-0P,  
[3-(3-Methoxypropoxy)-4-methylphenyl]methanol 857272-48-1P,  
3-Methoxypropyl 3-(3-methoxypropoxy)-4-methylbenzoate 857272-50-5P,  
tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[1-[(3-  
methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-  
carboxylate 857272-51-6P,  
7-Chloromethyl-1-(3-methoxypropyl)-3,4-dihydro-  
1H-quinolin-2-one 857272-52-7P,  
7-Hydroxymethyl-1-(3-methoxypropyl)-3,4-  
dihydro-1H-quinolin-2-one 857272-53-8P,  
7-Hydroxymethyl-3,4-dihydro-1H-quinolin-2-one 857272-54-9P, Ethyl  
4-(2-methoxycarbonylvinyl)-3-nitrobenzoate 857272-56-1P, tert-Butyl  
(3R,4R)-3-[2-(2-(2-acetylaminomethyl)phenoxy]ethoxy)-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-57-2P,  
tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[2-[(4-  
tolylsulfonfyl)oxy]ethoxy]piperidine-1-carboxylate 857272-58-3P,  
tert-Butyl (3R,4R)-3-(2-hydroxyethoxy)-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-59-4P,  
tert-Butyl (3R,4R)-3-allyloxy-4-[4-[3-(2-  
methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857272-61-8P,  
tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[1-[(3-  
methoxypropyl)-2-oxo-1,2-dihydroquinolin-7-yl]methoxy]piperidine-1-  
carboxylate 857272-62-9P,  
7-Chloromethyl-1-(3-methoxypropyl)-1H-quinolin-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
2-one 857272-63-0P, 7-Hydroxymethyl-1-(3-methoxypropyl)-1H-quinolin-2-one 857272-64-1P, [2-(3-Methoxypropoxy)quinolin-7-yl]methanol 857272-65-2P, 7-Hydroxymethyl-1H-quinolin-2-one 857272-67-4P,  
tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[[2-(3-methoxypropoxy)quinolin-7-yl]methoxy]piperidine-1-carboxylate 857272-68-5P, 7-Chloromethyl-2-(3-methoxypropoxy)quinoline 857272-70-9P,  
tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[[1',2'-dihydro-1'-(3-methoxypropyl)-2'-oxospiro[cyclopropane-1,3']-3H]indol]-6'-yl]methoxy]piperidine-1-carboxylate 857272-71-0P, 6'-Bromomethyl-1'-(3-methoxypropyl)spiro[cyclopropane-1,3']-3H]indol]-2'-(1'H)-one 857272-72-1P, 6'-Methyl-1'-(3-methoxypropyl)spiro[cyclopropane-1,3'-3H-indol]-2'-(1'H)-one 857272-73-2P, N-(2-Bromo-5-methylphenyl)-N-(3-methoxypropyl)cyclopropanecarboxamide 857272-74-3P, N-(2-Bromo-5-methylphenyl)cyclopropanecarboxamide 857272-76-5P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[[7-(3-methoxypropoxy)-2,3-dihydrobenzofuran-2-yl]methoxy]piperidine-1-carboxylate 857272-78-7P, tert-Butyl (3R,4R)-3-[[[4-fluoro-3-(3-methoxypropoxy)phenyl]methoxy]oxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-79-8P, 4-Chloromethyl-1-fluoro-2-(3-methoxypropoxy)benzene 857272-80-1P, [4-Fluoro-3-(3-methoxypropoxy)phenyl]methanol 857272-81-2P, 3-Methoxypropyl 4-fluoro-3-(3-methoxypropoxy)benzoate 857272-83-4P, Benzyl (3R,4R)-3-[[7-bromo-1-(3-methoxypropyl)-3-methyl-1H-indol-6-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-84-5P, Benzyl (3R,4R)-3-[(7-bromo-3-methyl-1H-indol-6-yl)methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-85-6P, Benzyl (3R,4R)-3-(2-bromo-3-nitrobenzyloxy)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-87-8P, Benzyl (3R,4R)-3-[[7-bromo-1-(3-methoxypropyl)-2-methyl-1H-indol-6-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-88-9P, Benzyl (3R,4R)-3-[(7-bromo-3-methyl-1H-indol-6-yl)methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857272-90-3P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[[1-(3-methoxypropyl)-1H-indazol-6-yl]methoxy]piperidine-1-carboxylate 857272-92-5P, [1-(3-Methoxypropyl)-1H-indazol-6-yl]methanol 857272-93-6P, Methyl 1-(3-methoxypropyl)-1H-indazole-6-carboxylate 857272-94-7P, Methyl 2-(3-methoxypropyl)-2H-indazole-6-carboxylate 857272-96-9P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[[2-(3-methoxypropyl)-2H-indazol-6-yl]methoxy]piperidine-1-carboxylate 857272-97-0P, 6-Chloromethyl-2-(3-methoxypropyl)-2H-indazole 857272-98-1P, [2-(3-Methoxypropyl)-2H-indazol-6-yl]methanol 857273-00-8P, tert-Butyl (3R,4R)-4-[4-[4-(2-methoxyphenoxy)butoxy]phenyl]-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857273-01-9P, tert-Butyl (3R,4R)-3-hydroxy-4-[4-(4-(2-methoxyphenoxy)butoxy]phenyl]piperidine-1-carboxylate 857273-04-2P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[2-[2-(2-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
tert-Butyl (3R,4R)-3-(1-(S)-ethoxycarbonylthoxy)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-40-6P, tert-Butyl (3R,4R)-3-[1-(R)-[2-(2-acetylaminoethyl)phenyl]carbamoyl]ethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-41-7P, tert-Butyl (3R,4R)-3-(1-(R)-carboxyethoxy)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-42-8P, tert-Butyl (3R,4R)-3-(1-(R)-ethoxycarbonylthoxy)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-44-0P, tert-Butyl (3R,4R)-3-[2-[2-(2-acetylaminoethyl)phenoxy]ethoxy]-4-(4-methoxyphenyl)piperidine-1-carboxylate 857273-45-1P, tert-Butyl (3R,4R)-4-(4-methoxyphenyl)-3-[2-[(4-tolylsulfonyl)oxy]ethoxy]piperidine-1-carboxylate 857273-46-2P, tert-Butyl (3R,4R)-3-(2-hydroxyethoxy)-4-(4-methoxyphenyl)piperidine-1-carboxylate 857273-47-3P, tert-Butyl (3R,4R)-3-hydroxy-4-(4-methoxyphenyl)piperidine-1-carboxylate 857273-49-5P, tert-Butyl (3R,4R)-3-[2-[2-(2-acetylaminoethyl)phenoxy]ethoxy]-4-[4-[4-(2-methoxyphenoxy)butoxy]phenyl]piperidine-1-carboxylate 857273-50-8P, tert-Butyl (3R,4R)-4-[4-(4-(2-methoxyphenoxy)butoxy]phenyl]-3-[2-[(4-tolylsulfonyl)oxy]ethoxy]piperidine-1-carboxylate 857273-52-0P, tert-Butyl (3R,4R)-3-(2-hydroxyethoxy)-4-[4-[4-(2-methoxyphenoxy)butoxy]phenyl]piperidine-1-carboxylate 857273-54-2P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[2-[2-[2-(2-oxopyrrolidin-1-yl)ethyl]phenoxy]ethoxy]piperidine-1-carboxylate 857273-56-4P, tert-Butyl (3R,4R)-3-[2-[2-(2-imidazol-1-yl)ethyl]phenoxy]ethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-58-6P, tert-Butyl (3R,4R)-3-[2-[2-(2-cyanoethyl)phenoxy]ethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-60-0P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[2-[2-[2-(2-oxooxazolidin-3-yl)ethyl]phenoxy]ethoxy]piperidine-1-carboxylate 857273-62-2P, tert-Butyl (3R,4R)-3-[[4-ethyl-3-(3-methoxypropoxy)phenyl]methoxy]oxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-63-3P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[[3-(3-methoxypropoxy)-4-vinylbenzyl]oxy]piperidine-1-carboxylate 857273-65-5P, 857273-66-6P, tert-Butyl (3R,4R)-4-(4-hydroxyphenyl)-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857273-67-7P, 857273-68-8P, 7-[[[(3R,4R)-4-(4-Hydroxyphenyl)piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857273-69-9P, tert-Butyl (3R,4R)-4-(4-hydroxyphenyl)-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857273-70-2P, tert-Butyl (3R,4R)-4-(4-allyloxyphenyl)-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857273-71-3P, 3-[[1-(2-Methoxyphenyl)ethoxy]propan-1-ol 857273-72-4P, 2-(2-Methoxyphenyl)-2-methyl-1-[1,3]dioxane 857273-74-6P, tert-Butyl (3R,4R)-4-[4-[2-[2-(2-methoxybenzyloxy)ethoxy]phenyl]-3-[1-(3-

methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857273-75-7P, 2-[2-(2-Methoxyphenyl)ethoxy]ethyl toluene-4-sulfonate 857273-76-8P, 2-[2-(2-Methoxyphenyl)ethoxy]ethanol 857273-77-9P, [2-(2-Methoxyphenyl)ethoxy]acetic acid 857273-79-1P,

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
(1,2,4)triazol-1-yl)ethyl]phenoxy]ethoxy]piperidine-1-carboxylate 857273-05-3P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[2-[2-[(4-tolylsulfonyl)oxy]ethyl]phenoxy]ethoxy]piperidine-1-carboxylate 857273-06-4P, tert-Butyl (3R,4R)-3-[2-[2-(2-hydroxyethyl)phenoxy]ethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-08-6P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[2-[2-(2-tetrazol-1-yl)ethyl]phenoxy]ethoxy]piperidine-1-carboxylate 857273-09-7P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[2-[2-(2-tetrazol-2-yl)ethyl]phenoxy]ethoxy]piperidine-1-carboxylate 857273-12-2P, Benzyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[[[4-methoxycarbonyl-3-(3-methoxypropoxy)phenyl]methoxy]oxy]piperidine-1-carboxylate 857273-13-3P, Methyl 4-bromomethyl-2-(3-methoxypropoxy)benzoate 857273-14-4P, Methyl 2-(3-methoxypropoxy)-4-methylbenzoate 857273-16-6P, tert-Butyl (3R,4R)-3-[2-[2-[2-[acetyl(methyl)amino]ethyl]phenoxy]ethoxy]-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857273-18-8P, tert-Butyl (3R,4R)-3-[[[4-chloro-3-(3-methoxypropoxy)phenyl]methoxy]oxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-19-9P, tert-Butyl (3R,4R)-3-(4-chloro-3-hydroxybenzyloxy)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-20-2P, tert-Butyl (3R,4R)-3-(3-allyloxy-4-chlorobenzyloxy)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-21-3P, 2-Allyloxy-1-chloro-4-chloromethylbenzene 857273-22-4P, (3-Allyloxy-4-chlorophenyl)methanol 857273-23-5P, Allyl 3-allyloxy-4-chlorobenzoate 857273-25-7P, tert-Butyl (3R,4R)-3-[2-[2-[2-[(imidazol-1-yl)carbonyl]oxy]ethyl]phenoxy]ethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-27-9P, Benzyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[[1-(3-methoxypropyl)-1H-indol-2-yl]methoxy]piperidine-1-carboxylate 857273-28-0P, Benzyl (3R,4R)-3-(1H-indol-2-yl)methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-29-1P, Benzyl (3R,4R)-3-[[1-methylsulfonyl-1H-indol-2-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-30-4P, Benzyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[(prop-2-ynyl)oxy]piperidine-1-carboxylate 857273-32-6P, tert-Butyl (3R,4R)-3-[[[2-(2-acetylaminoethyl)phenyl]carbamoyl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-33-7P, tert-Butyl (3R,4R)-3-(carboxymethoxy)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857273-34-8P, N-[2-(2-Aminophenyl)ethyl]acetamide 857273-36-0P, tert-Butyl (3R,4R)-3-[(S)-1-[[2-(2-acetylaminoethyl)phenyl]carbamoyl]ethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-37-1P, tert-Butyl (3R,4R)-3-(1-(S)-carboxyethoxy)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-38-2P,

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
tert-Butyl (3R,4R)-4-[4-[3-[(1-(2-methoxyphenyl)ethoxy]propoxy]phenyl]-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857273-83-7P, tert-Butyl (3R,4R)-3-[3-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857273-85-9P, tert-Butyl (3R,4R)-4-[4-[4-(2-fluorophenoxy)butoxy]phenyl]-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857273-87-1P, tert-Butyl (3R,4R)-4-[4-[4-[(2-ethylphenyl)oxy]butoxy]phenyl]-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857273-88-2P, 1-(4-Bromobutoxy)-2-ethylbenzene 857273-90-6P, tert-Butyl (3R,4R)-4-[4-[4-(2-cyanophenoxy)butoxy]phenyl]-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857273-91-7P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[2-[2-(2-methoxycarbonyl)ethyl]phenoxy]ethoxy]piperidine-1-carboxylate 857273-93-9P, tert-Butyl (3R,4R)-3-[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]-4-[4-[4-(3-methylindol-1-yl)butoxy]phenyl]piperidine-1-carboxylate 857273-94-0P, 1-(4-Bromobutyl)-3-methyl-1H-indole 857273-96-2P, tert-Butyl (3R,4R)-2-[2-[2-(3-cyanopropyl)phenoxy]ethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857273-97-3P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[2-[2-[3-[(4-tolylsulfonyl)oxy]propyl]phenoxy]ethoxy]piperidine-1-carboxylate 857273-98-4P, tert-Butyl (3R,4R)-3-[2-[2-(3-hydroxypropyl)phenoxy]ethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-00-1P, tert-Butyl (3R,4R)-3-[2-[2-[2-[(methylsulfonyl)amino]ethyl]phenoxy]ethoxy]-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857274-01-2P, tert-Butyl (3R,4R)-3-[2-[2-(2-aminoethyl)phenoxy]ethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-02-3P, tert-Butyl (3R,4R)-3-[2-[2-(2-azidoethyl)phenoxy]ethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-04-5P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[[2-(4-methoxybutyl)amino]phenyl]methoxy]piperidine-1-carboxylate 857274-05-6P, tert-Butyl (3R,4R)-3-(2-amino)benzyloxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-06-7P, tert-Butyl (3R,4R)-3-(2-bromobenzyloxy)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-08-9P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[[1-(3-methoxypropyl)-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-6-yl]methoxy]piperidine-1-carboxylate 857274-09-0P, 6-Bromomethyl-1-(3-methoxypropyl)-3,3-dimethyl-1,3-dihydroindol-2-one 857274-10-3P, 1-(3-Methoxypropyl)-3,3,6-trimethyl-1,3-dihydroindol-2-one 857274-11-4P, N-(2-Bromo-5-methylphenyl)-N-(3-methoxypropyl)isobutyramide 857274-12-5P, N-(2-Bromo-5-methylphenyl)isobutyramide 857274-17-0P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[[2-[(4-methoxybutyl) (methyl)amino]phenyl]methoxy]oxy]piperidine-1-carboxylate 857274-19-2P, tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]-3-[[3-[(2-methoxybenzyloxy)propoxy]phenyl] (phenyl)carbamoyl]methoxy]piperidine-1-carboxylate 857274-20-5P, tert-Butyl (3R,4R)-4-[4-[3-(2-

methoxybenzyloxy)propoxy]phenyl]-3-[(phenylcarbamoyl)methoxy]piperidine-1-



L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 carboxylate 857274-22-7P, tert-Butyl  
 (3R,4R)-3-[[7-(2-acetylaminomethyl)benzofuran-2-ylmethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-23-8P,  
 N-[2-(2-Chloromethylbenzofuran-7-yl)ethyl]acetamide 857274-24-9P,  
 N-[2-(2-Hydroxymethylbenzofuran-7-yl)ethyl]acetamide 857274-25-0P,  
 Methyl 7-(2-acetylaminomethyl)benzofuran-2-carboxylate 857274-26-1P,  
 Methyl 7-cyanomethylbenzofuran-2-carboxylate 857274-27-2P, Methyl  
 7-bromomethylbenzofuran-2-carboxylate 857274-28-3P, Methyl  
 7-methylbenzofuran-2-carboxylate 857274-30-7P, tert-Butyl  
 (3R,4R)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[2-[2-[(2-methoxybenzyl)amino]ethyl]phenoxy]ethoxy]piperidine-1-carboxylate  
 857274-33-0P, tert-Butyl (3R,4R)-3-[2-[2-(3-dimethylaminopropyl)phenoxy]ethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-35-2P,  
 tert-Butyl (3R,4R)-3-[[4-cyano-3-(3-methoxypropoxy)phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-37-4P, tert-Butyl (3R,4R)-3-[2-[2-(3-methylsulfonylpropyl)phenoxy]ethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-38-5P,  
 tert-Butyl  
 (3R,4R)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[2-[2-(3-methylsulfonylpropyl)phenoxy]ethoxy]piperidine-1-carboxylate 857274-40-9P, Benzyl (3R,4R)-3-[[4-carbamoyl-3-(3-methoxypropoxy)phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-41-0P,  
 Benzyl (3R,4R)-3-[[4-chlorocarbonyl-3-(3-methoxypropoxy)phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-42-1P,  
 Benzyl  
 (3R,4R)-3-[[4-carboxy-3-(3-methoxypropoxy)phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-44-3P, Benzyl  
 (3R,4R)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[[3-(3-methoxypropoxy)-4-(methoxycarbonyl)benzyl]oxy]piperidine-1-carboxylate 857274-46-5P, Benzyl  
 (3R,4R)-3-[[4-(dimethylcarbamoyl)-3-(3-methoxypropoxy)phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-48-7P, tert-Butyl (3R,4R)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[2-[2-(2-methylcarbamoyl)ethyl]phenoxy]ethoxy]piperidine-1-carboxylate 857274-50-1P, tert-Butyl (3R,4R)-3-[7-(2-acetylaminomethyl)-2,3-dihydrobenzofuran-2-ylmethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-52-3P, tert-Butyl (3R,4R)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[[2-(3-methoxypropoxy)phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-54-5P, tert-Butyl (3R,4R)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[[2-(4-methoxybutyl)phenyl]carbamoyl]methoxy]piperidine-1-carboxylate 857274-55-6P, 2-(4-Methoxybutyl)phenylamine 857274-56-7P, 1-(4-Methoxybut-1-ynyl)-2-nitrobenzene 857274-58-9P, Benzyl  
 (3R,4R)-3-[[1-(2-acetylaminomethyl)-7-bromo-3-methyl-1H-indol-6-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857274-93-2P, tert-Butyl (3R,4R)-4-[4-[3-[(2-methoxy-6-methoxyphenyl)ethoxy]ethoxy]phenyl]-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857274-94-3P, 2-(3-Bromopropyl)-1-methoxy-3-methylbenzene 857274-96-5P, tert-Butyl (3R,4R)-4-[4-[4-(2-methoxy-6-methylphenoxy)butoxy]phenyl]-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857274-97-6P, 2-(4-Bromobutoxy)-1-methoxy-3-methylbenzene 857274-99-8P, tert-Butyl  
 (3R,4R)-4-[4-[4-(3-chlorophenoxy)butoxy]phenyl]-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857275-01-5P, tert-Butyl  
 (3R,4R)-3-[[1-(2-acetylaminomethyl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-02-6P, tert-Butyl  
 (3R,4R)-3-[[1-(2-aminoethyl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-03-7P, tert-Butyl  
 (3R,4R)-3-[[1-(2-azidoethyl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate  
 R1: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of piperidines as renin inhibitors useful against hypertension and other disorders)  
 IT 857275-04-8P, tert-Butyl (3R,4R)-3-[[3,3-dimethyl-1-[2-[(4-tolylsulfonyl)oxy]ethyl]-2,3-dihydro-1H-indol-6-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-05-9P, tert-Butyl (3R,4R)-3-[[1-(2-hydroxyethyl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-06-0P, tert-Butyl (3R,4R)-3-[[3,3-dimethyl-1-[2-(triisopropylsilyl)oxy]ethyl]-2,3-dihydro-1H-indol-6-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-07-1P, tert-Butyl (3R,4R)-3-[[3,3-dimethyl-2-oxo-1-[2-(triisopropylsilyl)oxy]ethyl]-2,3-dihydro-1H-indol-6-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-08-2P, tert-Butyl (3R,4R)-3-[[4-bromo-3-[(isobutyl)2-(triisopropylsilyl)oxy]phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-09-3P, tert-Butyl (3R,4R)-3-[(4-bromo-3-isobutylaminobenzyloxy)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-10-6P, tert-Butyl (3R,4R)-3-(3-amino-4-bromobenzyloxy)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-11-7P, tert-Butyl (3R,4R)-3-(4-bromo-3-nitrobenzyloxy)-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-13-9P, tert-Butyl (3R,4R)-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]-3-[[2-(3-methoxypropyl)phenyl]methyl]carbamoyl]methoxy]piperidine-1-carboxylate 857275-15-1P, tert-Butyl (3R,4R)-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]-3-[[2-(4-methoxybutyl)phenyl]methyl]carbamoyl]methoxy]piperidine-1-carboxylate 857275-17-3P, tert-Butyl (3R,4R)-3-[2-[2-(2-acetylaminomethyl)phenoxy]ethoxy]phenyl]piperidine-1-carboxylate 857275-18-4P, tert-Butyl (3R,4R)-4-[4-[2-[2-(2-Methoxyphenyl)ethoxy]ethoxy]phenyl]-3-

Habt

12/10/2009

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 857274-59-0P, Benzyl (3R,4R)-3-[[1-(2-aminoethyl)-7-bromo-3-methyl-1H-indol-6-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-60-3P, Benzyl  
 (3R,4R)-3-[[7-bromo-1-(cyanomethyl)-3-methyl-1H-indol-6-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-62-5P, tert-Butyl (3R,4R)-3-[2-[3-(2-acetylaminomethyl)indol-1-yl]ethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857274-64-7P, tert-Butyl  
 (3R,4R)-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]-3-[[4-(2-methoxybutyl)phenyl]carbamoyl]methoxy]piperidine-1-carboxylate 857274-66-9P, Benzyl  
 (3R,4R)-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]-3-[[3-[(3-methoxypropoxy)-4-(pyrrolidin-1-yl)phenyl]methyl]oxy]piperidine-1-carboxylate 857274-67-0P, Benzyl  
 (3R,4R)-3-[[4-bromo-3-(3-methoxypropoxy)phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857274-68-1P, 1-Bromo-4-bromomethyl-2-(3-methoxypropoxy)benzene 857274-69-2P, 1-Bromo-2-(3-methoxypropoxy)-4-methylbenzene 857274-71-6P, tert-Butyl  
 (3R,4R)-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]-3-[[3-(3-methoxypropoxy)-4-(morpholin-4-yl)phenyl]methyl]oxy]piperidine-1-carboxylate 857274-73-8P, Benzyl  
 (3R,4R)-3-[[7-bromo-1-[2-[(cyclopropylcarbonyl)amino]ethyl]-3-methyl-1H-indol-6-yl]methoxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857274-75-0P, Benzyl  
 (3R,4R)-3-[[7-bromo-3-methyl-1-(2-propionylaminoethyl)-1H-indol-6-yl]methoxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857274-77-2P, tert-Butyl  
 (3R,4R)-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]-3-[2-[2-(2-propionylaminoethyl)phenoxy]ethoxy]piperidine-1-carboxylate 857274-79-4P, tert-Butyl (3R,4R)-3-[2-[2-[(cyclopropylcarbonyl)amino]ethyl]phenoxy]ethoxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857274-81-8P, tert-Butyl  
 (3R,4R)-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]-3-[2-[2-(3-methylureido)ethyl]phenoxy]ethoxy]piperidine-1-carboxylate 857274-83-0P, tert-Butyl (3R,4R)-4-[4-[3-(2,6-dimethoxyphenoxy)propoxy]phenyl]-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857274-85-2P, tert-Butyl (3R,4R)-4-[4-[4-(2,6-dimethoxyphenoxy)butoxy]phenyl]-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857274-87-4P, tert-Butyl  
 (3R,4R)-4-[4-[3-[(2-chlorophenoxy)propoxy]phenyl]-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857274-89-6P, tert-Butyl  
 (3R,4R)-4-[4-[3-[(2-cyanophenoxy)propoxy]phenyl]-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857274-91-0P, tert-Butyl  
 (3R,4R)-4-[4-[4-(2-chlorophenoxy)butoxy]phenyl]-3-[[1-(3-methoxypropyl)-2-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 [2-[(4-tolylsulfonyl)oxy]ethoxy]piperidine-1-carboxylate 857275-19-5P, tert-Butyl (3R,4R)-3-(2-hydroxyethoxy)-4-[4-[2-[2-(2-methoxyphenyl)ethoxy]ethoxy]phenyl]piperidine-1-carboxylate 857275-20-8P, tert-Butyl (3R,4R)-3-allyloxy-4-[4-[2-[2-(2-methoxyphenyl)ethoxy]ethoxy]phenyl]piperidine-1-carboxylate 857275-21-9P, tert-Butyl (3R,4R)-3-hydroxy-4-[4-[2-[2-(2-methoxyphenyl)ethoxy]ethoxy]phenyl]piperidine-1-carboxylate 857275-23-1P, Benzyl  
 (3R,4R)-3-[[2-[(3R)-[(acetylaminomethyl)pyrrolidin-1-yl]phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857275-24-2P, Benzyl (3R,4R)-3-[[2-[(3R)-cyanopyrrolidin-1-yl]phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857275-26-4P, Benzyl (3R,4R)-3-[[2-(3-methylsulfonyloxypyrrolidin-1-yl)phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857275-27-5P, Benzyl  
 (3R,4R)-3-[[2-[(3S)-hydroxypyrrolidin-1-yl]phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857275-28-6P, Benzyl (3R,4R)-3-(2-bromobenzyloxy)-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857275-30-0P, Benzyl  
 (3R,4R)-3-[[7-bromo-3-methyl-1-[2-(3-methylureido)ethyl]-1H-indol-6-yl]methoxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857275-32-2P,  
 6-[[[(3R,4R)-4-[4-[2-[2-(2-Methoxyphenyl)ethoxy]ethoxy]phenyl]piperidine-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one 857275-33-3P, tert-Butyl (3R,4R)-4-[4-[2-[2-(2-methoxyphenyl)ethoxy]ethoxy]phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857275-36-6P, tert-Butyl (3R,4R)-3-[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857275-37-7P, 3-(2-Methylbenzyloxy)propyl toluene-4-sulfonate 857275-38-8P, 3-(2-Methylbenzyloxy)propan-1-ol 857275-40-2P, tert-Butyl  
 (3R,4R)-3-[[4-(furan-2-yl)-3-(3-methoxypropoxy)phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857275-41-3P, tert-Butyl (3R,4R)-3-[[4-bromo-3-(3-methoxybenzyloxy)propoxy]phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857275-43-5P, tert-Butyl (3R,4R)-3-[[4-acetylamin-3-(3-methoxypropoxy)phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857275-44-6P, tert-Butyl (3R,4R)-3-[[4-amino-3-(3-methoxypropoxy)phenyl]methyl]oxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857275-46-8P, tert-Butyl (3R,4R)-3-[[2-(2-acetylaminomethyl)phenyl]methyl]carbamoyl]methoxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857275-47-9P, tert-Butyl  
 (3R,4R)-3-[[2-(2-aminoethyl)phenyl]methyl]carbamoyl]methoxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857275-48-0P, tert-Butyl (3R,4R)-3-[[2-(2-azidoethyl)phenyl]methyl]carbamoyl]methoxy]-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate 857275-49-1P, tert-Butyl (3R,4R)-4-[4-[3-[(2-methoxybenzyloxy)propoxy]phenyl]-3-[[methyl-2-[2-[(4-tolylsulfonyl)oxy]ethyl]phenyl]carbamoyl]methoxy]piperid

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 ine-1-carboxylate 857275-50-4P, tert-Butyl  
 (3R,4R)-3-[[[2-(2-hydroxyethyl)phenyl](methyl)carbamoyl]methoxy]-4-[4-[3-  
 [(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate  
 857275-52-6P, tert-Butyl (3R,4R)-4-[4-[3-(2-  
 methoxybenzyl)oxy]propoxy]phenyl]-3-[[[3-(2-  
 methoxyethyl)(methyl)carbamoyl]phenyl]methoxy]oxy]piperidine-1-carboxylate  
 857275-53-7P, tert-Butyl  
 (3R,4R)-3-(3-chlorocarbonylbenzyl)oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-54-8P,  
 tert-Butyl (3R,4R)-3-(3-carboxybenzyl)oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-55-9P,  
 tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[(3-  
 methoxycarbonylbenzyl)oxy]piperidine-1-carboxylate 857275-57-1P,  
 tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[[[3-(2-  
 methoxyethylcarbamoyl)phenyl]methoxy]oxy]piperidine-1-carboxylate  
 857275-59-3P, tert-Butyl (3R,4R)-3-[2-[2-(2-acetylaminomethyl)-6-  
 fluorophenoxy]ethoxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-60-6P,  
 N-[2-(3-Fluoro-2-hydroxyphenyl)ethyl]acetamide 857275-61-7P,  
 (3-Fluoro-2-hydroxyphenyl)acetonitrile 857275-63-9P, tert-Butyl  
 (3R,4R)-3-[2-[2-[2-(2-acetylaminomethyl)-3-methylphenyl]oxy]ethoxy]-4-[4-[3-  
 [(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate  
 857275-64-0P, N-[2-(2-Hydroxy-6-methylphenyl)ethyl]acetamide  
 857275-65-1P, (2-Hydroxy-6-methylphenyl)acetonitrile 857275-67-3P,  
 tert-Butyl (3R,4R)-3-[2-[2-(2-acetylaminomethyl)-6-  
 methylphenyl]oxy]ethoxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-68-4P,  
 N-[2-(2-Hydroxy-3-methylphenyl)ethyl]acetamide 857275-69-5P,  
 (2-Hydroxy-3-methylphenyl)acetonitrile 857275-71-9P, tert-Butyl  
 (3R,4R)-3-[2-[2-[2-(2-acetylaminomethyl)-4-methylphenyl]oxy]ethoxy]-4-[4-[3-  
 [(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate  
 857275-72-0P, (2-Hydroxy-5-methylphenyl)acetonitrile 857275-74-2P,  
 tert-Butyl  
 (3R,4R)-3-[2-[2-(2-acetylaminomethyl)-5-fluorophenoxy]ethoxy]-4-  
 [4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate  
 857275-75-3P, N-[2-(4-Fluoro-2-hydroxyphenyl)ethyl]acetamide  
 857275-76-4P, (4-Fluoro-2-hydroxyphenyl)acetonitrile 857275-78-6P,  
 tert-Butyl  
 (3R,4R)-3-[2-[2-(2-acetylaminomethyl)-4-fluorophenoxy]ethoxy]-4-  
 [4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate  
 857275-79-7P, N-[2-(5-Fluoro-2-hydroxyphenyl)ethyl]acetamide  
 857275-81-1P, tert-Butyl (3R,4R)-3-[2-[2-(2-acetylaminomethyl)-5-  
 methylphenyl]oxy]ethoxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-82-2P,  
 N-[2-(2-Hydroxy-4-methylphenyl)ethyl]acetamide 857275-83-3P,  
 (2-Hydroxy-4-methylphenyl)acetonitrile 857275-85-5P, tert-Butyl  
 (3R,4R)-3-[2-[2-(2-acetylaminomethyl)-3-fluorophenoxy]ethoxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-86-6P,  
 N-[2-(2-Fluoro-6-hydroxyphenyl)ethyl]acetamide 857275-87-7P,  
 (2-Fluoro-6-hydroxyphenyl)acetonitrile 857275-89-9P, tert-Butyl  
 (3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[2-[4-(4-  
 methoxybutyl) (methyl) amino]-4-methylbenzyl]oxy]piperidine-1-carboxylate  
 857275-90-2P, tert-Butyl (3R,4R)-4-[4-[3-(2-  
 methoxybenzyl)oxy]propoxy]phenyl]-3-[2-[4-(4-methoxybutylamino)-4-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 [4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate  
 857276-19-8P, tert-Butyl (3R,4R)-3-[2-[5-(2-acetylaminomethyl)-6-chloro-2-  
 methylpyrimidin-4-yl]oxy]ethoxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857276-20-1P,  
 tert-Butyl (3R,4R)-3-[2-[5-(2-azidoethyl)-6-chloro-2-methylpyrimidin-4-  
 yl]oxy]ethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-  
 carboxylate 857276-21-2P, tert-Butyl  
 (3R,4R)-3-[2-[6-chloro-2-methyl-5-[2-[4-(4-  
 tolylsulfonyl)oxy]ethyl]pyrimidin-4-yl]oxy]ethoxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857276-22-3P,  
 tert-Butyl (3R,4R)-3-[2-[6-chloro-5-(2-hydroxyethyl)-2-methylpyrimidin-4-  
 yl]oxy]ethoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-  
 carboxylate 857276-23-4P, tert-Butyl  
 (3R,4R)-3-[2-[6-chloro-5-(methoxycarbonyl)methyl]-2-methylpyrimidin-4-  
 yl]oxy]ethoxy]-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-  
 carboxylate 857276-25-6P, tert-Butyl  
 (3R,4R)-3-[2-[2-(2-acetylaminomethyl)-5-fluorophenoxy]ethoxy]-4-[4-[3-(2-  
 chlorophenoxy)propoxy]phenyl]piperidine-1-carboxylate 857276-26-7P,  
 tert-Butyl (3R,4R)-4-[4-[3-(2-chlorophenoxy)propoxy]phenyl]-3-[2-[4-(4-  
 tolylsulfonyl)oxy]ethoxy]piperidine-1-carboxylate 857276-27-8P,  
 tert-Butyl (3R,4R)-4-[4-[3-(2-chlorophenoxy)propoxy]phenyl]-3-(2-  
 hydroxyethoxy]piperidine-1-carboxylate 857276-28-9P, tert-Butyl  
 (3R,4R)-3-allyloxy-4-[4-[3-(2-chlorophenoxy)propoxy]phenyl]piperidine-1-  
 carboxylate 857276-30-3P, tert-Butyl  
 (3R,4R)-3-[2-[2-(2-acetylaminomethyl)phenoxy]ethoxy]-4-[4-[3-(2-  
 chlorophenoxy)propoxy]phenyl]piperidine-1-carboxylate 857276-32-5P,  
 tert-Butyl  
 (3R,4R)-3-[1-(3-methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-  
 7-yl]methoxy]-4-[4-[4-[[5-methoxy-1-imidazol-4-  
 yl]amino]butoxy]phenyl]piperidine-1-carboxylate 857276-33-6P,  
 tert-Butyl  
 (3R,4R)-4-[4-(4-aminobutoxy)phenyl]-3-[[1-(3-methoxypropyl)-2-oxo-1,2,3,4-  
 tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate 857276-34-7P,  
 tert-Butyl  
 (3R,4R)-4-[4-(3-cyanopropoxy)phenyl]-3-[[1-(3-methoxypropyl)-2-  
 oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidine-1-carboxylate  
 857276-36-9P, tert-Butyl (3R,4R)-3-[1-(3-methoxypropyl)-2-oxo-1,2,3,4-  
 tetrahydroquinolin-7-yl]methoxy]-4-[4-[4-[(3-methoxypropylidene-2-  
 yl)amino]butoxy]phenyl]piperidine-1-carboxylate 857276-38-1P,  
 tert-Butyl  
 (3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[3-[(2-  
 methoxyethyl)(methyl)carbamoyl]-4-methylbenzyl]oxy]piperidine-1-  
 carboxylate 857276-39-2P, tert-Butyl  
 (3R,4R)-3-[(3-chlorocarbonyl-4-methylbenzyl)oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857276-40-5P,  
 tert-Butyl (3R,4R)-3-(3-carboxy-4-methylbenzyl)oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857276-41-6P,  
 Methyl 5-chloromethyl-2-methylbenzoate 857276-43-8P, tert-Butyl  
 (3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[3-(2-  
 methoxyethylcarbamoyl)-4-methylbenzyl]oxy]piperidine-1-carboxylate  
 857276-45-0P, tert-Butyl (3R,4R)-4-[4-[3-(2-  
 methoxybenzyl)oxy]propoxy]phenyl]-3-[3-[(3-methoxypropionyl) (methyl) amino]-  
 4-methylbenzyl]oxy]piperidine-1-carboxylate 857276-46-1P,  
 N-(5-Chloromethyl-2-methylphenyl)-3-methoxy-N-methylpropionamide  
 857276-47-2P, N-(5-Hydroxymethyl-2-methylphenyl)-3-methoxy-N-  
 methylpropionamide 857276-48-3P,

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 methylbenzyl]oxy]piperidine-1-carboxylate 857275-91-3P, tert-Butyl  
 (3R,4R)-3-(2-amino-4-methylbenzyl)oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-92-4P,  
 tert-Butyl (3R,4R)-3-(2-bromo-4-methylbenzyl)oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-94-6P,  
 tert-Butyl  
 (3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[2-[2-[3-  
 (1H-tetrazol-5-yl)propyl]phenoxy]ethoxy]piperidine-1-carboxylate  
 857275-96-8P, tert-Butyl (3R,4R)-4-[4-[3-(2-  
 methoxybenzyl)oxy]propoxy]phenyl]-3-[[[3-(3-  
 methoxypropionyl) (methyl) amino]phenyl]methoxy]oxy]piperidine-1-carboxylate  
 857275-97-9P, tert-Butyl (3R,4R)-4-[4-[3-(2-  
 methoxybenzyl)oxy]propoxy]phenyl]-3-[[[3-(3-  
 methoxypropionylamino)phenyl]methoxy]oxy]piperidine-1-carboxylate  
 857275-98-0P, tert-Butyl (3R,4R)-3-(3-aminobenzyl)oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857275-99-1P,  
 tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[[3-  
 nitrobenzyl]oxy]piperidine-1-carboxylate 857276-01-8P, Benzyl  
 (3R,4R)-3-[[3-(2-acetylaminomethyl)-4-methylbenzyl]oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857276-02-9P,  
 Benzyl (3R,4R)-3-[[3-(2-aminomethyl)-4-methylbenzyl]oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857276-03-0P,  
 Benzyl (3R,4R)-3-[[3-(2-azidoethyl)-4-methylbenzyl]oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857276-04-1P,  
 Benzyl  
 (3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[[4-methyl-3-  
 [[4-(4-tolylsulfonyl)oxy]ethoxy]phenyl]methoxy]oxy]piperidine-1-carboxylate  
 857276-05-2P, Benzyl  
 (3R,4R)-3-[[3-(2-hydroxyethoxy)-4-methylbenzyl]oxy]-4-  
 [4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate  
 857276-06-3P, Benzyl  
 (3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-  
 [[4-methyl-3-[2-(triisopropylsilyl)oxy]ethoxy]phenyl]methoxy]oxy]piperidi-  
 ne-1-carboxylate 857276-07-4P, [2-(5-Chloromethyl-2-  
 methylphenoxy)ethoxy]triisopropylsilane 857276-08-5P,  
 [4-Methyl-3-[2-(triisopropylsilyl)oxy]ethoxy]phenyl]methanol  
 857276-09-6P, 2-(Triisopropylsilyl)oxy]ethyl  
 4-methyl-3-[2-(triisopropylsilyl)oxy]ethoxy]benzoate 857276-11-0P,  
 tert-Butyl  
 (3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[2-[2-(3-  
 methylcarbamoylpropyl)phenoxy]ethoxy]piperidine-1-carboxylate  
 857276-12-1P, 4-(2-Hydroxyphenyl)-N-methylbutylamide  
 857276-14-3P, 6-[[[(3R,4R)-4-[4-[3-(2-  
 Chlorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-  
 methoxypropyl)-4H-benzo[1,4]oxazin-3-one 857276-15-4P, tert-Butyl  
 (3R,4R)-4-[4-[3-(2-chlorophenoxy)propoxy]phenyl]-3-[[4-(3-methoxypropyl)-3-  
 oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate  
 857276-16-5P, tert-Butyl  
 (3R,4R)-4-[4-[3-(2-chlorophenoxy)propoxy]phenyl]-3-  
 3-hydroxypiperidine-1-carboxylate 857276-18-7P, tert-Butyl  
 (3R,4R)-3-[2-[5-(2-acetylaminomethyl)-2-methylpyrimidin-4-yl]oxy]ethoxy]-4-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 3-Methoxy-N-methyl-N-[2-methyl-5-[[[tetrahydropyran-2-  
 yl]oxy]methyl]phenyl]propionamide 857276-49-4P,  
 3-Methoxy-N-[2-methyl-5-[[[tetrahydropyran-2-  
 yl]oxy]methyl]phenyl]propionamide 857276-50-7P,  
 [2-Methyl-5-[[[tetrahydropyran-2-yl]oxy]methyl]phenyl]amine  
 857276-51-8P, 2-(4-Methyl-3-nitrobenzyl)oxy]tetrahydropyran  
 857276-53-0P,  
 tert-Butyl (3R,4R)-3-[[3-[isopropyl(3-  
 methoxypropionyl)amino]phenyl]methoxy]oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857276-54-1P,  
 tert-Butyl (3R,4R)-3-(3-isopropylaminobenzyl)oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857276-55-2P,  
 tert-Butyl (3R,4R)-3-(3-bromobenzyl)oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857276-57-4P,  
 tert-Butyl (3R,4R)-3-[[5-fluoro-2-[4-  
 methoxybutyl] (methyl) amino]phenyl]methoxy]oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857276-58-5P,  
 tert-Butyl (3R,4R)-3-[[5-fluoro-2-(4-  
 methoxybutylamino)phenyl]methoxy]oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857276-59-6P,  
 tert-Butyl (3R,4R)-3-(2-amino-5-fluorobenzyl)oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857276-60-9P,  
 tert-Butyl (3R,4R)-3-(2-bromo-5-fluorobenzyl)oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857276-61-0P,  
 1-Bromo-2-chloromethyl-4-fluorobenzene 857276-63-2P, tert-Butyl  
 (3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[[[3-1-(3-  
 methoxypropyl)-1H-imidazol-2-yl]phenyl]methoxy]oxy]piperidine-1-carboxylate  
 857276-64-3P, tert-Butyl (3R,4R)-4-[4-[3-(2-  
 methoxybenzyl)oxy]propoxy]phenyl]-3-[[[3-(4,4,5,5-tetramethyl-  
 1,3,2-dioxaborolan-2-yl)phenyl]methoxy]oxy]piperidine-1-carboxylate  
 857276-65-4P, 2-Bromo-1-(3-methoxypropyl)-1H-imidazole 857276-66-5P,  
 1-(3-Methoxypropyl)-1H-imidazole 857276-68-7P  
 , tert-Butyl (3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[2-[2-(3-  
 methoxypropionylamino)phenoxy]ethoxy]piperidine-1-carboxylate  
 857276-72-3P, tert-Butyl  
 (3R,4R)-3-[2-[2-(3-carboxypropyl)phenoxy]ethoxy]-  
 4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate  
 857276-74-5P, tert-Butyl (3R,4R)-3-[[[3-(3-  
 ethoxypropionyl) (methyl) amino]phenyl]methoxy]oxy]-4-[4-[3-[(2-  
 methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857276-75-6P,  
 tert-Butyl  
 (3R,4R)-3-[[[3-(3-ethoxypropionylamino)phenyl]methoxy]oxy]-4-[4-[3-  
 [[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate  
 857276-77-8P, 6-[[[(3R,4R)-4-[4-[3-(3-  
 Methoxyphenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-  
 methoxypropyl)-4H-benzo[1,4]oxazin-3-one 857276-78-9P, tert-Butyl  
 (3R,4R)-4-[4-[3-(3-methoxyphenoxy)propoxy]phenyl]-3-[[4-(3-methoxypropyl)-3-  
 oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-  
 carboxylate 857276-79-0P, tert-Butyl  
 (3R,4R)-3-hydroxy-4-[4-[3-(3-methoxyphenoxy)propoxy]phenyl]piperidine-1-  
 carboxylate 857276-81-4P,  
 6-[[[(3R,4R)-4-[4-[3-(3-Fluorophenoxy)propoxy]phenyl]piperidin-3-  
 yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
 857276-82-5P, tert-Butyl  
 (3R,4R)-4-[4-[3-(3-fluorophenoxy)propoxy]phenyl]-  
 3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
yl)methoxy]piperidine-1-carboxylate 857276-83-6P, tert-Butyl  
(3R,4R)-4-[4-[3-(3-fluorophenoxy)propoxy]phenyl]-3-hydroxypiperidine-1-  
carboxylate 857276-85-8P,  
6-[[[(3R,4R)-4-[4-[3-(2-Fluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
857276-86-9P, tert-Butyl  
(3R,4R)-4-[4-[3-(2-Fluorophenoxy)propoxy]phenyl]-  
3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857276-87-0P, tert-Butyl  
(3R,4R)-4-[4-[3-(2-Fluorophenoxy)propoxy]phenyl]-3-hydroxypiperidine-1-  
carboxylate 857276-89-2P,  
6-[[[(3R,4R)-4-[4-[3-(2,5-Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
857276-90-5P, tert-Butyl (3R,4R)-4-[4-[3-(2,5-  
difluorophenoxy)propoxy]phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-  
2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857276-91-6P,  
tert-Butyl (3R,4R)-4-[4-[3-(2,5-difluorophenoxy)propoxy]phenyl]-3-  
hydroxypiperidine-1-carboxylate 857276-92-7P,  
2-(3-Bromopropoxy)-1,4-difluorobenzene 857276-94-9P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[3-(o-  
tolylxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4H-benzo[1,4]oxazin-3-  
one 857276-95-0P, tert-Butyl (3R,4R)-3-[[4-(3-methoxypropyl)-3-oxo-3,4-  
dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-[3-(o-  
tolylxy)propoxy]phenyl]piperidine-1-carboxylate 857276-96-1P,  
tert-Butyl  
(3R,4R)-3-hydroxy-4-[4-[3-(o-tolylxy)propoxy]phenyl]piperidine-  
1-carboxylate 857276-98-3P,  
6-[[[(3R,4R)-4-[4-[3-(2-Methoxyphenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
857276-99-4P, tert-Butyl  
(3R,4R)-4-[4-[3-(2-methoxyphenoxy)propoxy]phenyl]-  
3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857277-00-0P, tert-Butyl  
(3R,4R)-3-hydroxy-4-[4-[3-(2-methoxyphenoxy)propoxy]phenyl]piperidine-1-  
carboxylate 857277-02-2P,  
6-[[[(3R,4R)-4-[4-[3-(3-Chlorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
857277-03-3P, tert-Butyl  
(3R,4R)-4-[4-[3-(3-chlorophenoxy)propoxy]phenyl]-  
3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857277-04-4P, tert-Butyl  
(3R,4R)-4-[4-[3-(3-chlorophenoxy)propoxy]phenyl]-3-hydroxypiperidine-1-  
carboxylate 857277-06-6P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[3-(m-  
tolylxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4H-benzo[1,4]oxazin-3-  
one 857277-07-7P, tert-Butyl (3R,4R)-3-[[4-(3-methoxypropyl)-3-oxo-3,4-  
dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-[3-(m-  
tolylxy)propoxy]phenyl]piperidine-1-carboxylate 857277-08-8P,  
tert-Butyl  
(3R,4R)-3-hydroxy-4-[4-[3-(m-tolylxy)propoxy]phenyl]piperidine-  
1-carboxylate 857277-10-2P, tert-Butyl  
(3R,4R)-3-[[4-[4-(3-methoxy-3-(3-methoxypropoxy)phenyl)methyl]oxy]-4-[4-[3-(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857277-11-3P,

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
methoxypropoxy]phenyl)methyl]oxy]piperidine-1-carboxylate 857277-40-8P,  
1-Chloromethyl-3-methoxy-2-(3-methoxypropoxy)benzene 857277-43-1P,  
Benzyl (3R,4R)-3-[2-[2-[2-(N-hydroxy-N-  
methylcarbamoyl)ethyl]phenoxy]ethoxy]-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857277-44-2P,  
Benzyl (3R,4R)-3-[2-[2-(2-carboxyethyl)phenoxy]ethoxy]-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857277-45-3P,  
Benzyl (3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[2-[2-(2-  
methoxycarbonyl)ethyl]phenoxy]ethoxy]piperidine-1-carboxylate  
857277-47-5P, 6-[[[(3R,4R)-4-[4-[3-[(Benzodioxol-5-yl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-  
benzo[1,4]oxazin-3-one 857277-48-6P, tert-Butyl  
(3R,4R)-4-[4-[3-[(benzodioxol-5-yl)oxy]propoxy]phenyl]-3-[[4-(3-  
methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857277-49-7P, tert-Butyl  
(3R,4R)-4-[4-[3-[(benzodioxol-5-yl)oxy]propoxy]phenyl]-3-hydroxypiperidine-  
1-carboxylate 857277-51-1P,  
6-[[[(3R,4R)-4-[4-[3-(2,4-Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
857277-52-2P, tert-Butyl (3R,4R)-4-[4-[3-(2,4-  
difluorophenoxy)propoxy]phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-  
2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857277-53-3P,  
tert-Butyl (3R,4R)-4-[4-[3-(2,4-difluorophenoxy)propoxy]phenyl]-3-  
hydroxypiperidine-1-carboxylate 857277-55-5P,  
6-[[[(3R,4R)-4-[4-[3-(2,3-Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
857277-56-6P, tert-Butyl (3R,4R)-4-[4-[3-(2,3-  
difluorophenoxy)propoxy]phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-  
2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857277-57-7P,  
tert-Butyl (3R,4R)-4-[4-[3-(2,3-difluorophenoxy)propoxy]phenyl]-3-  
hydroxypiperidine-1-carboxylate 857277-58-8P,  
1-(3-Bromopropoxy)-2,3-difluorobenzene 857277-60-2P,  
6-[[[(3R,4R)-4-[4-[3-(4-Fluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
857277-61-3P, tert-Butyl  
(3R,4R)-4-[4-[3-(4-fluorophenoxy)propoxy]phenyl]-  
3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857277-64-4P, tert-Butyl  
(3R,4R)-4-[4-[3-(4-fluorophenoxy)propoxy]phenyl]-3-hydroxypiperidine-1-  
carboxylate 857277-64-6P,  
6-[[[(3R,4R)-4-[4-[3-(2,6-Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
857277-65-7P, tert-Butyl (3R,4R)-4-[4-[3-(2,6-  
difluorophenoxy)propoxy]phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-  
2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857277-66-8P,  
tert-Butyl (3R,4R)-4-[4-[3-(2,6-difluorophenoxy)propoxy]phenyl]-3-  
hydroxypiperidine-1-carboxylate 857277-67-9P,  
2-(3-Bromopropoxy)-1,3-difluorobenzene 857277-69-1P,  
6-[[[(3R,4R)-4-[4-[3-(3,4-Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
857277-70-4P, tert-Butyl (3R,4R)-4-[4-[3-(3,4-  
difluorophenoxy)propoxy]phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-  
2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857277-71-5P,

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
4-Bromomethyl-1-ethoxy-2-(3-methoxypropoxy)benzene 857277-12-4P,  
1-Ethoxy-2-(3-methoxypropoxy)-4-methylbenzene 857277-13-5P,  
1-(2-Ethoxy-5-methylphenyl)ethanone 857277-15-7P, tert-Butyl  
(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[[[(2R)-4-(4-  
methoxybutyryl)-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl]methoxy]piperidine-1-  
carboxylate 857277-16-8P, tert-Butyl  
(3R,4R)-3-[[[(2R)-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl]methoxy]-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857277-17-9P,  
tert-Butyl  
(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[[[(2R)-4-(4-  
(4-tolylsulfonyl)-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl]methoxy]piperidine-  
1-carboxylate 857277-18-0P, tert-Butyl  
(3R,4R)-3-[[[(2R)-3-[(2-fluorophenyl)(4-tolylsulfonyl)amino]-2-  
hydroxypropoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-  
carboxylate 857277-19-1P, tert-Butyl  
(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[(R)-  
oxiranylmethoxy]piperidine-1-carboxylate 857277-21-5P, tert-Butyl  
(3R,4R)-3-[2-[2-(2-acetylaminomethyl)-5-chlorophenoxy]ethoxy]-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857277-22-6P,  
N-[2-(4-Chloro-2-hydroxyphenyl)ethyl]acetamide 857277-24-8P, tert-Butyl  
(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[[[(2R)-4-(4-  
methoxybutyryl)-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl]methoxy]piperidine-1-  
carboxylate 857277-25-9P, tert-Butyl  
(3R,4R)-3-[[[(2S)-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl]methoxy]-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857277-26-0P,  
tert-Butyl  
(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[[[(2S)-4-(4-  
(4-tolylsulfonyl)-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl]methoxy]piperidine-  
1-carboxylate 857277-27-1P, tert-Butyl  
(3R,4R)-3-[[[(2S)-3-[(2-fluorophenyl)(4-tolylsulfonyl)amino]-2-  
hydroxypropoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-  
carboxylate 857277-28-2P, tert-Butyl  
(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[(S)-  
oxiranylmethoxy]piperidine-1-carboxylate 857277-30-6P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[3-phenoxypropoxy]phenyl]piperidin-3-yl]oxy]methyl]-4H-benzo[1,4]oxazin-3-one 857277-31-7P, tert-Butyl  
(3R,4R)-3-[[[(4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-[3-(3-phenoxypropoxy)phenyl]piperidine-1-carboxylate  
857277-32-8P, tert-Butyl (3R,4R)-3-hydroxy-4-[4-[3-  
phenoxypropoxy]phenyl]piperidine-1-carboxylate 857277-35-1P, tert-Butyl  
(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[[[(3-methoxy-2-(2-  
methoxyethoxy)phenyl)methyl]oxy]piperidine-1-carboxylate 857277-36-2P,  
1-Chloromethyl-3-methoxy-2-(2-methoxyethoxy)benzene 857277-37-3P,  
[3-Methoxy-2-(2-methoxyethoxy)phenyl]methanol 857277-39-5P, tert-Butyl  
(3R,4R)-4-[4-[3-(2-methoxybenzyl)oxy]propoxy]phenyl]-3-[[[(3-methoxy-2-(3-  
yl)methoxy]-4-[4-[3-[(3-trifluoromethylphenyl)oxy]propoxy]phenyl]piperidin-  
e-1-carboxylate 857277-81-7P, tert-Butyl  
(3R,4R)-3-hydroxy-4-[4-[3-[(3-  
trifluoromethylphenyl)oxy]propoxy]phenyl]piperidine-1-carboxylate  
857277-83-9P, 6-[[[(3R,4R)-4-[4-[3-  
(Cyclohexyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-  
methoxypropyl)-4H-benzo[1,4]oxazin-3-one 857277-84-0P, tert-Butyl  
(3R,4R)-4-[4-[3-(cyclohexyloxy)propoxy]phenyl]-3-[[4-(3-methoxypropyl)-3-  
oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate  
857277-85-1P, tert-Butyl  
(3R,4R)-4-[4-[3-(cyclohexyloxy)propoxy]phenyl]-3-  
hydroxypiperidine-1-carboxylate 857277-86-2P, 3-(Cyclohexyloxy)propyl  
toluene-4-sulfonate 857277-88-4P,  
6-[[[(3R,4R)-4-[4-(2-(R)-Methoxy-3-phenoxypropoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
857277-89-5P, Benzyl  
(3R,4R)-4-[4-(2-(R)-methoxy-3-phenoxypropoxy)phenyl]-  
3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857277-90-8P, Benzyl  
857277-462-4-[4-(3-hydroxy-3-phenoxypropoxy)phenyl]-3-[[4-(3-  
methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857277-91-9P, Benzyl  
(3R,4R)-4-(4-hydroxyphenyl)-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-  
benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857277-92-0P,  
Benzyl (3R,4R)-4-(4-allyloxyphenyl)-3-[[4-(3-methoxypropyl)-3-oxo-3,4-  
dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate  
857277-93-1P, Benzyl (3R,4R)-4-(4-allyloxyphenyl)-3-hydroxypiperidine-1-  
carboxylate 857277-94-2P, (3R,4R)-4-(4-Allyloxyphenyl)piperidin-3-ol  
857277-96-4P 857277-97-5P, tert-Butyl  
(3R,4R)-3-[2-(2-hydroxybenzyl)phenoxy]ethoxy]-4-[4-[3-[(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857278-16-1P,  
tert-Butyl (3R,4R)-3-[2-[5-fluoro-2-[2-  
[(methoxycarbonyl)amino]ethyl]phenoxy]ethoxy]-4-[4-[3-(2-  
methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857278-17-2P,  
Methyl N-[2-(4-fluoro-2-hydroxyphenyl)ethyl]carbamate 857278-22-9P,  
Benzyl (3R,4R)-4-[4-[2-(3-fluorobenzyloxy)amino]ethoxy]phenyl]-3-[[4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-



L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)  
yl)methoxy]piperidine-1-carboxylate 857279-94-8P, Benzyl  
(3R,4R)-4-[4-[[3-(2-methoxybenzylloxy)propoxy]phenyl]-3-[[1,3,3-trimethyl-2-oxo-2,3-dihydro-1H-indol-7-yl]methoxy]piperidine-1-carboxylate 857279-97-1P, Benzyl  
(3R,4R)-4-[4-[[2-(2-difluoro-3-phenoxypropoxy)phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857279-98-2P, Benzyl  
(3R,4R)-4-[4-[[2-(2-difluoro-3-phenoxypropoxy)phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857279-99-3P, Benzyl  
(3R,4R)-4-[4-[[2-(2-difluoro-3-phenoxypropoxy)phenyl]-3-hydroxypiperidine-1-carboxylate 857280-00-3P, 2,2-Difluoro-3-phenoxypropyl toluene-4-sulfonate 857280-01-4P, O,O'-Bis(4-toluenesulfonyl)-2,2-difluoropropane-1,3-diol 857280-03-6P, Benzyl  
(3R,4R)-3-[2-[[2-(2-(acetylamino)ethyl]-5-fluorophenoxy]ethoxy]-4-[[4-[[[(3S)-1-phenylpyrrolidin-3-yl]oxy]phenyl]piperidine-1-carboxylate 857280-04-7P, Benzyl (3R,4R)-3-[2-[[2-(2-(acetylamino)ethyl]-5-fluorophenoxy]ethoxy]-4-[[4-[[[(3S)-1-phenylpyrrolidin-3-yl]oxy]phenyl]piperidine-1-carboxylate 857280-05-8P, Benzyl  
(3R,4R)-3-[2-[[2-(2-(acetylamino)ethyl)-5-fluorophenoxy]ethoxy]-4-[[4-[[[(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]oxy]phenyl]piperidine-1-carboxylate 857280-06-9P, Benzyl (3R,4R)-3-[2-[[2-(2-(acetylaminioethyl)-5-fluorophenoxy]ethoxy]-4-[[4-(4-hydroxyphenyl)piperidine-1-carboxylate 857280-09-2P, Benzyl (3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[[4-[[[(3S)-2-oxo-1-phenylpyrrolidin-3-yl]oxy]phenyl]piperidine-1-carboxylate 857280-10-5P, (3R)-2-Oxo-1-phenylpyrrolidin-3-yl toluene-4-sulfonate 857280-11-6P, Benzyl  
(3R,4R)-4-[4-(4-hydroxyphenyl)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-12-7P, 3-(S)-Hydroxy-1-phenylpyrrolidin-2-one 857280-14-9P, Benzyl  
(3R,4R)-4-[4-[[1-(benzoxazol-2-yl)azetidin-3-yl]oxy]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-15-0P, Benzyl  
(3R,4R)-4-[4-[[1-(benzoxazol-2-yl)azetidin-3-yl]oxy]phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-16-1P, Benzyl  
(3R,4R)-4-[4-[[azetidin-3-yloxy]phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-17-2P, Benzyl (3R,4R)-4-[4-[[1-(tert-butoxycarbonyl)azetidin-3-yl]oxy]phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-18-3P, Benzyl (3R,4R)-4-[4-[[1-(tert-butoxycarbonyl)azetidin-3-yloxy]phenyl]-3-hydroxypiperidine-1-carboxylate 857280-20-7P  
, Benzyl (3R,4R)-3-[4-[[3-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[[4-[[1-(thiazol-2-yl)azetidin-3-yl]oxy]phenyl]piperidine-1-carboxylate 857280-21-8P, Benzyl  
(3R,4R)-3-[4-[[3-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)  
9-Hydroxymethyl-1-[[2-(2-(trimethylsilyl)ethoxy)methyl]-1,3,4,5-tetrahydrobenzo[b]azepin-2-one 857280-66-1P, Methyl  
2-oxo-1-[[2-(2-(trimethylsilyl)ethoxy)methyl]-2,3,4,5-tetrahydro-1H-benzo[b]azepine-9-carboxylate 857280-67-2P, Methyl  
2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepine-9-carboxylate 857280-71-8P, Benzyl (3R,4R)-4-[4-[[3-(2-fluorobenzylloxy)propoxy]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-72-9P, 3-(2-Fluorobenzylloxy)propyl toluene-4-sulfonate 857280-74-1P, Benzyl  
(3R,4R)-4-[4-[[2-[[2-(4-fluorophenyl)ethyl]amino]ethoxy]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-76-3P, Benzyl  
(3R,4R)-4-[4-[[1-(benzothiazol-2-yl)azetidin-3-yl]oxy]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-77-4P, Benzyl  
(3R,4R)-4-[4-[[1-(benzothiazol-2-yl)azetidin-3-yl]oxy]phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-79-6P, Benzyl  
(3R,4R)-4-[4-[[2-[[2-(2-fluorophenyl)ethyl]amino]ethoxy]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-80-9P, Benzyl  
(3R,4R)-4-[4-[[2-[[2-(2-Fluorophenyl)acetyl]amino]ethoxy]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-97-8P, Benzyl  
(3R,4R)-4-[4-[[2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethyl]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-98-9P, Benzyl  
(3R,4R)-4-[4-(4-carboxymethylphenyl)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-99-0P, Benzyl  
(3R,4R)-4-[4-[[2-(2-diazoacetyl)phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857281-01-7P, Benzyl (3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-[[2-(3-phenylpyrrolidin-1-yl)ethoxy]phenyl]piperidine-1-carboxylate 857281-05-1P, Benzyl  
(3R,4R)-4-[4-[[3-(2,5-difluorophenoxy)propyl]amino]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857281-06-2P, 3-(2,5-Difluorophenoxy)propylamine 857281-07-3P, tert-Butyl [3-(2-(2,5-difluorophenoxy)propyl)carbamate 857281-09-5P, Benzyl (3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-

benzo[1,4]oxazin-6-yl]methoxy]-4-(4-propoxyphenyl)piperidine-1-carboxylate 857281-15-3P, Benzyl  
(3R,4R)-3-[[1-ethyl-2-oxo-2,3-dihydro-1H-benzimidazol-4-yl]methoxy]-4-[4-[[3-[[2-(2-methoxybenzylloxy)propoxy]phenyl]piperidine-1-carboxylate 857281-16-4P, Benzyl  
(3R,4R)-3-[[1-ethyl-2-oxo-3-[[2-(2-(trimethylsilyl)ethoxy)methyl]-2,3-dihydro-1H-benzimidazol-4-yl]methoxy]-4-[[3-[[2-(2-methoxybenzylloxy)propoxy]phenyl]piperidine-1-carboxylate 857281-17-5P, 4-Bromomethyl-1-ethyl-3-[[2-(2-(trimethylsilyl)ethoxy)methyl]-1,3-dihydrobenzimidazol-2-one 857281-18-6P, 1-Ethyl-4-methyl-3-[[2-(2-(trimethylsilyl)ethoxy)methyl]-1,3-dihydrobenzimidazol-2-one 857281-19-7P, 1-Ethyl-4-methyl-1,3-dihydrobenzimidazol-2-one 857281-22-2P, Benzyl  
(3R,4R)-4-(4-methoxyphenyl)-3-[[1(R)-[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]ethoxy]piperidine-1-carboxylate 857281-23-3P, Benzyl  
(3R,4R)-4-(4-methoxyphenyl)-3-[[1(R)-[4-(3-methoxypropyl)-3-oxo-3,4-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)  
yl)methoxy]-4-[4-[[1-(thiazol-2-yl)azetidin-3-yl]oxy]phenyl]piperidine-1-carboxylate 857280-23-0P 857280-36-5P, Benzyl  
(3R,4R)-4-[4-[[2-(2-(benzylloxy)carbonyl)amino]-4-phenylbutoxy]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-37-6P, (S)-2-[[2-(Benzylloxy)carbonyl]amino]-4-phenylbutyl toluene-4-sulfonate 857280-39-8P, Benzyl (3R,4R)-4-[4-[[2-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-40-1P, Benzyl  
(3R,4R)-4-[4-[[2-(3-methoxyphenoxy)ethoxy]phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-41-2P, 2-(3-Methoxyphenoxy)ethyl toluene-4-sulfonate 857280-43-4P, Benzyl (3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-(pyrrolidin-1-yl)phenyl]piperidine-1-carboxylate 857280-44-5P, Benzyl  
(3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-[[4-(trifluoromethylsulfonyl)oxy]phenyl]piperidine-1-carboxylate 857280-47-8P, Benzyl  
(3R,4R)-4-[4-[[2-(3-ethoxyphenoxy)ethoxy]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-48-9P, Benzyl  
(3R,4R)-4-[4-[[2-(3-ethoxyphenoxy)ethoxy]phenyl]-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-49-0P, Benzyl  
(3R,4R)-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-51-4P, Benzyl  
(3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[[4-[[1-phenylazetidin-3-yl]oxy]methyl]phenyl]piperidine-1-carboxylate 857280-52-5P, Benzyl  
(3R,4R)-4-(4-chloromethylphenyl)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-53-6P, 1-Phenylazetidin-3-ol 857280-55-8P, Benzyl  
(3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[[4-[[3-phenylpyrrolidin-1-yl]methyl]phenyl]piperidine-1-carboxylate 857280-57-0P, Benzyl  
(3R,4R)-4-[4-[[2-(2,5-difluorophenoxy)ethoxy]methyl]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-58-1P, 2-(2,5-Difluorophenoxy)ethanol  
857280-59-2P, Benzyl (3R,4R)-4-(4-hydroxymethylphenyl)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857280-60-5P, [2-(2,5-Difluorophenoxy)ethoxy]triisopropylsilane 857280-62-7P, tert-Butyl (3R,4R)-4-[4-[[3-(2-methoxybenzylloxy)propoxy]phenyl]-3-[[2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-9-yl]methoxy]piperidine-1-carboxylate 857280-63-8P, tert-Butyl  
(3R,4R)-4-[4-[[3-(2-methoxybenzylloxy)propoxy]phenyl]-3-[[2-oxo-1-[[2-(trimethylsilyl)ethoxy]methyl]-2,3,4,5-tetrahydro-1H-benzo[b]azepin-9-yl]methoxy]piperidine-1-carboxylate 857280-64-9P, 9-Chloromethyl-1-[[2-(2-(trimethylsilyl)ethoxy)methyl]-1,3,4,5-tetrahydrobenzo[b]azepin-2-one 857280-65-0P,

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)  
dihydro-2H-benzo[1,4]oxazin-6-yl]ethoxy]piperidine-1-carboxylate 857281-24-4P, Benzyl (3R,4R)-4-(4-methoxyphenyl)-3-[[1(S)-[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]ethoxy]piperidine-1-carboxylate 857281-25-5P, 6-(1-Hydroxyethyl)-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one 857281-27-7P, 4-(3-Methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxaldehyde 857281-29-9P, Benzyl  
(3R,4R)-4-(4-methoxyphenyl)-3-[[1(S)-[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]ethoxy]piperidine-1-carboxylate 857281-32-4P, Benzyl (3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[[4-[[tetrahydrofuran-3-yl]oxy]phenyl]piperidine-1-carboxylate 857281-36-8P, Benzyl  
(3R,4R)-4-(4-isopropoxyphenyl)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857281-40-4P, Benzyl (3R,4R)-4-[4-[[imidazol-1-yl]methyl]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857281-42-6P, Benzyl (3R,4R)-3-[[4-(4-aminoethyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-[[3-[[2-methoxybenzylloxy]propoxy]phenyl]piperidine-1-carboxylate 857281-43-7P, Benzyl  
(3R,4R)-3-[[4-(4-aminobutyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-[[3-[[2-methoxybenzylloxy]propoxy]phenyl]piperidine-1-carboxylate 857281-44-8P, Benzyl  
(3R,4R)-4-[4-[[3-(2-methoxybenzylloxy)propoxy]phenyl]-3-[[3-oxo-4-[4-[[4-tolylsulfonyl]oxy]butyl]-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857281-45-9P, Benzyl  
(3R,4R)-3-[[4-(4-hydroxybutyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-[[3-[[2-methoxybenzylloxy]propoxy]phenyl]piperidine-1-carboxylate 857281-46-0P, Benzyl  
(3R,4R)-4-[4-[[3-(2-methoxybenzylloxy)propoxy]phenyl]-3-[[3-oxo-4-[4-(triisopropylsilyl)oxy]butyl]-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857281-48-2P, 6-Chloromethyl-4-[4-(triisopropylsilyl)oxy]butyl-4H-benzo[1,4]oxazin-3-one 857281-49-3P, 6-Hydroxymethyl-4-[4-(triisopropylsilyl)oxy]butyl-4H-benzo[1,4]oxazin-3-one 857281-52-8P, Benzyl  
(3R,4R)-4-(4-ethoxymethylphenyl)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857281-58-4P, Benzyl (3R,4R)-4-[4-[[3-(2,5-difluorophenylamino)propoxy]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857281-59-5P, 3-(2,5-Difluorophenylamino)propan-1-ol 857281-60-8P, N-(2,5-Difluorophenyl)-3-hydroxypropionamide  
Rt: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of piperidines as renin inhibitors useful against hypertension and other disorders)  
IT 857281-62-0P, tert-Butyl (3R,4R)-4-[4-[[3-(2-methoxybenzylloxy)propoxy]phenyl]-3-[[2-(3-methoxypropoxy)phenyl]methyl]oxy]piperidine-1-carboxylate 857281-63-1P, 1-Chloromethyl-2-(3-methoxypropoxy)benzene 857281-65-3P, Benzyl  
(3R,4R)-4-(4-benzylloxyphenyl)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857281-67-5P, Benzyl  
(3R,4R)-4-[4-(2-dimethylaminoethoxy)phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857281-70-0P, Benzyl (3R,4R)-4-(4-methoxyphenyl)-3-[[4-(3-methoxypropyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 1-carboxylate 857281-71-1P, 6-Chloromethyl-4-(3-methoxypropyl)-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one 857281-72-2P,  
 6-Hydroxymethyl-4-(3-methoxypropyl)-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one 857281-73-3P, 6-Hydroxymethyl-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one 857281-75-5P, Benzyl  
 (3R,4R)-4-[4-(3-dimethylaminopropoxy)phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857281-76-6P, Benzyl  
 (3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-[3-[(4-tolylsulfonyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857281-79-9P, Benzyl  
 (3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-(4-phenoxyphenyl)piperidine-1-carboxylate 857281-90-4P, Benzyl (3R,4R)-4-(4-isopropoxymethylphenyl)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857281-94-8P, Benzyl  
 (3R,4R)-3-[[4-[4-[(benzoyloxy)carbonyl]methyl]amino]butyl]-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-[3-(2-methoxybenzoyloxy)propoxy]phenyl]piperidine-1-carboxylate 857281-95-9P, Benzyl  
 (3R,4R)-3-[[4-[4-[(benzoyloxy)carbonyl]methyl]amino]butyl]-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-[3-(2-methoxybenzoyloxy)propoxy]phenyl]piperidine-1-carboxylate 857281-96-0P, Benzyl  
 (3R,4R)-3-[[4-[4-[(benzoyloxy)carbonyl]amino]butyl]-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-[3-(2-methoxybenzoyloxy)propoxy]phenyl]piperidine-1-carboxylate 857281-98-2P, Benzyl (3R,4R)-4-(3-fluoro-4-methoxyphenyl)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857281-99-3P, Benzyl (3R,4R)-4-(3-fluoro-4-methoxyphenyl)-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857282-00-9P, Benzyl  
 (3R,4R)-4-(3-fluoro-4-methoxyphenyl)-3-hydroxypiperidine-1-carboxylate 857282-01-0P, Benzyl (3R,4R)-4-(3-fluoro-4-hydroxyphenyl)-3-hydroxypiperidine-1-carboxylate 857282-03-2P, tert-Butyl  
 (3R,4R)-3-[[4-(4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-8-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857282-04-3P, tert-Butyl  
 (3R,4R)-3-[[4-(4-dimethyl-2-oxo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,4-dihydro-2H-benzo[d][1,3]oxazin-8-yl]methoxy]-4-[4-[3-[(2-methoxybenzyl)oxy]propoxy]phenyl]piperidine-1-carboxylate 857282-05-4P, 8-Bromomethyl-4,4-dimethyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,4-dihydrobenzo[d][1,3]oxazin-2-one 857282-06-5P, 4,4,8-Trimethyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1,4-dihydrobenzo[d][1,3]oxazin-2-one 857282-07-6P, 4,4,8-Trimethyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one 857282-09-8P, Benzyl (3R,4R)-4-[4-[(benzodioxol-5-yl)oxy]methyl]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857282-11-2P, Benzyl  
 (3R,4R)-4-[4-(3-hydroxypropoxy)phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857282-13-4P,

L10 2 ANSWERS CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 Benzyl (3R,4R)-4-[4-[(1H-indol-4-yloxy)methyl]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857282-18-9P, Benzyl  
 (3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-[[3-[(methylcarbamoyl)methyl]phenyl]oxy]methyl]phenyl]piperidine-1-carboxylate 857282-19-0P, Benzyl  
 (3R,4R)-4-[4-[[3-[(ethoxycarbonyl)methyl]phenyl]oxy]methyl]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857282-21-4P, Benzyl  
 (3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-[[1-methyl-1H-indol-4-yl]oxy]methyl]phenyl]piperidine-1-carboxylate 857282-23-6P, Benzyl  
 (3R,4R)-4-[4-[[3-[(carbamoyl)methyl]phenyl]oxy]methyl]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857282-25-8P, Benzyl  
 (3R,4R)-4-[4-[[3-(1H-imidazol-4-yl)phenoxy]methyl]phenyl]-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidine-1-carboxylate 857282-26-9P, 3-(1-Trityl-1H-imidazol-4-yl)phenol 857282-28-1P, Benzyl (3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-(4-phenoxyphenyl)piperidine-1-carboxylate 857282-29-2P, Benzyl  
 (3R,4R)-3-[[4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-(4-phenoxyphenyl)piperidine-1-carboxylate 857282-30-5P, Benzyl (3R,4R)-3-hydroxy-4-(4-phenoxyphenyl)piperidine-1-carboxylate 857282-32-7P, Benzyl  
 (3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]-4-[4-(4-methylcarbamoylbut-1-ynyl)phenyl]piperidine-1-carboxylate 1048690-12-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of piperidines as renin inhibitors useful against hypertension and other disorders)


ALL ANSWERS HAVE BEEN SCANNED

=> d ibib abs hitrn fhitstr l10 tot

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2006:1037703 CAPLUS  
DOCUMENT NUMBER: 145:397375  
TITLE: Preparation of 4-(4-piperidinyl)phenols and related compounds as aspartic protease inhibitors  
INVENTOR(S): Herold, Peter; Mah, Robert; Stutz, Stefan; Stojanovic, Aleksandar; Tschinke, Vincenzo; Jotterand, Nathalie; Schumacher, Christoph  
PATENT ASSIGNEE(S): Speedel Experimenta A.-G., Switz.  
SOURCE: Eur. Pat. Appl., 67pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1707202	A1	20061004	EP 2006-111981	20060330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
PRIORITY APPLN. INFO.:		EP 2005-102559	A	20050331

OTHER SOURCE(S): MARPAT 145:397375  
GI



AB Title compds. I [X = X'-Zn-R1; n = 0-1; W = W'm-R2; m = 0-1; W' = S, O; X' = bond, S, O, etc.; Z = alkyl, alkenyl, O, etc.; R1 = oxazolyl, indolyl, pyrrolyl, etc.; R2 = Ph, naphthyl, cyclohexyl, etc.; R3 = H, OH, alkoxy, etc.; R4 = H, alkyl, alkenyl, etc.; Q = ethylene] and their

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
pharmaceutically acceptable salts were prepd. For example, the Rf-value for piperidinylphenol II was provided. In cathepsin D inhibition assays, compds. I exhibited IC50 values ranging from 0.01  $\mu$ M-100 nM. Of note compds. I are claimed to be useful as inhibitors of  $\beta$ -secretase, cathepsin D, plasmeprin II and the HIV protease.

IT 857272-00-5 857272-10-7 857272-11-8  
857272-18-5 857272-32-3 857272-42-5  
857272-49-2 857272-60-7 857272-66-3  
857272-69-6 857272-75-4 857272-82-3  
857272-86-7 857272-89-0 857272-95-8  
857272-99-2 857273-26-8 857273-64-4  
857273-73-5 857273-78-0 857273-82-6  
857273-84-8 857273-86-0 857273-89-3  
857273-92-8 857274-07-8 857274-13-6  
857274-14-7 857274-21-6 857274-49-8  
857274-57-8 857274-72-7 857274-74-9  
857274-82-9 857274-84-1 857274-86-3  
857274-88-5 857274-90-9 857274-92-1  
857274-95-4 857274-98-7 857275-00-4  
857275-29-7 857275-31-1 857275-34-4  
857275-35-5 857276-13-2 857276-31-4  
857276-35-8 857276-76-7 857276-80-3  
857276-84-7 857276-88-1 857276-93-8  
857276-97-2 857277-01-1 857277-05-5  
857277-14-6 857277-23-7 857277-29-3  
857277-46-4 857277-50-0 857277-54-4  
857277-59-9 857277-63-5 857277-68-0  
857277-73-7 857277-78-2 857277-82-8  
857277-87-3 857277-98-6 857277-99-7  
857278-00-3 857278-01-4 857278-02-5  
857278-03-6 857278-04-7 857278-05-8  
857278-21-8 857278-27-4 857278-41-2  
857278-42-3 857278-48-9 857278-49-0  
857278-53-6 857278-54-7 857278-55-8  
857278-56-9 857278-62-7 857278-63-8  
857278-64-9 857278-65-0 857278-66-1  
857278-67-2 857278-68-3 857278-69-4  
857278-70-7 857278-71-8 857278-72-9  
857278-73-0 857278-74-1 857278-75-2  
857278-76-3 857278-77-4 857278-78-5  
857278-79-6 857278-80-9 857278-81-0  
857278-82-1 857278-83-2 857278-84-3  
857278-91-2 857278-92-3 857278-99-0  
857279-01-7 857279-02-8 857279-03-9  
857279-16-4 857279-26-6 857279-31-3  
857279-35-7 857279-36-8 857279-37-9  
857279-38-0 857279-45-9 857279-53-9  
857279-54-0 857279-55-1 857279-64-2  
857279-69-7 857279-76-6 857279-80-2  
857279-82-4 857279-88-0 857279-91-5  
857279-92-6 857279-93-7 857279-95-9  
857279-96-0 857280-07-0 857280-08-1  
857280-13-8 857280-19-4 857280-22-9  
857280-24-1 857280-25-2 857280-26-3

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

857280-27-4 857280-28-5 857280-29-6  
857280-30-9 857280-31-0 857280-32-1  
857280-33-2 857280-34-3 857280-35-4  
857280-38-7 857280-42-3 857280-45-6  
857280-46-7 857280-50-3 857280-54-7  
857280-56-9 857280-61-6 857280-68-3  
857280-69-4 857280-70-7 857280-73-0  
857280-75-2 857280-78-5 857280-81-0  
857280-82-1 857280-83-2 857280-84-3  
857280-86-5 857280-87-6 857280-88-7  
857280-89-8 857280-90-1 857280-91-2  
857280-92-3 857280-93-4 857280-94-5  
857280-95-6 857280-96-7 857281-00-6  
857281-03-9 857281-04-0 857281-08-4  
857281-10-8 857281-11-9 857281-12-0  
857281-13-1 857281-14-2 857281-20-0  
857281-21-1 857281-28-8 857281-30-2  
857281-31-3 857281-33-5 857281-34-6  
857281-35-7 857281-37-9 857281-38-0  
857281-39-1 857281-41-5 857281-51-7  
857281-53-9 857281-54-0 857281-55-1  
857281-56-2 857281-57-3 857281-64-2  
857281-66-4 857281-69-7 857281-74-4  
857281-77-7 857281-78-8 857281-80-2  
857281-81-3 857281-82-4 857281-84-6  
857281-85-7 857281-86-8 857281-87-9  
857281-88-0 857281-89-1 857281-91-5  
857281-92-6 857281-93-7 857281-97-1  
857282-02-1 857282-08-7 857282-10-1  
857282-12-3 857282-14-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(prepn. of 4-(4-piperidinyl)phenols and related compds. as aspartic protease inhibitors)

IT 857282-15-6 857282-16-7 857282-17-8  
857282-20-3 857282-22-5 857282-24-7  
857282-27-0 857282-31-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of 4-(4-piperidinyl)phenols and related compds. as aspartic protease inhibitors)


IT 857272-00-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of 4-(4-piperidinyl)phenols and related compds. as aspartic protease inhibitors)

RN 857272-00-5 CAPLUS  
CN 2H-1,4-Benzoxazin-3-(4H)-one, 6-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3-piperidinyl]oxy]methyl]-4-(3-methoxypropyl)- (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT




L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS ON STN  
ACCESSION NUMBER: 2005:588898 CAPLUS  
DOCUMENT NUMBER: 143:115449  
TITLE: Preparation of piperidines as renin inhibitors useful  
against hypertension and other disorders  
INVENTOR(S): Herold, Peter; Mah, Robert; Stutz, Stefan;  
Stojanovic, Aleksandar; Tschinke, Vincenzo; Jotterand, Nathalie  
PATENT ASSIGNEE(S): Speedel Experimenta A.-G., Switz.  
SOURCE: PCT Int. Appl., 252 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061457	A1	20050707	WO 2004-EP52389	20040930
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NM, NC, PG, PH, PT, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KE, MD, RU, JY, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IL, IN, IS, IT, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NM, NC, PG, PH, PT, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
EP 1670760	A1	20060621	EP 2004-820600	20040930
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, BG, CZ, EE, HU, PL, SK			
EP 1961752	A1	20080827	EP 2008-100329	20040930
EP 1961752	A3	20081119		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
US 20070010511	A1	20070111	US 2006-574108	20060331
US 2009012095	A1	20090108	US 2008-51038	20080201
PRIORITY APPLIN. INFO.:			CH 2003-16593	A 20031001

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OTHER SOURCE(S): CASREACT 143:115449; MARPAT 143:115449  
GI

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



AB Novel substituted piperidines (shown as I and II; variables defined below;

trans-4-[4-(3-(2-methoxybenzyloxy)propoxy)phenyl]-3-[[3-methoxy-5-(3-methoxypropoxy)benzoyl]oxy]piperidine (shown as III) are described. The compds. are suitable in particular as renin inhibitors and are highly potent. A test that measures the formation of angiotensin I in human plasma revealed that I exhibit inhibiting actions in the in vitro systems at min. concns. of approx.10-6 to .approx.10 mol/L. Compds. I effectively reduce blood pressure in an in vivo test involving normotensive marmosets at doses of approx.0.003 to approx.0.3 mg/kg i.v. and oral doses of approx.0.3 to approx.3 mg/kg. For I, R1 is (un)substituted oxydihydral, indolyl, pyrryl, pyrazolyl, triaziny, 2-oxodihydrobenzo[d][1,3]oxaziny, 4-oxodihydroimidazoly, 5-oxo-4H-[1,2,4]triaziny, 3-oxo-4H-benzo[1,4]thiaziny, tetrahydroquinolaxiny, 1,1,3-trioxidihydro-2H-1λ6-benzo[1,4]thiaziny, 1-oxopyridyl, dihydro-2H-benzo[1,4]oxaziny, 2-oxotetrahydrobenzo[e][1,4]diazepiny, etc. For II: R1 is aryl or heteroaryl. For I and II: R2 is (un)substituted Ph, naphthyl, acenaphthyl, cyclohexyl, pyridyl, pyrimidinyl, pyrazinyl, oxypyridinyl, diaziny, triazoly, thienyl, oxazolyl, oxadiazolyl, pyrryl, furyl, tetrazolyl or imidazolyl. R3 is H, hydroxy, Cl-6-alkoxy or Cl-6-alkenyl; R4 is H, Cl-1-6-alkyl, C2-6-alkenyl, Cl-1-6-alkoxy, hydroxy-Cl-1-6-alkyl, Cl-1-6-alkoxy-Cl-1-6-alkyl, benzyl, oxo, etc.; or R3 and R4 in I together are a bond. Q is ethylene or is absent for I or is ethylene or methylene for II; X is a bond, O, or S, or is a >CHRR1, >CHOR2, -OCO-, >CO, >C(=NR)R1, -OCHRR1 or -OCHRR1-CO-NR3- group and the bond starting from an O or S atom leads to a saturated C atom of the Z group or to

L10	ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)		
	R1; W is O or S; Z is Cl-6-alkylene, C2-6-alkenylene, hydroxy-Cl-6-alkylidene, -O-, -S-, -O-alk-, -S-alk-, -alk-O-, -alk-S- or -alk-NR9-, where alk is Cl-6-alkylene; n = 0-1; m = 0-1 addnl. details including provisos are given in the claims. Although the methods of prepn. are not claimed, example prepn. and/or characterization data for 360 I and II are included. For example, III was prepd. from by deprotection of tert-Bu 4-[[3-(3-benzyloxypropoxy)phenyl]-3-[[[3-(3-methoxypropoxy)phenyl]-4-[[3-(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate, which was prepd. by either formation between tert-Bu 3-hydroxy-4-[[3-(2-methoxybenzyloxy)propoxy]phenyl]piperidine-1-carboxylate and 1-chloromethyl-3-methoxy-5-(3-methoxypropoxy)benzene		
	using NaH in DMF.		
IT	1044670-79-2	1044670-83-8	1044670-85-0
	1044670-86-1	1044670-87-2	1044670-88-3
	1044670-95-2	1044670-97-4	1044671-03-5
	1044671-06-8	1044671-11-5	1044671-14-8
	1044671-15-9	1044671-17-1	1044671-22-8
	1044671-25-1	1044671-26-2	1044671-27-3
	1044671-29-5	1044671-32-0	1044671-33-1
	1044671-34-2	1044671-35-3	1044671-36-4
	1044671-41-1	1044671-42-2	1044671-43-3
	1044671-44-4	1044671-49-9	1044671-52-4
	1044671-55-7	1044671-57-9	1044671-60-4
	1044671-64-8	1044671-66-0	1044671-67-1
	1044671-69-3	1044671-71-7	1044671-72-8
	1044671-74-0	1044671-75-1	1044671-77-3
	1044671-83-1	1044671-84-2	1044671-85-3
	1044671-87-5	1044671-89-7	1044671-92-2
	1044671-96-6	1044671-98-8	1044672-01-6
	1044672-05-0	1044672-06-1	1044672-07-2
	1044672-08-3	1044672-10-7	1044672-11-8
	1044672-15-2	1044672-23-2	1044672-25-4
	1044672-27-6	1044672-30-1	1044672-32-3
	1044672-36-7	1044672-37-8	1044672-41-4
	1044672-43-6	1044672-46-9	1044672-47-0
	1044672-50-5	1044672-51-6	1044672-54-9
	1044672-55-0	1044672-57-2	1044672-58-3
	1044672-59-4	1044672-60-7	1044672-63-0
	1044672-64-1	1044672-65-2	1044672-66-3
	1044672-67-4	1044672-68-5	1044672-69-6
	1044672-70-9	1044672-72-1	1044672-73-2
	1044672-74-3	1044672-75-4	1044672-76-5
	1044672-77-6	1044672-78-7	1044672-79-8
	1044672-81-2	1044672-84-5	1044672-85-6
	1044672-86-7	1044672-87-8	1044672-88-9
	1044672-90-3	1044672-92-5	1044672-93-6
	1044672-95-8	1044672-96-9	1044672-97-0
	1044672-99-2	1044673-00-8	1044673-01-9
	1044673-02-0	1044673-04-2	1044673-06-4
	1044673-07-5	1044673-08-6	1044673-10-0
	1044673-11-1	1044673-12-2	1044673-13-3
	1044673-14-4	1044673-15-5	1044673-16-6
	1044673-20-2	1044673-21-3	1044673-22-4
	1044673-24-6	1044673-26-8	1044673-27-9
	1044673-29-1	1044673-30-4	1044673-34-8
	1044673-35-9	1044673-38-2	1044673-39-3
	1044673-42-8	1044673-43-9	1044673-44-0

L10	ANSWER 2 OF 2	CAPLUS	COPYRIGHT 2009 ACS ON STN	(Continued)
	1044673-45-1	1044673-46-2	1044673-47-3	
	1044673-48-4	1044673-49-5	1044673-50-8	
	1044673-51-9	1044673-52-0	1044673-55-3	
	1044673-57-5	1044673-58-6	1044673-60-0	
	1044673-62-2	1044673-65-5	1044673-67-7	
	1044673-69-9	1044673-72-4	1044673-73-5	
	1044673-74-6	1044673-75-7	1044673-76-8	
	1044673-77-9	1044673-78-0	1044673-79-1	
	1044673-81-5	1044673-82-6	1044673-83-7	
	1044673-85-9	1044673-86-0	1044673-90-6	
	1044673-93-9	1044673-94-0	1044673-97-3	
	1044673-99-5	1044674-00-1	1044674-02-3	
	1044674-03-4	1044674-05-6	1044674-07-8	
	1044674-12-5	1044674-13-6	1044674-19-2	
	1044674-23-8	1044674-25-0	1044674-26-1	
	1044674-28-3	1044674-33-0	1044674-36-3	
	1044674-39-6	1044674-40-0	1044674-41-0	
	1044674-42-1	1044674-48-7	1044674-49-8	
	1044674-55-6	1044674-56-7	1044674-57-8	
	1044674-58-9	1044674-65-8	1044674-66-9	
	1044674-67-0	1044674-68-1	1044674-69-2	
	1044674-70-5	1044674-73-8	1044674-74-9	
	1044674-75-0	1044674-79-4	1044674-83-0	
	1044674-85-2	1044674-86-3	1044674-87-4	
	1044674-88-5	1044674-90-9	1044674-92-1	
	1044674-95-4	1044674-97-6	1044674-99-8	
	1044675-02-6	1044675-03-7	1044675-04-8	
	1044675-07-1	1044675-10-6	1044675-11-7	
	1044675-12-8	1044675-13-9	1044675-14-0	
	RL: PPHH (Prophetic)			
	(Frequ. of piperidines as renin inhibitors useful against hypertension			
	and other disorders)			
IT	857272-00-5P, 6-[[[[(3R,4R)-4-{4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yloxy)methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one 857272-69-6P, 6'-[[[(3R,4R)-4-{4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yloxy)methyl]-1'-(3-methoxypropyl)spiro[cyclopropane-1,3'-[3H]indol]-2'(1'H)-one 857273-73-5P,			
	7-[[[(3R,4R)-4-{4-[2-(2-(2-Methoxyphenylethoxy)ethoxy]phenyl)piperidin-3-yloxy)methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857278-92-3P, 7-[[[(3R,4R)-4-{4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yloxy)methyl]-1,3-dihydroindol-2-one 857279-82-4P, Methyl 7-[[[(3R,4R)-4-{4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yloxy)methyl]-1H-benzimidazole-2-carboxylate 857279-93-7P, 7-[[[(3R,4R)-4-{4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yloxy)methyl]-1,3-trimethyl-1,3-dihydroindol-2-one 857281-69-7P, 6'-[[[(3R,4R)-4-(4-Methoxyphenyl)piperidin-3-yloxy)methyl]-4-(3-methoxypropyl)-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one 857281-91-5P, 6-[[[[(3R,4R)-4-{4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yloxy)methyl]-4-(3-methoxypropyl)-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one			
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation of drug candidate or reagents/intermediates (uses))			
	(drug candidate; preparation of piperidines as renin inhibitors useful against hypertension and other disorders)			

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 IT 857272-10-7P, 6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857272-11-8P, 5-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3-(3-methoxypropyl)benzoxazol-2(3H)-one 857272-18-5P, (3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]-3-[[7-(3-methoxypropoxy)benzofuran-2-yl]methoxy]piperidine 857272-32-3P, 6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-1H-indole 857272-42-5P, 857272-49-2P, 7-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857272-60-7P, 7-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-1H-quinolin-2-one 857272-66-3P, 7-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-(3-methoxypropoxy)quinoline 857272-75-4P, (3R,4R)-4-[4-[4-(2-Methoxybenzyloxy)propoxy]phenyl]-3-[[7-(3-methoxypropoxy)-2,3-dihydrobenzofuran-2-yl]methoxy]piperidine 857272-82-3P, 6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3-methyl-1H-indole 857272-86-7P, 6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-2-methyl-1H-indole 857272-89-0P, 6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-2H-indazole 857272-95-8P, 6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2-(3-methoxypropyl)-2H-indazole 857272-99-2P, 7-[[[(3R,4R)-4-[4-[4-(2-Methoxyphenoxy)butoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857273-26-8P, 2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-1H-indole 857273-64-4P 857273-78-0P  
 7-[[[(3R,4R)-4-[4-[3-(3-Hydroxypropoxy)phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857273-82-6P, 1-(3-Methoxypropyl)-7-[[[(3R,4R)-4-[4-[4-(o-tolyloxy)butoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-1H-quinolin-2-one 857273-84-8P, 7-[[[(3R,4R)-4-[4-[4-(2-Fluorophenoxy)butoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857273-86-0P, 7-[[[(3R,4R)-4-[4-[4-[2-Ethylphenyl]oxy]butoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857273-89-3P, 2-[4-[4-[(3R,4R)-4-[4-[3-(1-(3-Methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)methoxy]piperidin-4-yl]phenoxy]butoxy]benzonitrile 857273-92-8P, 1-(3-Methoxypropyl)-7-[[[(3R,4R)-4-[4-[4-(3-methylindol-1-yl)butoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-1H-quinolin-2-one 857274-07-8P, 6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,3-dimethyl-1,3-dihydroindol-2-one 857274-13-6P

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 857275-34-4P, 7-[[[(3R,4R)-4-[4-[2-[2-(2-Methoxyphenyl)ethoxy]ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-1,2,3,4-tetrahydroquinoline 857275-35-5P, 1-(3-Methoxypropyl)-7-[[[(3R,4R)-4-[4-[3-(2-methylbenzyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-1H-quinolin-2-one 857276-13-2P, 6-[[[(3R,4R)-4-[4-[3-(2-Chlorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857276-31-4P, 1-(3-Methoxypropyl)-7-[[[(3R,4R)-4-[4-[4-(5-methoxypyrimidin-4-yl)amino]butoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-1H-quinolin-2-one 857276-35-8P, 1-(3-Methoxypropyl)-7-[[[(3R,4R)-4-[4-[4-(3-methoxypyridin-2-yl)amino]butoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-1H-quinolin-2-one 857276-76-7P, 6-[[[(3R,4R)-4-[4-[3-(3-Methoxyphenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857276-80-3P, 6-[[[(3R,4R)-4-[4-[3-(3-Fluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857276-84-7P, 6-[[[(3R,4R)-4-[4-[3-(2-Fluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857276-86-1P, 6-[[[(3R,4R)-4-[4-[3-(2,5-Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857276-93-8P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[3-(o-tolyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857276-97-2P, 6-[[[(3R,4R)-4-[4-[3-(2-Methoxyphenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-01-1P, 6-[[[(3R,4R)-4-[4-[3-(3-Chlorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-05-5P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[3-(m-tolyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857277-14-6P, 4-Methoxy-1-[(2R)-2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2,3-dihydrobenzo[1,4]oxazin-4-yl]butan-1-one 857277-23-7P, 4-Methoxy-1-[(2S)-2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2,3-dihydrobenzo[1,4]oxazin-4-yl]butan-1-one 857277-29-3P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[3-(3-phenoxypropoxy)phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857277-46-4P, 6-[[[(3R,4R)-4-[4-[3-(Benzodioxol-5-yl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-50-0P, 6-[[[(3R,4R)-4-[4-[3-(2,4-Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-54-4P, 6-[[[(3R,4R)-4-[4-[3-(2,3-Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-59-9P, 6-[[[(3R,4R)-4-[4-[3-(4-Fluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-63-5P, 6-[[[(3R,4R)-4-[4-[3-(2,6-Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857277-68-0P, 6-[[[(3R,4R)-4-[4-[3-(3,4-

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
 , 2',3'-Dihydro-6'-[[[(3R,4R)-4-[4-[3-(2-methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1'-(3-methoxypropyl)spiro[cyclopropane-1,3'-1H-indol] 857274-14-7P, 6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,3-dimethyl-2,3-dihydro-1H-indole 857274-21-6P, N-[2-[2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]benzofuran-7-yl]ethyl]acetamide 857274-49-8P,  
 N-[2-[2-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2,3-dihydrobenzofuran-7-yl]ethyl]acetamide 857274-57-8P, N-[2-[6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3-methylindol-1-yl]ethyl]acetamide 857274-72-7P,  
 N-[2-[6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3-methylindol-1-yl]ethyl]cyclopropanecarboxamide 857274-74-9P, N-[2-[6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3-methylindol-1-yl]ethyl]propionamide 857274-82-9P, 7-[[[(3R,4R)-4-[4-[3-(2,6-Dimethoxyphenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857274-84-1P, 7-[[[(3R,4R)-4-[4-[4-(2,6-Dimethoxyphenoxy)butoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-2-methyl-1H-quinolin-2-one 857274-86-3P, 7-[[[(3R,4R)-4-[4-[3-(2-Chlorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857274-88-5P, 2-[3-[4-[(3R,4R)-3-[[1-(3-Methoxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl]methoxy]piperidin-4-yl]phenoxy]propoxy]benzonitrile 857274-90-9P, 7-[[[(3R,4R)-4-[4-[4-(2-Chlorophenoxy)butoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857274-92-1P, 7-[[[(3R,4R)-4-[4-[3-(2-Methoxy-6-methylphenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857274-95-4P,  
 7-[[[(3R,4R)-4-[4-[4-(2-Methoxy-6-methylphenoxy)butoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857274-98-7P, 7-[[[(3R,4R)-4-[4-[4-(3-Chlorophenoxy)butoxy]phenyl]piperidin-3-yl]oxy]methyl]-1-(3-methoxypropyl)-3,4-dihydro-1H-quinolin-2-one 857275-00-4P,  
 N-[2-[6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,3-dimethyl-2,3-dihydroindol-1-yl]ethyl]acetamide 857275-29-7P, 1-[2-[6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-3-methylindol-1-yl]ethyl]-3-methylurea 857275-31-1P,  
 6-[[[(3R,4R)-4-[4-[2-[2-(2-Methoxyphenyl)ethoxy]ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]ethanone 857278-53-6P,  
 3-[3-[4-[(3R,4R)-3-[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy]propoxy]phenol 857278-04-7P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[2-(1-phenylcyclopropyl)methoxy]ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine 857278-05-8P, 6-[[[(3R,4R)-4-(4-Methoxyphenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-21-8P, 3-Fluoro-N-[2-[4-[(3R,4R)-3-[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy]ethyl]benzamide 857278-27-4P, N-[2-[6-[[[(3R,4R)-4-[4-[3-(2,5-Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2,3-dihydrobenzo[1,4]oxazin-4-yl]ethyl]acetamide 857278-41-2P, Methyl 2-[6-[[[(3R,4R)-4-[4-[3-(2,5-difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-2,3-dihydrobenzo[1,4]oxazin-4-yl]ethyl]carbamate 857278-42-3P, 6-[[[(3R,4R)-4-[4-[2-(2,5-Difluorobenzoyloxy)ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-48-9P, 6-[[[(3R,4R)-4-[4-[2-(2-Methoxybenzyloxy)ethoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-49-0P, 2-Cyclopropyl-1-[(3S)-3-[4-[(3R,4R)-3-[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy]pyrrolidin-1-yl]ethanone 857278-53-6P, Cyclohexyl[(3S)-3-[4-[(3R,4R)-3-[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy]pyrrolidin-1-yl]methanone 857278-54-7P, [(3S)-3-[4-[(3R,4R)-3-[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]methoxy]piperidin-4-yl]phenoxy]pyrrolidin-1-yl] (tetrahydropyran-4-yl) methanone 857278-55-8P, [3-[4-[(3R,4R)-3-[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
yl)methoxy]piperidin-4-yl]phenyloxy]azetidin-1-yl]Phenylmethanone  
857278-56-9P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(3S)-1-

phenylpyrrolidin-3-yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857278-62-7P,  
6-[[[(3R,4R)-4-[4-[[[(3S)-1-(2-Fluorophenyl)pyrrolidin-3-  
yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazine 857278-63-8P,  
6-[[[(3R,4R)-4-[4-[[[(3S)-1-(4-Fluorophenyl)pyrrolidin-3-  
yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazine 857278-64-9P,  
6-[[[(3R,4R)-4-[4-[[[(3S)-1-(3-Fluorophenyl)pyrrolidin-3-  
yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazine 857278-65-0P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(1-phenylazetidin-3-  
yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine  
857278-66-1P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(1-

phenylpiperidin-4-yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857278-67-2P,  
6-[[[(3R,4R)-4-[4-[[[(3S)-1-(3-Methoxyphenyl)pyrrolidin-3-  
yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazine 857278-68-3P,

4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(3S)-1-(pyridin-2-yl)pyrrolidin-3-  
yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine  
857278-69-4P, 6-[[[(3R,4R)-4-[4-[[[(3S)-1-(3-  
Chlorophenyl)pyrrolidin-3-yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857278-70-7P,  
6-[[[(3R,4R)-4-[4-[[[(3S)-1-(2-Chlorophenyl)pyrrolidin-3-  
yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazine 857278-71-8P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(3S,5S)-5-methyl-1-

phenylpyrrolidin-3-yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857278-72-9P,  
6-[[[(3R,4R)-4-[4-[[[(3S)-1-(2-Methoxyphenyl)pyrrolidin-3-  
yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazine 857278-73-0P,  
6-[[[(3R,4R)-4-[4-[[[(3S)-1-(Benzodioxol-5-yl)pyrrolidin-3-  
yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazine 857278-74-1P,  
6-[[[(3R,4R)-4-[4-[[[(1-(2-Fluorophenyl)azetidin-3-yloxy]phenyl]piperidin-3-  
yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857278-75-2P, 6-[[[(3R,4R)-4-[4-[[[(1-(3-Fluorophenyl)azetidin-3-  
yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazine 857278-76-3P,

6-[[[(3R,4R)-4-[4-[[[(1-(4-Fluorophenyl)azetidin-3-yl)oxy]phenyl]piperidin-3-  
yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857278-77-4P, 6-[[[(3R,4R)-4-[4-[[[(1-(Benzodioxol-5-yl)azetidin-3-  
yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazine 857278-78-5P,

6-[[[(3R,4R)-4-[4-[1-(2,5-Difluorophenyl)azetidin-3-yloxy]phenyl]piperidin-

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

phenylpiperazin-1-yl)methyl]phenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-  
2H-benzo[1,4]oxazine 857279-54-0P,  
[4-[[[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-  
yl)methoxy]piperidin-4-yl]benzyl]((3S)-1-phenylpyrrolidin-3-yl)amine  
857279-55-1P, [4-[[[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-  
benzo[1,4]oxazin-6-yl)methoxy]piperidin-4-yl]benzyl]((3R)-1-  
phenylpyrrolidin-3-yl)amine 857279-64-2P,  
4-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-  
yl)oxy]methyl]-1H-benzimidazole 857279-69-7P,  
N-[[[(3R)-1-[4-[[[(3R,4R)-3-[[4-(3-Methoxypropyl)-3-oxo-3,4-dihydro-2H-  
benzo[1,4]oxazin-6-yl)methoxy]piperidin-4-yl]phenyl]pyrrolidin-3-yl]-N-  
methylbenzamide 857279-76-6P,  
6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-  
yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]thiazine  
857279-80-2P, 4-[[[(3R,4R)-4-[4-[3-(2-  
Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl)oxy]methyl]-1-methyl-1H-  
benzimidazole 857279-88-0P,

6-[[[(3R,4R)-4-[4-[[[(3S)-1-Cyclohexylpyrrolidin-3-yl)oxy]phenyl]piperidin-  
3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857279-91-5P, [7-[[[(3R,4R)-4-[4-[3-(2-  
Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl)oxy]methyl]-1H-benzimidazol-  
2-yl)methanol 857279-92-6P,  
7-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-  
yl)oxy]methyl]-3,3-dimethyl-2,3-dihydro-1H-indole 857279-95-9P,  
7-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-  
yl)oxy]methyl]-1,3,3-trimethyl-2,3-dihydro-1H-indole  
857279-96-0P, 6-[[[(3R,4R)-4-[4-[2-(2-Difluoro-3-  
phenoxypropoxy)phenyl]piperidin-3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-  
dihydro-2H-benzo[1,4]oxazine 857280-07-0P,  
6-[[[(3R,4R)-4-[4-[1-Benzylazetidin-3-yloxy]phenyl]piperidin-3-  
yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-08-1P, 3(S)-[4-[[[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazin-6-yl)methoxy]piperidin-4-yl]phenoxy]-1-  
phenylpyrrolidin-2-one 857280-13-8P,

6-[[[(3R,4R)-4-[4-[4-[[[(1-Benzoxazol-2-yl)azetidin-3-yl)oxy]phenyl]piperidin-  
3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-19-4P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(1-thiazol-2-  
yl)azetidin-3-yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857280-22-9P,  
4-[[[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-  
yl)methoxy]piperidin-4-yl]phenyl 3-Phenylpyrrolidine-1-carboxylate  
857280-24-1P, 4-[[[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-  
benzo[1,4]oxazin-6-yl)methoxy]piperidin-4-yl]phenyl  
3,4-dihydro-2H-quinoline-1-carboxylate 857280-25-2P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(3S)-1-phenylpyrrolidin-3-  
yl)oxy]methyl]phenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857280-26-3P,

6-[[[(3R,4R)-4-[4-[4-[[[(2-Methoxybenzyloxy)ethoxy]methyl]phenyl]piperidin-3-  
yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-27-4P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(tetrahydrofuran-3-yl)oxy]methyl]phenyl]piperidin-3-yl)oxy]methyl]-3,4-  
dihydro-2H-benzo[1,4]oxazine 857280-28-5P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(tetrahydropyran-4-

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857278-79-6P, 6-[[[(3R,4R)-4-[4-[[[(3R,4R)-4-[4-[[[(3S)-1-

xyloxy]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-  
benzo[1,4]oxazine 857278-80-9P,

6-[[[(3R,4R)-4-[4-[1-(3,5-Difluorophenyl)azetidin-3-yloxy]phenyl]piperidin-  
3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857278-81-0P, 6-[[[(3R,4R)-4-[4-[[[(1-(4-Methoxyphenyl)azetidin-3-  
yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazine 857278-82-1P,

6-[[[(3R,4R)-4-[4-[[[(1-(3-Methoxyphenyl)azetidin-3-yl)oxy]phenyl]piperidin-  
3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857278-83-2P, 6-[[[(3R,4R)-4-[4-[[[(1-(2-Methoxyphenyl)azetidin-3-  
yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazine 857278-84-3P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(4-phenylpiperidin-1-  
yl)carbonyl]phenyl]piperidin-3-yl)oxy]methyl]-4H-benzo[1,4]oxazin-3-one  
857278-91-2P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(4-  
phenylpiperazin-1-yl)carbonyl]phenyl]piperidin-3-yl)oxy]methyl]-4H-  
benzo[1,4]oxazin-3-one 857278-99-0P,  
(Cyclohexylmethyl)[2-[4-[[[(3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-  
benzo[1,4]oxazin-6-yl)methoxy]piperidin-4-yl]phenoxy]ethyl]amine  
857279-01-7P, Cyclohexyl[3-[4-[[[(3R,4R)-3-[[4-(3-methoxypropyl)-3,4-  
dihydro-2H-benzo[1,4]oxazin-6-yl)methoxy]piperidin-4-  
yl]phenoxy]propyl]amine 857279-02-8P,  
[2-(2-Methoxyphenyl)ethyl][2-[4-[[[(3R,4R)-3-[[4-(3-methoxypropyl)-3,4-  
dihydro-2H-benzo[1,4]oxazin-6-yl)methoxy]piperidin-4-  
yl]phenoxy]ethyl]amine 857279-03-9P,

(2,5-Difluorobenzyl)[2-[4-[[[(3R,4R)-3-[[4-(3-methoxypropyl)-3,4-dihydro-2H-  
benzo[1,4]oxazin-6-yl)methoxy]piperidin-4-yl]phenoxy]ethyl]amine  
857279-16-4P, 8-[[[(3R,4R)-4-[4-[3-(2-  
Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl)oxy]methyl]-4,4-dimethyl-  
3,4-dihydro-1H-quinolin-2-one 857279-26-6P,  
4-[[[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-  
yl)methoxy]piperidin-4-yl]-N-(2-phenoxyethyl)benzamide  
857279-31-3P, [4-[[[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-  
benzo[1,4]oxazin-6-yl)methoxy]piperidin-4-yl]phenyl]((3R)-3-  
phenoxypropyl)-1-yl)methanone 857279-35-7P,  
4-[[[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-  
yl)methoxy]piperidin-4-yl]-N-methyl-N-(2-phenoxyethyl)benzamide  
857279-36-8P, [4-[[[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-  
benzo[1,4]oxazin-6-yl)methoxy]piperidin-4-yl]phenyl]((3-phenoxyazetidin-1-  
yl)methanone 857279-37-9P,  
[4-[[[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-  
yl)methoxy]piperidin-4-yl]phenyl]((3-phenylpyrrolidin-1-yl)methanone  
857279-38-0P, 4-[[[(3R,4R)-4-[4-[3-(2-  
Methoxybenzyloxy)propoxy]phenyl]piperidin-3-yl)oxy]methyl]-2-(3-  
methoxypropyl)-1H-benzimidazole 857279-45-9P,  
[2-(2,5-Difluorophenoxy)ethyl][4-[[[(3R,4R)-3-[[4-(3-methoxypropyl)-3,4-  
dihydro-2H-benzo[1,4]oxazin-6-yl)methoxy]piperidin-4-yl]benzyl]amine  
857279-53-9P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(4-

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

yl)oxy]methyl]phenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857280-29-6P,  
6-[[[(3R,4R)-4-[4-[[[(Cyclopropylmethoxy)methyl]phenyl]piperidin-3-  
yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-30-9P, 6-[[[(3R,4R)-4-[4-[[[(2-  
Cyclopropylethoxymethyl]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-31-0P,

6-[[[(3R,4R)-4-[4-[[[(2-Methoxyethoxymethyl]phenyl]piperidin-3-yl)oxy]methyl]-  
4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-32-1P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(4-  
propoxymethylphenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857280-33-2P,  
6-[[[(3R,4R)-4-[4-[[[(4-Butoxymethyl]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine 857280-34-3P,

4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(3S)-1-(thiazol-2-yl)pyrrolidin-3-  
yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-35-4P, [(1S)-1-[[[(3R,4R)-3-[[4-(3-Methoxypropyl)-3,4-

dihydro-2H-benzo[1,4]oxazin-6-yl)methoxy]piperidin-4-yl]phenoxy]methyl]-3-  
phenyl]propyl]amine 857280-38-7P,  
6-[[[(3R,4R)-4-[4-[[[(2-Methoxyphenoxy)ethoxy]phenyl]piperidin-3-  
yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-42-3P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(pyrrolidin-1-  
yl)phenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-45-6P, 6-[[[(3R,4R)-4-[4-[[[(Azetidin-1-yl)phenyl]piperidin-3-  
yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-46-7P, 6-[[[(3R,4R)-4-[4-[[[(2-3-

Ethoxyphenoxy)ethoxy]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-methoxypropyl)-  
3,4-dihydro-2H-benzo[1,4]oxazine 857280-50-3P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(1-phenylazetidin-3-  
yl)oxy]methyl]phenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857280-54-7P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(3-phenylpyrrolidin-1-  
yl)methyl]phenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857280-56-9P,


6-[[[(3R,4R)-4-[4-[[[(2,5-Difluorophenoxy)ethoxy]methyl]phenyl]piperidin-  
3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-61-6P 857280-68-3P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(R)-3-phenoxypyrrolidin-1-  
yl)methyl]phenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857280-69-4P,  
4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[[[(3-phenylazetidin-1-  
yl)methyl]phenyl]piperidin-3-yl)oxy]methyl]-3,4-dihydro-2H-  
benzo[1,4]oxazine 857280-70-7P,  
6-[[[(3R,4R)-4-[4-[[[(3-(2-Fluorobenzoyloxy)propoxy]phenyl]piperidin-3-  
yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine  
857280-73-0P, [2-[4-[[[(3R,4R)-3-[[4-[[[(3-  
methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)methoxy]piperidin-4-  
yl]phenoxy]ethyl]amine 857280-75-2P,  
6-[[[(3R,4R)-4-[4-[[[(1-Benzothiazol-2-yl)azetidin-3-  
yl)oxy]phenyl]piperidin-3-yl)oxy]methyl]-4-(3-methoxypropyl)-3,4-dihydro-  
2H-benzo[1,4]oxazine 857280-78-5P,  
[2-[4-[[[(3R,4R)-3-[[4-(3-methoxypropyl)-3,4-  
dihydro-2H-benzo[1,4]oxazin-6-yl)methoxy]piperidin-4-



L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

methoxypropyl)-4H-benzo[1,4]oxazin-3-one 857277-02-2P,  
 6-[[[(3R,4R)-4-[4-[3-(3-Chlorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
 857277-06-6P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[3-(m-  
 tolyloxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4H-benzo[1,4]oxazin-3-  
 one 857277-30-6P, 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-(3-  
 phenoxypropoxy)phenyl]piperidin-3-yl]oxy]methyl]-4H-benzo[1,4]oxazin-3-one  
 857277-47-5P, 6-[[[(3R,4R)-4-[4-[3-[(Benzodioxol-5-  
 yl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-  
 benzo[1,4]oxazin-3-one 857277-51-1P,  
 6-[[[(3R,4R)-4-[4-[3-(2,4-Difluorophenoxy)propoxy]phenyl]piperidin-3-  
 yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
 857277-55-5P, 6-[[[(3R,4R)-4-[4-[3-(2,3-  
 Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-  
 methoxypropyl)-4H-benzo[1,4]oxazin-3-one 857277-60-2P,  
 6-[[[(3R,4R)-4-[4-[3-(4-Fluorophenoxy)propoxy]phenyl]piperidin-3-  
 yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
 857277-64-6P, 6-[[[(3R,4R)-4-[4-[3-(2,6-  
 Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-  
 methoxypropyl)-4H-benzo[1,4]oxazin-3-one 857277-69-1P,  
 6-[[[(3R,4R)-4-[4-[3-(3,4-Difluorophenoxy)propoxy]phenyl]piperidin-3-  
 yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
 857277-74-8P, 6-[[[(3R,4R)-4-[4-[3-(3,5-  
 Difluorophenoxy)propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4-(3-  
 methoxypropyl)-4H-benzo[1,4]oxazin-3-one 857277-79-3P,  
 4-(3-Methoxypropyl)-6-[[[(3R,4R)-4-[4-[3-[(3-  
 trifluoromethylphenyl)oxy]propoxy]phenyl]piperidin-3-yl]oxy]methyl]-4H-  
 benzo[1,4]oxazin-3-one 857277-83-9P,  
 6-[[[(3R,4R)-4-[4-[3-(Cyclohexyloxy)propoxy]phenyl]piperidin-3-  
 yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one  
 857277-88-4P, 6-[[[(3R,4R)-4-[4-(2-(R)-Methoxy-3-  
 phenoxypropoxy)phenyl]piperidin-3-yl]oxy]methyl]-4-(3-methoxypropyl)-4H-  
 benzo[1,4]oxazin-3-one 857279-77-7P,  
 6-[[[(3R,4R)-4-[4-[3-(2-Methoxybenzyloxy)propoxy]phenyl]piperidin-3-  
 yl]oxy]methyl]-4-(3-methoxypropyl)-4H-benzo[1,4]thiazin-3-one  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. of piperidines as renin inhibitors useful against hypertension  
 and other disorders)  
 IT 1044670-79-2  
 RL: PRPH (Prophetic)  
 (Preparation of piperidines as renin inhibitors useful against  
 hypertension  
 and other disorders)  
 RN 1044670-79-2 CAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 3-phenyl-,  
 4-[3-[[[3,4-dihydro-4-(3-methoxypropyl)-2H-1,4-benzoxazin-6-yl]methoxy]-4-  
 piperidinyl]phenyl ester (CA INDEX NAME)

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS  
 RECORD (12 CITINGS)  
 REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR  
 THIS  
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE